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Abstract 
Transcription, the essential process by which cells translate genetic information 
stored in DNA into RNA, is a highly regulated and discontinuous process.  Elongation is 
frequently blocked by DNA damage, pause sites, or intrinsic or external inhibitors.  Due 
to the essential nature of transcription, the cell has numerous ways of dealing with these 
blockages to transcription, only some of which are understood.  We examined the fate of 
RNA polymerase stalled by DNA-protein crosslinks (DPCs), as well as elongation 
inhibitors Streptolydigin (Stl) and Actinomycin D (ActD). 
Our lab previously showed the importance of the tmRNA system for survival 
during DPC-formation, implying that transcription and translation are blocked by 
DPCs.  Using 5-azacytidine-cytosine methyltransferase crosslinks as a model system for 
DPCs in E. coli, we tested knockout mutants of factors known to affect transcription 
using cell growth assays.  Of these mutants, only dksA mutants were hypersensitive.  
However, western blots for tmRNA tagging showed that dksA mutants have increased 
rather than decreased tmRNA tagging, indicating that another unknown factor is 
responsible for enabling tmRNA activity.  We also used the same cell growth assay to 
look for potential repair pathways for DPCs and found that dnaK knockouts were 
slightly resistant to DPCs while dnaJ knockous are sensitive.  We propose a potential 
DnaK-independent role for DnaJ in DPC repair. 
  
v 
To isolate the effects of transcription elongation stalling, we treated cells with the 
elongation inhibitors Stl and ActD.  Previous in vivo studies implied that Stl-inhibited 
polymerases are released from the DNA transcript via an unknown release factor.  Using 
cell growth assays, Western blots for tmRNA tagging, and in vitro studies, we showed 
the transcription-coupled repair (TCR) factor Mfd is responsible for releasing both Stl- 
and ActD-stalled RNAP.  We also treated rpoB mutants with ActD and found several 
ActD resistant mutants, implying alterations to RNAP are sufficient to eliminate ActD 
inhibition.    
The tmRNA western blots also implied that Mfd has termination abilities in 
wildtype cells, leading us to perform RNAseq analysis on mfd knockout and 
overexpressing cells.  We found that global transcription patterns are changed by 
altering Mfd levels, thus allowing us to propose a novel transcription regulatory role for 
Mfd. 
Our studies show that polymerases stalled by DPCs and by elongation inhibitors 
are resolved by different mechanisms, emphasizing the importance of understanding 
the different pathways invovled in transcription elongation clearing.  We also show that 
inhibitors such as ActD are effective against cells overexpressing the TCR pathway, 
which could have potential implications for the treatment of platinum-resistant tumors 
that have elevated levels of TCR. 
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1. Background   
The general purpose of this dissertation is to examine the mechanisms by which 
cells address stalled transcription.  Transcription is the process by which genetic 
information is translated from DNA into RNA.  Due to its essential nature, transcription 
is a highly regulated and discontinuous process.  RNA polymerase (RNAP), the protein 
responsible for transcription, frequently stalls at natural pause sites, either in a 
temporary manner or in a longer, permanently arrested backtracked state.  It has been 
well documented that these natural pauses during elongation lead to careful regulation 
of RNAP by allowing time for trans-acting elongation or termination factors to act on the 
stalled polymerase (1-3).  RNAP can also encounter roadblocks in the form of DNA 
damage or exogenous transcription inhibitors.   
Stalled RNAP is problematic for the cell as not only does deleteriously-stalled 
RNAP reduce the production of RNA and protein, but it also inhibits other enzymes that 
translocate along DNA.  Understanding how cells respond to blocked transcription 
allows for a deeper understanding about this vital process.  Furthermore, it provides 
insight into the mechanism of the elongation inhibitors themselves.  This dissertation 
specifically focuses on the model organism Escherichia coli, which is a useful tool for 
understanding basic procecces that are directly applicable to higher, more complex 
organisms.  
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1.1 Stages of transcription 
The bulk of transcription is carried out by core RNAP, a roughly 400 kDa 
enzyme comprised of five subunits: σ2 ββ’ω.  This core unit is highly conserved across all 
domains of life, emphasizing its essential nature and making the study of bacterial 
transcription relevant for the understanding of the transcription of higher organisms (4-
7).   RNAP is generally shaped like a “crab claw”, with the β and β’ subunits making the 
pincers of the claw.  The catalytic active site is located at the base of the “hinge” of the 
claw.  Other key structural components include the RNA exit channel, where the nascent 
RNA chain exits, and the secondary channel that leads to the catalytic site (4).   
 Core RNAP requires the binding of σ factor to form the holoenzyme and 
recognize sequence specific promoters.  The selective binding of σ factors is a key 
regulatory step in transcription, as different σ factors respond to various environmental 
and stress stimuli and initiate the transcription of relevant genes.   E. coli has seven σ 
factors, with σ70, which is responsible for general housekeeping transcription, being the 
most abundant.  σ’s primary role is to orchestrate various steps of initiation, including 
recognition of promoter DNA and melting of the DNA at the transcription start site (8), 
though σ factors may also have an influence on transcription elongation (9-11).   
Initiation begins with the holoenzyme binding to the -35 and -10 sequences of the 
promoter in an open conformation and melting the DNA, starting with the -11 position.   
 3 
 
 
 
 
 
 
 
 
Figure 1: Structure of ternary RNAP complex 
Schematic model of the structure of a ternary transcription complex. Double-stranded 
DNA is represented as blue cylinders. The DNA template strand is shown as a blue line; 
the nontemplate strand, a cyan line; the RNA transcript, a red line. Very little 
information is available to position the nontemplate DNA strand within the model; it is 
shown here for illustrative purposes only. (Left) View with intact RNAP molecule. 
(Bottom) Same view but with parts of the RNAP cut away (shown in gray) to reveal the 
inner workings of the complex, which are labeled (4). 
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RNAP then undergoes multiple rounds of abortive initiation, transcribing short 
transcripts that are rapidly released  (12).  The amount of promoter escape is dependent 
on promoter strength and regulation by initiation factors such as GreA and NusA (12-
14) (for a list of all referenced genes and functions, see Appendix I).   When the complex 
escapes past the first ~13-15 nt, allowing for a 7-9 bp RNA/DNA hybrid,  RNAP 
undergoes a conformational shift into the closed complex to form the elongation 
complex (15).  It is generally believed that σ is also released during the transition from 
initiation to elongation, although some researchers argue that σ is capable of traveling 
with or rebinding to the elongation complex (16-18). 
Unlike initiation, elongation is a very stable and processive process.  RNA 
polymerase can transcribe up to 80 nt/s, averaging 40 ntp/s in vivo, and can transcribe 
transcripts tens of kilobases long (19).  The elongation complex (EC) is comprised of the 
DNA template, RNAP, the nascent RNA chain, and various elongation factors that 
travel with the EC (such as NusA) (20). RNAP forms three interactions with nucleic 
acids, leading to the stability of the EC: the HBS (RNA:DNA hybrid binding site), RBS 
(‘tight’ RNA-binding site), and UBS (‘weak’ upstream RNA-binding site) (21).  During 
elongation, double-stranded DNA enters through the main channel until it is separated 
by fork loop 2 and the bridge helix, where non-template DNA exits past loop 2 and 
template DNA enters the catalytic active site.  In the active site, template DNA and the 
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nascent RNA chain form an 8 ± 1 bp RNA-DNA hybrid, with the incoming NTPs 
entering the catalytic site though the secondary channel and the growing RNA chain 
exiting out the RNA exit channel.  The template DNA then passes out of the RNAP and 
reanneals with the non-template strand ((15,22) and references therein). 
To form a new transcript RNAP undergoes potentially thousands of rounds of 
the nucleotide addition cycle (NAC).  During the NAC the RNA 3’ nt slides from the  i + 
1 site to the i site in the catalytic active site, opening up the NTP binding site for the 
incoming NTP.  The incoming NTP first binds to the preinsertion site while RNAP is in 
an inactive “open” conformation, allowing for proper substrate recognition.  RNAP then 
shifts into a “closed” conformation with the NTP transferring to the insertion site.  
Nucleotide addition is complete with the formation of the phosphodiester bond, and 
release of PPi (23-26).   
Despite its processivity, transcription is highly discontinuous.  Natural pause 
sites allow for essential regulation of transcription production and help to coordinate 
polymerase and ribosome activity in bacteria (27).  Complexes can also be deleteriously 
stalled by a number of causes, such as DNA damage, exogenous RNAP inhibitors, and 
colliding replication forks (see below).  Once stalled, elongation complexes can undergo 
a variety of fates including transcription restart, backtracking, or termination, depending 
on the cause of stalling.   
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In bacteria there are three stages of pausing: class I, class II, and ubiquitous 
pauses (28).  Class 1 pauses are classified by the formation of RNA secondary structures, 
primarily hairpins.  While the mechanism is still not fully understood, it is believed that 
the hairpin interacts with RNAP, stabilizing an active site rearrangement that 
temporarily halts the normal NAC (29). Class II hairpins are classified by RNAP 
backtracking.  During backtracking, RNAP moves upstream along the DNA by various 
amounts, resulting in the removal of the 3’ end of the nascent RNA from the catalytic 
center and extrusion of the tail through the secondary channel of RNAP.  Under certain 
circumstances this pausing can lead to elongation arrest or recycling (30).  Backtracked 
RNAP can also result in double-stranded breaks and genome instability if a replication 
fork collides (31).  Ubiquitous pauses are the least understood form of pausing, with 
only a rough consensus sequence proposed and no other hallmarks of identification (32).  
Single molecule studies with ubiquitous pauses also showed they are not associated 
with backtracking (33).     
Normal termination occurs in either a Rho-dependent or Rho-independent 
manner.  Intrinsic termination occurs at sequence dependent sites, and account for 
termination at roughly 50% of annotated genes and 70% of noncoding RNA in E. coli 
(34).  Intrinsic termination sites are comprised of a GC-rich palindromic element that 
forms a hairpin (comprised of a 8-9 bp stem and 4-8 nt loop) in free RNA, followed by an 
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6-8 bp oligo(T) sequence (T-stretch) (35).  Elongating RNAP pauses at the unstable T-
stretch, allowing time for the formation of the hairpin.  Hairpin formation causes partial 
melting of the T-stretch, resulting in breaking the UBS and RBS contacts and weakening 
the HBS contacts.  The transcription bubble is thus weakened and the DNA rewinds as 
RNAP is released (reviewed in (36)).  In Rho-dependent termination, Rho recognizes 
and binds to C-rich rut (Rho utilization) sites on the nascent RNA chain.  The RNA then 
translocates through Rho until there is little space between Rho and RNAP.  This 
translocation requires there to be little to no impeding factors on the RNA, such as 
ribosomes or RNA secondary structures.  Because the RNA translocates through Rho as 
RNAP is actively transcribing, RNAP is typically required to pause before Rho 
termination occurs, although backtracked and strong class I pauses are resistant to Rho-
dependent termination.  The exact mechanism of termination once Rho reaches RNAP is 
also still under debate, with current models including unraveling of the RNA:DNA 
hybrid due to tension caused by translocation and destabilizing conformational changes 
in RNAP due to allosteric binding of Rho (reviewed in (37)).  Other factors are known to 
release RNAP when stalled at DNA damage or during replication-transcription 
collisions and are reviewed in section 1.4. 
In addition to the inhibition of RNA production, failure of transcription to 
properly elongate or terminate can increase the number of collisions between the stalled 
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RNAP and other proteins translocating along the DNA.  This is particularly problematic 
in the case of replication-transcription collisions, which potentially lead to replisome 
stalling and genome instability (31,38,39).  Therefore, it is of importance to understand 
how the cell responds to and clears blockages in transcription.  Our lab became 
interested in the fate of transcription complexes that were stalled in such a way that they 
could not be easily restarted, such as at a covalently bound protein or by a specific 
elongation inhibitor.  This dissertation examines the fate of RNAP stalled by DNA-
protein complexes and the elongation inhibitors Streptolydigin and Actinomycin D. 
 
1.2 Physical block to RNAP: DNA-Protein Crosslinks 
1.2.1. Causes and consequences of DNA-protein crosslinks  
DNA-protein crosslinks (DPCs) occur when a protein becomes covalently bound 
to DNA. There are currently 4 classes of DPCs: the first three involve topoisomerases 
and DNA polymerases trapped at single-strand nicks and double-strand breaks, and the 
fourth involves proteins trapped on undisrupted double-stranded DNA (40).  DPCs 
referred to in this document are Class IV DPCs.   DPCs are caused by a number of 
agents, including ultraviolet light, radiation, metals and metalloids, various aldehydes, 
reactive oxygen species, and chemotherapeutic agents.  Crosslinking mechanisms 
include direct covalent bond formation,  chemical/drug linkers, or coordination with a 
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metal atom (41).  Therefore, DPCs are chemically distinct and are influenced by a variety 
of factors.  Due to the variable nature of DPCs, their consequences are difficult to 
interpret, but are known to include blockage of replication and transcription, formation 
of DNA double-stranded breaks, and cell death (42-44).  In addition, DPCs have been 
implied to contribute to the cytotoxic, mutagenic, and carcinogenic effects of various 
chemical agents and chemotherapeutic drugs (44).  Due to the wide range of types of 
DPCs and, therefore, the various causes and consequences, this background will be 
limited specifically to crosslinks induced by aza-C. 
Aza-C is a cytidine analog with ribose sugar and a nitrogen atom at the carbon 5 
(C5) position.  In both mammalian and bacterial cells aza-C treatment leads to its 
incorporation into both RNA and DNA.  A related compound, 5-aza-deoxycytidine (5-
aza-dC), has a similar structure with a deoxyribose sugar, and thus incorporates 
primarily into DNA.  aza-C and 5-aza-dC incorporates randomly into the genome, and 
incorporation into the inner C of CCWGG sequences leads to the covalent trapping of 
the EcoRII DNA-cytosine MTase (45) (see below for details and mechanism).  This leads 
to a variety of effects including decreased MTase activity (44), replication fork blockage 
(42) , and transcription blockage (46).  aza-C treatment also leads to inhibition of protein 
synthesis, although this is most likely due to its incorporation into RNA.  Incorporation 
into tRNA inhibits tRNA MTases and thus tRNA methylation and processing, most 
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likely leading to the effect on protein synthesis (44) .  Ultimately, aza-C treatment leads 
to decreased cell growth at low doses and cell death at high doses, although this effect is 
dependent on the presence of a cytosine MTase (47).  To corroborate this, it has been 
shown that the level of cellular resistance to aza-C and 5-aza-dC is inversely related to 
active MTase levels (44)  and the presence of a MTase overexpression plasmid 
dramatically increases cell sensitivity to aza-C (47) . 
1.2.2. Mechanism of MTase binding to cytidine and 5-azacytidine 
In normal DNA methylation, 5-methylcytosine is formed by the transfer of a 
methyl group from S-adenosylmethionine (AdoMet) to C5 of the target cytosine in a 
reaction catalyzed by cytosine-5-MTases.  A highly conserved catalytic cysteine of 
MTase forms a covalent bond with C6 of the target cytosine, which causes a shift of 
electrons to C5 and subsequent attack on the donor methyl group from AdoMet.  The 
remaining proton on C5 is then abstracted followed by β elimination, which reforms the 
double-bond between C5 and C6 and releases the enzyme (44).   
In 1994 Klimasauskas et al. crystallized a ternary structure between a 13-mer 
oligonucleotide containing methylated 5-flourocytosine, the HhaI cytosine MTase 
(M.HhaI) and the reaction product S-adenosyl-L-homocysteine.  They found that upon 
recognition of the target cytosine (Cyt) is flipped completely out of the DNA helix into 
the active site of M. HhaI.  This “flipped-out” conformation aligns Cyt with the bound 
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AdoMet, and the conserved active-site loop in M.HhaI undergoes a large conformation 
shift towards the DNA binding cleft.  The sulfhydryl group of the catalytic Cys-81, 
which performs the nucleophilic attack on Cyt, is brought to close proximity of Cyt as a 
result of the conformation shift (48).  Further work by Klimasauskas et al showed that 
when M.HhaI binds to the recognition sequence it is in dynamic equilibrium with a 
variety of “open” and “closed” conformations.  Subsequent binding of AdoMet then 
facilitates the stabilization of the “closed” conformation where Cyt is locked in the active 
site of M.HhaI.   At this time the active cytosine performs its nucleophilic attack, causing 
a shift of electrons that results in C6 taking on sp3 character.  This facilitates attack of C5 
on AdoMet, resulting in methyl transfer (49).  This methyl transfer initiates the release of 
M.HhaI.  First, the presence of the methyl group on C5 puts steric tension on Pro80 of 
M.HhaI, which is proposed to initiate a shift in equilibrium from the “closed” 
conformation to the “open” conformation of the enzyme.  In addition, the presence of 
two water molecules located 4.4 Å and 4.2 Å from C5 provides general bases to facilitate 
the elimination of a proton from C5, resulting in the reformation of the double bond 
between C5 and C6 and the release of the enzyme (50). 
As previously mentioned, aza-C has a nitrogen at the C6 position, which 
drastically alters the chemistry of the MTase reaction.  First, unlike the reaction with 
normal Cyt, a stable covalent interaction between DNA-cytosine MTases can form in the 
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presence or absence of Ado-Met.  This led Santi et al. to propose an AdoMet independent 
reaction mechanism: base recognition and subsequent MTase (M.HhaII was the MTase 
used in their studies) binding occurs via the formation of a covalent bond between the 
conserved catalytic cysteine residue of MTase and C5 of aza-C.  This reaction then leads 
to the protonation of N6 in aza-C (45).  This proposal would suggest that methylation of 
aza-C is not necessary for covalent bond formation; however, there is some 
disagreement over whether or not the methylation occurs.  In support of Santi’s 
proposal, Brank and Christman found that transfer of radiolabeled methyl groups from 
AdoMet to aza-C-containing oligonucleotides by M.HhaI was barely detectable (44).  In 
contrast, Gabbara and Bhagwat were able to detect such transfer using the EcoRII MTase 
(M.EcoRII), leading to a revised proposal that in the presence of AdoMet N5 is 
methylated, but that an AdoMet-independent covalent bond could form in the absence 
of AdoMet (51).  In either case, the presence of a nitrogen at the 5 position eliminates the 
possibility for the subsequent β-elimination step, blocking the formation of the 5,6 
double-bond and preventing the release of the enzyme.  In addition, Brank and 
Christman also tested the mobility of M.HhaI:aza-C-oligonucleotide complexes and 
found that in the presence or absence of AdoMet M.HhaI was always in the “closed” 
conformation, regardless of temperature (44).  This again supports the original proposal 
by Santi et al. that aza-C inhibits DNA-cytosine MTases by covalently trapping the  
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Figure 2: Methyl transfer reaction onto cytidine and 5-azacytidine 
In normal DNA methylation, a highly conserved catalytic cysteine of MTase forms a 
covalent bond with C6 of the target cytosine, which causes a shift of electrons to C5 and 
subsequent attack on the donor methyl group from AdoMet.  The remaining proton on 
C5 is then abstracted followed by β elimination, which reforms the double-bond 
between C5 and C6 and releases the enzyme (44).  With aza-C, the nitrogen at the 5 
position prevents the β elimination and the enzyme is covalently trapped. 
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enzyme at recognition sites.  These complexes are extremely stable; they last up to 2-3 
weeks when the complex is formed in the presence of AdoMet (44), and are stable to 
denaturation by Na-DodSO4 (45), DNaseI digestion (52), 6 M urea (52), and precipitation 
by ethanol (52). 
1.2.3. Significance of 5-azacytidine study 
5-azacytidine-induced crosslinks are intriguing to study for multiple reasons.  
First, as previously mentioned, aza-C can serve as a model system for DPC study.  Our 
lab uses the EcoRII MTase in our bacterial studies, which is a 60kDa protein with a 
recognition sequence of CCWGG.  This becomes critical as different types of DPCs not 
only have different consequences, but the way the cell processes them varies as well.  
For example, Nakano and colleagues have shown that the size of the protein can affect 
the way that DPCs are processed: proteins 12-14 kDa and smaller can be processed by 
nucleotide excision repair (NER), while DPCs formed by larger proteins are potentially 
processed by homologous recombination (40); however, DPC processing is even less 
clear cut than this, as NER efficiency varies with the size of protein (53).   Knowing the 
sequence that MTase targets also adds a technical advantage for directed studies. 
In addition to its role in DPC study, aza-C has clinical implications as well.  aza-
C and the related compound 5-aza-deoxycytidine are FDA-approved hypomethylating 
agents for the treatment of myelodysplastic syndromes (MDS), in particular for 
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intermediate and high risk MDS (54).  They have also been shown to be effective against 
acute and chronic myelogenous leukemia (AML and CML, respectively) (55).  There are 
more than 10,000 cases of MDS diagnosed in the U.S. per year, with a 3-year survival 
rate of 35%; in addition, high-risk MDS has an average survival rate of 0.4-1.2 years with 
a high risk for development of AML.  However, aza-C treatment has been shown to 
increase overall response rate (measured as the combination of partial and complete 
remission), overall survival, and prolong transformation to AML all at statistically 
significant levels.  Prior to the use of hypomethylating agents cytotoxic therapy or 
supportive care were the primary means of treatment.  Both of these cause potentially 
fatal secondary complications, whereas hypomethylating agents have a favorable side-
effect profile (54). 
Clearly aza-C and 5-aza-dC have vast potential for clinical significance.  
However, despite more than 40 years of research the mechanisms behind aza-C’s 
cytotoxic and clinical activities are still not fully understood.  Cytosine methylation 
affects mammalian cell expression (44)  and it is suspected that reactivation of silenced 
tumor suppressor genes leads to the anticancer effect of hypomethylating agents (56); 
however, the aza-C-MTase adducts can also have a negative effect, such as proposed 
toxicity to bone marrow cells (56).  The complexity of clinical consequences of aza-C 
treatment makes it imperative to understand the full consequences of aza-C 
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incorporation at a biochemical level so that the full potential of aza-C and related 
compounds as anticancer agents can be maximized. 
 
1.3 Exogenous elongation inhibitors 
1.3.1 Streptolydigin  
Streptolydigin (Stl) is a transcription elongation inhibitor that inhibits RNA chain 
elongation (57-59).  It is comprised of a streptolol moiety, a bulky tetramic acid group, 
and a sugar group (Figure 3).  Unlike typical DNA binding elongation inhibitors (see 
below) Stl binds directly to RNAP.  The Stl  binding site in RNAP is ~20 Å from the 
active site and forms two main interactions: the streptolol moiety binds hydrophobically 
to the N-terminal portion of the bridge helix on the β’ subunit, and the tetramic acid 
group interacts with the central portion of the bridge helix and the trigger loop of the β 
subunit.  These interactions stabilize the straight-bridge-helix RNAP-active-center 
conformational state (60,61).  Crystal structures with RNAP and Stl and apo-holoenzyme 
show that the bridge helix is in a straight conformation when Stl binds, indicating that 
RNAP is most likely in the “open” conformation (61).     
The mechanism of Stl inhibition of elongation is thought to be the stabilization of 
the bridge helix and the trigger loop.  This stabilization prevents normal conformational  
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Figure 3: Structure of Stretpolydigin and Actinomycin D 
Panel A is the chemical structure of Streptolydigin.  Stl consists of a streptolol moiety, a 
bulky tetramic acid group, and a sugar group.  Panel B is the structure for Actinomycin 
D.  The planar phenoxazone ring system is shown in green and the pentapeptide side 
chains shown in red (62). 
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changes necessary for translocation of the growing nascent chain, effectively freezing 
RNAP in an inactive conformation (60,61).  Streptolydigin does not appear to alter 
nucleotide binding to RNAP, phosphodiester bond formation, or DNA translocation 
(61).  Elongation complexes stalled by Stl are very stable in vitro; complexes are still 
bound to DNA after 50 minutes of high Streptolydigin treatment, and removal of Stl 
results in resumption of transcription after a delay (59).  However, in striking contrast, 
Stl-stalled elongation complexes are irreversibly destabilized in vivo, presumably due to 
being released by some unidentified release factor (58). 
 
1.3.2. Actinomycin D 
Actinomycin D (ActD) is a small molecule comprised of a planar tricyclic 
phenoxazone ring and two cyclic pentapeptide side chains with antibiotic and 
anticancer capabilities (62,63).  It is primarily known as a DNA intercalator, with the 
ability to intercalate into double stranded DNA, bind to single-stranded DNA, and 
hemi-intercalate into single stranded DNA.  Crystal structures have shown that 
phenoxazone ring system intercalates preferentially between dinucleotide sequences of 
dGpC.  The pentapeptide chains lie in the narrow groove of the structure and form 
hydrogen bonds with guanine residues on the chain opposite of ActD intercalation (64).  
A more recent force spectroscopy study showed the ActD can intercalate into stable B-
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DNA with very slow on and off-rates.  Destabilization (in the form of DNA stretching) 
increasing the binding stability 20-fold , the on rate of intercalation by 100-fold, and the 
off rate of release 5 fold (62). 
Despite years of research, the exact mechanism by which ActD carries out its 
antibiotic and anticancer capabilities is still under debate.  Early studies found that ActD 
preferentially bound to distorted double helical DNA, particularly β-DNA found in 
transcription bubbles, and proposed that binding of ActD to the leading edge of the 
transcription bubble effectively “pins” RNAP in place and inhibits transcription 
elongation (64).  The authors of the force spectroscopy study supported this model and 
proposed that the increased transcriptional activity of tumors is what makes ActD so 
effective.  Other models propose that ActD binds to B-DNA, stabilizing double-stranded 
DNA and blocking replication forks (65).  To the best of our knowledge, direct 
interaction of ActD with RNA or DNA polymerases has not been addressed.       
 
1.4 Fate of paused or stalled RNAP 
A common way the cell recycles stalled elongation complexes is through the 
activity of TRCF (transcription repair coupling factor), also known as Mfd (mutation 
frequency decline).  Mfd is a member of the helicase superfamily 2, and has ATPase, 
translocase, and dsDNA binding activity but not strand-separating helicase activity (66).    
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Mfd couples transcription termination and DNA repair by recycling stalled polymerase 
and recruiting nucleotide excision repair factors to the site of the DNA lesion.  
Mechanistically, Mfd is recruited to a stalled elongation complex through its RNAP 
binding domain D4, binding directly upstream of the transcription bubble (30,67).  
Subsequent DNA binding leads to a conformational shift, causing movement of the 
helical hairpin into the dsDNA binding cleft.  This hairpin serves as a ratchet, pushing 
RNAP forward and DNA backwards.  Depending on sequence and RNAP 
conformation, Mfd then either enhances forward translocation or removes the stalled 
RNAP from the DNA.  For instance, if RNAP is backtracked, MFD uses its ATP 
dependent translocase activity to push forward backtracked RNAP.  This concomitantly 
rewinds the transcription bubble from upstream and unwinds the RNA/DNA hybrid 
(67,68).   When  there is a physical obstruction in the way, such as a DNA-bound protein 
or DNA lesion, this ratcheting motion is proposed to dislodge RNAP from DNA (66,69).  
If the block was induced by DNA damage, once RNAP has been cleared from the DNA 
UvrA is recruited to the site via Mfd’s UvrA binding site in the N-terminal UvrB 
homology domains (66,67) to begin the process of nucleotide excision repair.  
In addition to Mfd, bacterial cells have other pathways to resolve 
replication/transcription complexes stalled at protein roadblocks or other blocking 
lesions. The DinG, UvrD, and Rep helicases have been implicated in preventing or 
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mitigating the damage from collisions between the replication machinery and bound 
proteins (such as RNA polymerase), and at least Rep and UvrD have protein removal 
activity in vitro (70-73).  Transcription terminator Rho has been shown to prevent double 
stranded DNA breaks, presumably by removing RNAP ahead of the replisome and 
preventing damaging collisions (74).  It also has been shown to remove polymerases 
stalled at a tightly bound protein in vitro (75).  Another transcription factor, HepA, has 
been shown to activate transcription by recycling RNAP, and potentially plays a role 
during DNA damage (76,77).  
In some cases the transcription blocked by a lesion may be able to bypass the 
lesion altogether, through the assistance of transcription factors or trailing RNA 
polymerases in the case of transcription. GreA and GreB are elongation factors that 
travel with the transcription complex, and have been shown to induce cleavage of the 3' 
proximal dinucleotide from the nascent RNA by RNAP, allowing for restart of 
transcription at the new 3’ end (78,79). GreA and GreB also stimulate activation of 
backtracked elongation complexes (80). DksA, along with ppGpp, has numerous effects 
on elongation complexes and has been shown to prevent replication/transcription 
collisions (73,81). Trailing RNA polymerases have also been shown to help push stalled 
elongation complexes past roadblocks (82). 
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1.5 Major questions to be addressed 
The purpose of my dissertation research is to understand the molecular response 
to transcription inhibition with the downstream application of enhancing cancer and 
antibiotic therapies.  Due to the variety of different fates and cellular consequences that 
stalled elongation complexes might have, this dissertation focuses specifically on the 
case where transcription cannot be easily restarted with the aid of elongation factors.  To 
model this system, we look at three different inhibitors: DNA-protein crosslinks, 
Streptolydigin, and Actinomycin D.   
As mentioned above, it has been shown that a specific form of DNA damage 
known as DNA-protein crosslinks (DPCs) lead to blockage of elongating transcription 
complexes in vitro, but to date the fate of these transcription complexes in vivo remains 
unknown.  In the first part of this work, we utilize crosslinks formed between aza-C and 
cytosine MTase as our DPC model system. The main questions we ask are: 1) What 
happens to transcription blocked at a DPC and 2) How do DPCs get repaired (as this 
might influence the fate of already-stalled transcription complexes)?  Our lab previously 
conducted a transposon mutagenesis screen looking for Aza-C hypersensitive mutants 
and identified 24 mutations in 16 genes (83).  One gene was ssrA, which encodes the 
tmRNA gene product in E. coli.  tmRNA is responsible for recycling stalled ribosomes 
and tagging the resulting truncated peptides for degradation.  Since transcription and 
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translation are coupled in bacteria, the involvement of the tmRNA system implies that 
transcription is blocked as well.  tmRNA binds to the A-site of the ribosome, and a 
nascent RNA chain that is still attached to a translating ribosome would occlude the A-
site.  Therefore a third question we address is how tmRNA accesses the stalled 
ribosome. 
The transcription elongation inhibitor Stl binds directly to RNAP and traps it in 
an inactive conformation that cannot be restarted by simply being “pushed forward”.  
Previous work showed that Stl-inhibited polymerases are released from the DNA 
transcript in vivo, and it is likely that transcription complexes blocked at DPCs are also 
released (58).  ActD is a eukaryotic transcription elongation inhibitor that is known to 
intercalate into DNA, but the specific mechanism behind RNAP inhibition in bacteria is 
still unknown.    Therefore the main questions we address in this section are: 1) What is 
the release factor responsible for clearing Stl-stalled RNAP and 2) does the same release 
factor(s) work for ActD treatment?  Because so little is known about the exact 
mechanism of ActD inhibition of transcription, we will also be looking for RNAP 
mutants that are resistant to ActD treatment. 
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2. Functions that protect Escherichia coli from DNA-
protein crosslinks 
Portions of this chapter have been published in Molecular Microbiology (84).  
The transposon mutagenesis screen mentioned in this section was conducted by Sunny 
Wu and Kenny Kuo. 
2.1 Introduction 
In this Chapter, we aim to understand the effects of DNA-protein crosslinks 
(DPC) on transcription elongation.   DPCs are a form of DNA damage that occur when 
proteins become aberrantly covalently attached to DNA.  They can be caused by a 
number of factors such as formaldehyde, UV and IR treatment, metals and metalloids, 
reactive oxygen species, and chemotherapeutic agents.  The variety of causes as well as 
the types and locations of proteins that form DPCs makes them very difficult to study, 
and as a result DPCs are the least understood form of DNA damage.  To combat the 
challenges of DPC study, our lab uses 5-azacytidine (aza-C), a cytidine analog that 
covalently traps cytosine methlytransferases at specific recognition sites, as a model 
system. 
It has been shown that DPCs have a number of cellular consequences including 
blocking replication, transcription (in vitro), and recombination (42-44).  We have also 
previously reported that the tmRNA system is required for cell survival during DPC 
formation, implying translation is alo blocked (84).  We report here that the tmRNA 
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system is required to recycle the stalled ribosomes.  The first step in tmRNA-mediated 
ribosome recycling is tmRNA binding to the empty A-site of a ribosome, which leads to 
the question of how tmRNA is able to access the stalled ribosomes if they are still on the 
nascent transcript.  We were unable to identify any RNase mutants that were 
hypersensitive to aza-C, implying that A-site cleavage is not responsible for tmRNA 
tagging.  A main focus of this chapter is thus to identify potential RNAP releasing 
proteins.  Since the repair of DPCs might be coupled to the clearing of the blocked 
transcription complexes, we also look for potential repair pathways that lead to the 
clearing of DPCs.  
 
2.2 Results 
Requirement of the tmRNA system during DPC formation implies transcription 
blockage in vivo 
Our lab previously conducted a transposon mutagenesis screen for aza-C 
hypersensitive mutants in an attempt to identify proteins involved in the repair and 
tolerance of DPCs.  This screen resulted in the identification of a total of 24 insertion 
mutations, localized to 16 different genes, qualified as aza-C hypersensitive (83).  This 
screen both confirmed genes already identified as aza-C hypersensitive and isolated new 
ones. One of the unique genes isolated was the ssrA gene, which encodes the tmRNA 
gene in E. coli (84).  Because transcription and translation happen concurrently in 
bacteria, the requirement of the tmRNA system – which is known to recycle stalled 
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ribosomes – for cell survival implies both translation and transcription are blocked 
during DPC formation.  Knockouts of smpB, an essential cofactor to tmRNA, were also 
shown to be hypersensitive, further confirming involvement of the tmRNA system (84).   
In addition to  recycling stalled ribosomes, tmRNA also adds a degradation tag 
to the truncated peptides during trans-translation and prevents accumulation of 
unproductive products (85).   To separate the different functions of tmRNA and 
distinguish which is responsible for cell survival during DPC formation, we used the 
mutant ssrA-H6 gene, which encodes a tmRNA with a hexahistidine stretch of codons in 
place of the coding sequence for a functional proteolysis signal (86).  This mutant 
tmRNA is functional for dissociating blocked ribosome complexes but causes a gross 
deficiency in downstream proteolysis.  We introduced a p15A-derived plasmid with the 
ssrA-H6 mutant, wild-type ssrA or empty vector into ssrA knockout cells.  Due to 
plasmid compatibility issues, we used an M.EcoRII expression plasmid, pR234, in which 
the methyltransferase expression is under control of a Ptac promoter (87). Expression 
from this plasmid is leaky in the absence of IPTG, and so we also generated a set of 
strains in which the M.EcoRII coding sequence had been deleted from the expression 
plasmid to use as negative controls.  The ssrA deletion cells expressing M.EcoRII but no 
plasmid-borne tmRNA showed strong sensitivity to aza-C, while the cells with the  
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Figure 4: tmRNA is required to recycle ribosomes. 
Aza-C hypersensitivity is relieved by the ssrA-H6 mutant. Overnight cultures of strain 
HK22 ssrA::kan derivatives carrying two plasmids were diluted to 4 x 108 cells/ml. The 
identities of the plasmids are indicated on the left: ssrA+ (pKW11); ssrA-H6 (pKW24); 
ssrA (pKW1); M.EcoRII (pR234); vector (pRK1). Ten-fold serial dilutions were generated 
across a microtitre plate and 5 ml of each dilution was spotted onto LB plates with no 
aza-C (left panels), aza-C at 2 mg/mL (middle panel), or aza-C at 5 mg/ml (right panel).  
Plates were photographed after overnight incubation at 37°C. 
 
 
 
 
 
mutant ssrA-H6 gene were resistant (Fig. 4).  This implies that the ribosome recycling 
ability of tmRNA, not the degradation of the stalled peptides, is required for survival. 
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RNase activity is not responsible for creating tmRNA substrates 
In the well-studied tmRNA pathway, the first step of ribosome release involves 
tmRNA binding to the empty A-site of the ribosome (85).  For this to occur, the ribosome 
normally translates to the end of a truncated mRNA transcript (lacking a stop codon), or 
the transcript is cleaved to generate an empty A-site (88,89). In the case of DPCs and 
blocked transcription/translation complexes, how does tmRNA access the stalled 
ribosomes?  
One model is that a ribonuclease cleaves the nascent transcript near the A-site of 
a stalled translation complex, generating a truncated transcript and a premature 3’ 
mRNA end for any upstream ribosomes on the same transcript.  If A-site cleavage is 
critical for tmRNA function at DPC-blocked transcription/translation complexes, we 
would expect to observe aza-C hypersensitivity in cells that are deficient in RNase II, 
which is implicated in A-site cleavage (see (90) and Discussion).  For this and all 
subsequent drug sensitivity profiles, sensitivity levels were conducted by measuring 
growth curves in the presence of varying concentrations of aza-C in 96-well plates using 
a Biotek ELx808™ Absorbance Microplate Reader (which allows incubation at 37°C and 
agitation for aeration). Sensitivity levels were compared by processing the growth 
curves in a manner that corrects for differences in growth rates. For each mutant and the 
wild type, we first determined the growth rate of the drug-free culture during its 
exponential phase (OD560 values from 0.01 to 0.1; in every case, these data points 
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matched a simple exponential curve with R2 values of greater than 0.99). We next 
determined the first time point at which the growth rate had fallen to half that value (or 
less), and plotted the accumulated cell density (as a fraction of the drug-free value) at 
that time point for the various drug concentrations.  Using this test, we found no 
different in sensitivity levels between wildtype and rnaseII mutants (Figure 5).  These 
results argue that A-site cleavage, at least by the most common pathway, is not 
necessary for tmRNA activity in this situation.  We also tested mutants lacking other 
exonucleases with known roles in tRNA processing (RNase D, PH, and LS). However, 
knockout cells for each of these were no more sensitive to aza-C treatment than wild-
type cells (data not shown).  
 
Candidate approach: Functions potentially involved in clearing DPC-stalled 
transcription/translation complexes 
An alternative model to A-site cleavage for tmRNA activity is that RNAP is 
released before tmRNA activity can occur.  RNAP release would lead to the release of 
the nascent transcript, allowing translation to continue to the end of the truncated 
transcript and resulting in an empty A-site.  Therefore we attempted to identify the 
release factor responsible for creating substrates for the tmRNA system.  A well-studied 
mechanism for releasing RNA polymerase blocked by DNA damage (e.g. UV-induced  
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Figure 5: Aza-C hypersensitivity profiles of potential transcription altering knockout 
strains. 
HK22 (WT) or mutant derivatives (containing pBAD-MEcoRII) were tested for aza-C 
sensitivity using a microtiter plate sensitivity assay. A standardized point in the growth 
curve was first determined for each cell line, namely the time at which the growth rate of 
the no-drug culture dropped to 50% of the earlier exponential rate. The OD630 value at 
this time was then taken for each drug concentration and divided by the no-drug control 
to account for differences in growth rate.  Three independent cultures were measured 
for each strain, with the exception of the rep mutant, where 6 independent cultures were 
grown and measured due to the poor growth and slight variability of this strain.  The 
error bars indicate the standard deviation for these cultures.  
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pyrimidine dimers) involves the Mfd helicase, which also couples transcriptional 
blockage to excision repair (66,91).  Mfd therefore is a likely candidate for releasing 
DPC-stalled transcription complexes.  Strikingly, a previous member of our lab found 
the mfd single mutant was no more sensitive than the wild-type, strongly arguing 
against a role of transcription-coupled repair during DPC formation. 
Termination factor Rho is involved in terminating transcription at many natural 
terminators, and also induces termination when translation is blocked due to an 
upstream nonsense mutation (transcriptional polarity) (3). Furthermore, Rho protein 
induces termination and release of RNA polymerase blocked in vitro by a tightly bound 
protein (75). These results suggest Rho is a reasonable candidate for the alternative 
polymerase release function.  In order to test the possible involvement of Rho, we used 
the Rho-specific inhibitor bicyclomycin (92). If Rho is involved in releasing RNA 
polymerase blocked by aza-C-induced DPCs we predicted that bicyclomycin would be 
synergistic with aza-C for growth inhibition.  We used cells that express M.EcoRII from 
the pBAD-MEcoRII plasmid, and prepared microtitre plates with a double drug (aza-C 
and bicyclomycin) serial dilution in checkerboard fashion, thereby testing numerous 
combinations of drug concentrations for growth inhibition.  
To assess whether or not the drugs act synergistically, we processed the data in 
two different manners. First, we looked for synergy using a graphical representation in 
which the two drug concentrations constitute the x and y axes, and the amounts 
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required to inhibit growth to 95%, 75% or 50% (isoboles) are plotted in different colors.  
Synergistic drug interactions are revealed by a concave shape to the isobolic curve, 
antagonistic interactions by a convex shape, and lack of drug interaction by a relatively 
straight line (93). The data from four separate experiments are all plotted in Figure 6, 
with the theoretical lines for no drug interaction shown as dashed lines (connecting the 
two experimentally determined values for each drug alone). The multiple data points 
fall quite near the theoretical line for no drug interaction, with no indication of a 
synergistic (concave line) relationship and a slight but unconvincing hint of an 
antagonistic (convex line) relationship. 
The second method commonly used to assess synergy, supported by the 
American Society for Microbiology, is the so-called fractional inhibitory concentration 
(FIC) index ((94); also see Instructions to Authors for the ASM Journal Antimicrobial 
Agents and Chemotherapy).  For each level of drug A, the FIC is calculated for the first 
concentration of drug B that gave the indicated level of inhibition, with FIC = [(MIC of 
drug A tested in combination) / (MIC of drug A tested alone)] + [(MIC of drug B-tested 
in combination) / (MIC of drug B-tested alone)]. The American Society for Microbiology 
recommends that synergy is supported by FIC index values less than 0.5, while 
antagonism is supported by FIC index values greater than 4 (an FIC of 0.5 could reflect a 
situation where 1/4 the concentration of each drug is required in combination to give the  
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Figure 6: Isobolic tests for synergy with Rho inhibitor bicyclomycin 
Growth curves were measured in each well of a 96-well microtitre plate, with varying 
concentrations of bicyclomycin (right to left) and aza-C. The strain for the 
bicyclomycin/aza-C experiment were (A) HK22 pBAD-MEcoRII (B) hepA, (C) greA and 
(D) greB. A detailed description of the data analysis and processing are presented in 
Methods.  Briefly, at each concentration of bicyclomycin (Bcm), the concentration of aza-
C necessary to inhibit growth by 95% (blue), 75% (gold) or 50% (green) was estimated. In 
addition, the concentration of bicyclomycin necessary for those levels of growth 
inhibition (in the absence of the second drug) was estimated from the bicyclomycin 
inhibition curve. The data from each of four repetitions (on different days) were plotted 
with different symbols (squares, diamonds, circles and triangles). The dashed lines 
connect the average determined MIC value of each drug alone. 
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Table 1: FIC values from the aza-C / bicyclomycin titrations. 
 
From the OD630 measurements at the set end point the fractional inhibitory 
concentrations (FIC) were calculated. For each level of aza-C, the FIC was calculated for 
the first concentration of bicyclomycin (Bcm) that gave the indicated level of inhibition 
(95%, 75% or 50%), and for each concentration of Bcm, the FIC was calculated for the 
first concentration of aza-C that gave 95%, 75% or 50% inhibition.  This Table 
summarizes these FIC values from four different experiments for the three different 
levels of growth inhibition. The MIC values for each drug alone in each experiment are 
also shown (with no FIC value). The average and standard deviations from all FIC 
values are shown at the bottom. 
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same growth inhibition as each drug alone at 1x concentration; the theoretical value for 
no interaction whatsoever is 1.0). In the same tests shown graphically in Fig. 6, we found 
the following FIC index values: 0.95 (±0.11) for 95% inhibition; 1.01 (± 0.16) for 75% 
inhibition; and 0.84 (±0.06) for 50% inhibition (see Table 1). These FIC values clearly do 
not support a synergistic (or antagonistic) relationship between aza-C and bicyclomycin.  
With the caveat that multiple drug experiments need to be interpreted with caution, 
these results argue against an involvement of termination factor Rho in releasing RNA 
polymerase blocked by DPCs. 
As mentioned previously, other factors are known to release RNAP in different 
stressful situations.  Two candidates that arose in the transposon screen mentioned 
above, DinG and UvrD, along with the helicase Rep, were implicated as having 
overlapping roles to avoid transcription-replication conflicts, particularly when the 
collisions were from opposite directions (70).  However, if either helicase was releasing 
the nascent transcript to allow access by the tmRNA system, we would expect decreased 
SsrA tagging in its absence. We found no such decrease in spite of the clear 
hypersensitivity of each mutant (data not shown).  
The third helicase implicated in transcription-replication conflicts by Boubakri et 
al. (70), Rep, was not identified in the transposon screen above, but could have been 
missed since the screen was not saturating. Rep is of particular interest because it was 
recently shown to play a major role in minimizing replication pausing at sites of bound  
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protein, particularly transcription complexes, presumably by displacing the (non-
covalently) bound protein (95). In the microtiter plate liquid growth assay, rep cells 
showed slight resistance to aza-C treatment (Figure 5 and Figure 7), however spot tests 
of rep cells on solid media showed no change in aza-C sensitivity compared to the wild 
type (Figure 8). The slight resistance in the microtiter plate assay could be an indirect 
effect of the relatively poor growth of the rep cells (see no-drug curves in Figure 7). 
Overall, these experiments provided no support for the model that accessory helicases 
release the transcript from DPC-stalled transcription complexes to allow access by the 
tmRNA system. 
HepA is another factor known to be involved in RNAP recycling and we 
therefore tested hepA cells for aza-C sensitivity.  Again we found that hepA cells were no 
more sensitive to aza-C than wild-type (Figure 5; perhaps even slightly resistant).  
Furthermore, treating hepA with bicyclomycin (Rho inhibitor) did not lead to sensitivity, 
arguing against redundant roles of Rho with HepA (Figure 6).  
Since no potential release factor emerged from these tests, we turned to factors 
known to stimulate elongation past blocking lesions, namely GreA, GreB, and DksA. 
Strains carrying greA or greB mutations showed no change in sensitivity to aza-C, 
implying that these factors play no role in relieving DPC-induced elongation blockage 
(Figure 5). In addition, treating greA or greB cells with bicyclomycin also did not lead to 
aza-C hypersensitivity (Figure 6). 
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Figure 7: Aza-C hypersensitivity profiles for slow growing rep and dksA strains. 
Panels A and B are representative growth curves for HK22 (WT) and rep cells containing 
pBAD-MEcoRII, and panels C and D are representative growth curves for HK22 (WT) 
and dksA cells containing pBAD-MEcoRII.  Overnight cultures were diluted to OD560 = 
each) of LB containing the indicated amounts of aza-C in 96-well plates. Cells were 
grown for 12 hours at 37°C and cell turbidity was measured every 15 minutes.  The data 
in Figures 5 and 9 for the rep and dksA cells were calculated from these growth curves. 
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Figure 8: Spot tests for aza-C resistance of rep and dnaK strains. 
HK22 dnaK and HK22 rep cells containing pBAD-MEcoRII were diluted from overnight 
culture to approximately 4 x 108 cells/ml. Ten-fold serial dilutions were generated across 
a 96-well plate and 5 μl of each dilution was spotted onto LB plates containing 5% 
arabinose and aza-C at 0, 5 or 10 µg/mL.  Plates were photographed after overnight 
incubation at 37°C.  Spot tests were conducted to either confirm resistance or to rule out 
resistance in the microtiter plates due to the slow growing nature of the mutants. 
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Under our standard sensitivity test conditions, the dksA knockout strain showed 
similar aza-C sensitivity as the wildtype (Figure 5). However, when the effect of aza-C 
was measured later in growth (when the growth rate of the no-drug control culture 
dropped to 10% of its maximal value), the dksA cells appeared modestly hypersensitive 
(Figure 9A). One caveat is that the very poor growth of the dksA mutant might somehow 
skew the sensitivity results (see the no drug curves in Figure 7).  In addition, 
overexpressing DksA from the pCA24N plasmid lead to resistance of aza-C, even when 
measured at the 50% maximum growth rate time point (Figure 9B).   
The simplest explanation for these growth results is that, under these conditions, 
DksA releases RNAP and the transcript from DPC-stalled complexes. If so, inactivation 
of DksA should decrease or eliminate SsrA tagging.  We conducted Western blots using 
a primary antibody against the degradation tag of tmRNA.  Truncated peptides that 
contain the degradation tag from tmRNA are typically degraded by proteases, including 
the ClpXP and Lon and proteases (96,97).   HK22 cells are protease proficient, so any 
tagging that is detected is the result of the proteolysis system being overwhelmed.   
However, Western blots for SsrA tagging levels (in late-growth cells) revealed 
slightly elevated levels of tagging induced by aza-C in dksA cells relative to wild-type 
cells (Figure 9C).  This result argues against a role of DksA in releasing RNA polymerase 
and the transcript. The slight increase in tagging is consistent with a speculative 
alternative model, in which DksA helps RNAP bypass the DPC lesion without removing  
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Figure 9: dksA knockouts are slightly hypersensitive to aza-C but do not have 
decreased tmRNA tagging. 
Panel A is the comparative titration curves for the HK22 dksA strain shown in Figures 5 
and 7, with the exception that the OD560 values plotted were from the time at which the 
growth rate of the no-drug culture dropped to 90% of the maximum exponential rate.  
Panel B is a comparative titration curve for cells overexpressing DksA activity.  Panel C 
is the quantitation of western blots from extracts from HK22 (WT) or dksA cells with 
pBAD-MEcoRII using polyclonal antibodies to the degradation tag of tmRNA. HK22 
cells are proficient in the protease systems, and accordingly peptide accumulation is due 
to oversaturation of those systems.  Error bars for all panels are the standard deviations 
for three independent cultures.       
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 it from the DNA, while some competing process releases the polymerase and transcript 
(see Discussion).  E. coli RNAP can transcribe through reversibly bound proteins in vitro 
(82,98,99)  and T7 RNAP can transcribe through a 44 kDa DPC in vitro, albeit with low 
frequency (100).  While these results are consistent with a novel and interesting role for 
DksA in DPC biology, we were unable to identify any function required for tmRNA 
access after transcription/translation blockage by DPC (see Discussion). 
 
Clarifications of genes identified in the aza-C hypersensitivity screen 
 As mentioned above, little is known about the exact repair mechanisms for 
DPCs, especially of bulky proteins like the EcoRII methyltransferase.  Therefore another 
goal of our lab is to identify the protein(s) responsible for DPC repair.  For the purposes 
of this dissertation we are also interested in the repair mechanism as it might shed some  
light on the fate of stalled transcription.  If a transcription complex is stalled at a DPC 
it would be logical that the RNAP must be cleared first before repair can occur simply 
due to steric clashes; however, our inability to identify a RNAP clearing protein suggests 
that other mechanisms are possible.    
The hypersensitivity screen identified 24 mutations in 16 genes which included 
genes involved in recombination, cell division, translation, tRNA modification and 
chaperone pathways (83).  Exact location for each mutant was determined and is 
summarized in Table 2 (while previous lab members isolated the listed mutants, the  
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Table 2: Summary of transposon-insertion mutants hypersensitive to DPC inducer 
aza-C 
a The 9-bp repeat was determined using a single primer that anneals within the 
transposon. Only one of the two junctions was sequenced, and we inferred the other 
junction because this transposon creates 9-bp repeats. The last nucleotide of the inferred 
repeat shows the last intact nucleotide of the gene, reading in the 5’ to 3’ direction with 
respect to the reference strand of the genome (regardless of the direction of the gene). 
 
b Positions are given with reference to MG1655 sequence accession number U00096.3, 
with the exception of the Mu genes, which are given with reference to the sequence of 
bacteriophage Mu  accession number AF083977.1. 
 
Gene 
 
9 bp repeat
a
 Last Nucleotide
b
 Function 
dinG CATTATTGT 834439 DNA helicase 
dnaJ GCCATGAAA 14260 Chaperone 
ftsK GCTTCCATC 937143 Cell division 
 CTGGCAGCC 934308  
hflC GTATTGAAG 4403912 Protease regulator 
miaA ACGCTCTTC 4388831 tRNA modification 
mnmE GGGCTAAGT 3887200 tRNA modification 
 GGCCGGGAA 3887126  
mnmG CCCATGATG 3924896 tRNA modification 
 AATCTGACC 3924521  
Mu 6 GGTAAAAGG 4732 Unknown 
Mu kil GTCTTAATG 4508 Host cell death 
Mu 9 GCATTGTAT 5759 Unknown 
recA GGTGAGAAG 2822884 Recombination 
 GGCTCATCA 2823258  
recC TCCTGGCAC 2959669 Recombination 
 GCTTTGACC 2960353  
 GGCTATGGC 2961293  
recG GGCTTATGG 3825559 Recombination 
 GTGTAGCTC 3826850  
ssrA GCTTAGAGC 2755729 tmRNA 
trmH  GCTGGGTAC 3824728 tRNA modification; 
polar effect on RecG 
uvrD GATCCACGC 3998683 DNA helicase 
 CGTCTTACC 3998092  
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identification of the exact location of some of the insertions is unique to this 
dissertation).  Insertion mutants in genes recA, recC, recG, ftsK, trmH, uvrD, and three 
different bacteriophage Mu genes were the most hypersensitive, whereas mutants in 
dinG, miaA, mnmE, and mnmG showed more modest levels of sensitivity (for sensitivity 
data on ssrA, dnaJ and hflC mutants, see (84)). 
  One trmH knockout mutant was identified in the aza-C sensitivity screen. TrmH 
is a tRNA methyltransferase, and one could speculate that TrmH is thereby important in 
the activity of tmRNA. Alternatively, insertion mutants in trmH have been shown to 
have polar effects on recG (101). Because we identified recG knockout mutants in the 
screen, the aza-C sensitivity of the trmH insertion could be due to a similar polar effect. 
To distinguish between these models, we transformed the trmH::kan cells with a plasmid 
from the Aska collection overexpressing RecG (102). The trmH::kan cells with pCA24N-
RecG were no longer hypersensitivity to aza-C (Figure 10 A).  Moreover, trmH cells that 
were made by P1 transducing from the Keio collection, which creates an in-frame 
deletion of trmH, were not hypersensitive to aza-C (Figure 10B).   We conclude that the 
trmH insertion is hypersensitive due to a polar effect on RecG expression. 
Three insertions that led to strong aza-C hypersensitivity were localized within 
bacteriophage Mu genes (kil, 6 and 9). The HK21 parental strain is not a traditional Mu 
lysogen, but it does have a dinD::lacZ fusion construct that is known to contain Mu  
 
 44 
 
 
Figure 10: trmH::kan insertion is hypersensitive due to a polar effect on RecG 
expression 
In Panel A, aza-C hypersensitivity profiles were calculated for trmH::kan mutants 
complemented with a plasmid overexpressing RecG or a vector control.  RecG activity 
relieved the hypersensitivity of the trmH::kan insertion.  In Panel B, trmH mutants were 
created using the Keio collection, creating an in-frame deletion of trmH.  Error bars for 
each panel are the standard deviation for three independent cultures. 
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prophage DNA (103,104). For other reasons, we had subjected strain JH39, the E. coli 
strain from which the dinD::lacZ fusion was moved, to next-generation sequencing 
analysis. This confirmed the presence of phage Mu DNA, and allowed us to assemble 
the complete sequence of the dinD::lacZ fusion construct (see below) (Table 3). The three 
transposon insertion mutants were in Mu genes kil, 6 and 9, with the transposon always 
in the orientation that aligns the kanamycin-resistance gene with the Mu early reading 
frames in this region. Each of the three insertion mutants could therefore presumably 
activate expression of Mu gene gam, which is only 42 bp downstream of the most distal 
transposon (the one in gene 9), by read-through transcription. Gam is normally 
transcribed as part of an early operon during Mu infection, starting at the Pe promoter 
(105,106), but would not normally be expressed in lysogens (or presumably from the 
dinD::lacZ construct) (107). The Mu Gam protein inhibits nucleases, including RecBC, by 
binding to DNA ends (108). We therefore infer that these three insertions activate Gam 
expression, essentially creating a phenocopy of a RecBC knockout mutant (Shee et al. 
(109) recently showed that Gam expression induces recBC knockout phenotypes). 
Consistent with this model, the HK22 Mu 9::kan cells are hypersensitive to both nalidixic 
acid and ciprofloxacin, well-documented phenotypes of RecBC knockout mutants 
(Figure 11). Expression of the toxic product of the Mu kil gene should not occur in any of 
the three mutants because the insertions are within or downstream of kil. 
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Figure 11: Spot test for quinolone hypersensitivity of strain with insertion in Mu 9 
Wild-type or the insertion mutant with a transposon in Mu gene 9, both containing 
pBAD-MEcoRII, were diluted from overnight culture to approximately 4 x 108 cells/ml. 
Ten-fold serial dilutions were generated across a 96-well plate and 5 μl of each dilution 
was spotted onto LB plates with no drug (left panel), ciprofloxacin (Cipro, 0.01 µg/mL, 
middle panel) or nalidixic acid (Nal, 2 µg/mL, right panel). Plates were photographed 
after overnight incubation at 37°C. 
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dinD::lacZ fusion sequence 
The sequence of the dinD::lacZ fusion was determined by deep sequencing of 
DNA from strain JH39, followed by reconstructing the genome sequence using the  
alignment program Geneious and NCBI Blast. The sequence of the fusion is summarized 
in Table 3, and can be reconstructed by accessing the sequences and positions listed in 
descending order in the Table. The order of the numbers in the “Positions” column 
represents the direction of each sequence fragment in the fusion.  
The dinD::lacZ fusion was originally created by infecting cells with the Mud(ApR, 
lac) phage and isolating strains that induced β-galactosidase activity during mitomycin 
C treatment (104,110). The Mud(ApR,lac) phage contains a temperature-sensitive 
mutation in the Mu repressor (cts62) which induces phage gene transcription at high 
temperatures, making the cells temperature sensitive for growth. Strain JH39 was 
created using the dinD1::MudI(ApRlac) fusion, but with selection for derivatives that had 
lost the temperature sensitivity and the ability of the Mu phage to transpose (104,111). 
The sequence shows an IS1 insertion in gene A of Mu, which explains the loss of 
transposition. This IS1 element has a 298-bp deletion, with an area of microhomology 
near the deletion site that may have been involved in the deletion formation. The Mu 
sequence still contains the cts62 mutation, and therefore another mutation(s) must 
suppress the temperature sensitivity. Likely candidates are: (1) the IS1 insertion in gene 
A, because IS1 (including this deletion derivative) carries a transcriptional terminator  
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Table 3: Sequence summary of the dinD::lacZ fusion construct  
Organism Accession # Features Mutations/Deviations Position 
MG1655 U00096.3   dinD   
  
3817760 -  
3818210 
Bacteriophage Mu AF083977.1     36717 - 
36670 
Bacteriophage Mu AF083977.1      36662 - 
36705   
MG1655 U00096.3   Part of trpA, all 
of trpB 
Possible C insertion at 
1316460, 1316454, 
A/T ambiguity at 
1316456 
1316464 - 
1315071 
MG1655 U00096.3   lacZ, lacY, lacA, 
cynX, cynS 
  366297 - 
359483   
Unknown     Insertion: 
TTCGCGCGCC 
  
E. coli Tn3 V00613.1   Ampicillin 
resistance 
  3571-4957   
Bacteriophage Mu AF083977.1   C19284G
a
 25884 - 
16130 
E. coli K12 mobile 
genetic element IS30
b
 
X00792.1     1221-1  
Bacteriophage Mu AF083977.1  Includes gam and 
gene 9 
  16131 - 
3183   
E. coli insertion 
sequence 1
c
 
V00609.1 
  
 IS1 variant   768-758 
E. coli insertion 
sequence 1
d
 
V00609.1 
  
 IS1 variant A/G ambiguity at 127,  
G396A, T393G, 
A304G, G301A, 
G298T, G262T 
460-1 
Bacteriophage Mu AF083977.1     3190 - 1 
MG1655 U00096.3  dinD   3818206 - 
3818584 
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(112) and the toxic Mu gene kil (also called gene 5) is downstream; and (2) the IS30 
element, which interrupts the late gene region of Mu and might thereby prevent 
expression of one or more toxic late genes. The Mu sequence in this element reveals an 
inverted repeat of 43 bp near the C end of Mu, most likely due to non-standard fusion 
formation during the transposition of the MudI(ApRlac) element into dinD or the 
fusion/deletion of Mu and trpB (the latter mutation is called ΔFI by Kenyon and Walker; 
non-standard fusion formation is described in (113)). The Mu sequence also contains a 
point mutation in gene T.    
  
Candidate approach: Functions potentially involved in DPC repair 
Because the screen proved to be non-saturating (i.e- smpB mutants are clearly 
hypersensitive to aza-C treatment yet were not identified in the screen), we also 
conducted a candidate-based screen to directly address the involvement of proteins that 
might be expected to impact survival after DPC formation. Deletion mutations in a 
variety of genes were moved, usually from the Keio knockout collection (114), into the 
HK22 background by phage P1-mediated transduction. Transductants were verified by  
PCR and the pBAD-MEcoRII plasmid was transformed into the strain in order to test 
aza-C sensitivity. 
One set of genes tested were those whose products might be expected to be 
directly involved in the repair or tolerance of DPCs or downstream DNA damage. The  
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SbcCD complex has been shown to remove proteins bound to DNA in vitro by 
introducing double strand breaks (115), and one could imagine a repair pathway similar 
to that used to trigger meiotic recombination near SPO11 complexes (116). UmuCD (also 
known as pol V) is a translesion polymerase that is expressed during the late phases of 
the SOS response (117), and perhaps base insertion opposite the DPC could be involved 
in some tolerance pathway. RecF is part of the RecFOR recombination pathway, which is 
alternative to the RecBC pathway for RecA-mediated recombination (118). RecFOR is 
important in stalled fork processing after UV damage (119,120), and aza-C-induced 
DPCs cause fork stalling (42). Knockout mutants for each of these functions expressing 
M.EcoRII displayed essentially wild-type sensitivity to aza-C in cells in the microtiter 
plate assay (Figure 12). We conclude that none of these functions play important roles, 
or if they do, there are overlapping alternative functions that can take their place 
efficiently. 
Both dnaJ and hflC knockouts are hypersensitive, raising the intriguing possibility 
that these proteins could be involved in proteolysis of the protein that is covalently 
linked to DNA (84). Since DnaJ and DnaK frequently act together (121,122), we also 
generated a dnaK knockout mutant and tested its sensitivity to aza-C. We were surprised 
to find that the dnaK mutant is somewhat resistant to aza-C treatment (Figures 8, 12 and 
13).  This implies that the dnaJ mutant sensitivity is due to a DnaJ activity that is DnaK- 
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Figure 12: Aza-C hypersensitivity of potential repair proteins. 
The indicated cells were grown and drug titration curves were calculated as in Figure 2, 
using an endpoint time of 50% of the max growth rate.  For each experiment, wild-type 
and the indicated mutant was grown in three independent cultures with the exception of 
sbcC mutants, where 6 independent cultures were grown.  Error bars are the standard 
deviation for the respective number of independent cultures. 
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Figure 13: Aza-C hypersensitivity profiles for dnaK cells 
Panels A and B are growth curves for WT and the slow growing dnaK cells, respectively.  
The growth curves in Panel B were used to calculate the drug titration curve in Figure 
12.  Panel C is the drug titration curve using the same dnaK cells and calculated similarly 
to the curves in Figure 12, with the exception that OD560 were plotted from the time at 
which the growth rate of the no-drug culture dropped to 90% of the earlier exponential 
rate.   
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independent, and perhaps DnaK normally sequesters DnaJ and reduces its ability to 
function in a DPC-relevant pathway (also see Discussion).  
 
2.3 Discussion 
The data presented here expands upon our previously proposed “chain-
reaction” model during DPC formation in which RNA polymerase is blocked by the 
DPC, and then translating ribosomes on the attached nascent transcript are blocked by 
the stalled polymerase and potentially backed up in an array of stalled ribosomes 
behind the RNA polymerase. We have shown here that the tmRNA system functions to 
aid in cell survival by clearing the stalled ribosomes.  Another question that we address 
is how tmRNA is able to access the empty A-site on the ribosome for the trans-
translation process. Presumably, either the RNA at the A-site is cleaved to release the 
ribosome-RNA (5’ end) complex from the stalled RNA polymerase-RNA (3’ end) 
complex, or the RNA polymerase and nascent RNA are released first, allowing 
translation to proceed to the premature end of the transcript. A-site cleavage normally 
occurs by a two-step pathway when ribosomes are stalled in the middle of a transcript, 
such as at rare codons (89,90,123,124). First, RNase II 3’-5’ exonuclease activity is 
required to degrade the message to the leading edge of the ribosome (although the 3’ 
end would be blocked in the case of a DPC-stalled transcription complex).  This 
degradation then facilitates a second nuclease activity, presumably by the ribosome 
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itself. We found that knockout of RNase II, RNase D, RNase PH, or RNase LS did not 
cause hypersensitivity to aza-C, arguing against the A-site cleavage model for tmRNA 
function after DPC formation.   
The second model proposes that RNA polymerase and nascent transcript are 
released by some active process, to license tmRNA action on the released transcript. 
Presumably, release and reutilization of RNA polymerase would be important even if 
tmRNA gains access to the transcript through A-site cleavage, so the fate of the RNA 
polymerase is relevant in any case. In vitro studies have shown that RNA polymerase is 
blocked by aza-C-induced DPCs (43), and also that RNA polymerase blocked by a 
tightly bound non-cleaving mutant EcoRI endonuclease is stable for up to 1 hour (75). 
These results imply that release of RNA polymerase requires some additional release 
factor(s) whose identity remains obscure.  
A well-studied mechanism for releasing RNA polymerase complexes blocked by 
certain obstructions in the template DNA involves the Mfd helicase (66,125).  However, 
our lab previously found mfd mutants were not hypersensitive to aza-C, suggesting that 
Mfd is not involved in releasing transcription complexes blocked by DPCs (84).  
We also tested for the possible involvement of transcription termination factor 
Rho by asking whether the Rho inhibitor bicyclomycin acts in a synergistic fashion with 
aza-C. We found no evidence for any drug interaction, arguing against Rho 
involvement. Interestingly, Rho induces termination and release of RNA polymerase 
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blocked in vitro by a tightly bound protein (75).  In that case, however, the nascent RNA 
was not bound by ribosomes, which are known to inhibit Rho action (3).  In summary, 
neither Mfd nor Rho appears to play an important role in surviving transcriptional 
blockage by aza-C induced DPCs.  
In the aza-C hypersensitivity screen conducted previously, we found that 
mutational inactivation of helicase DinG or UvrD causes hypersensitivity to aza-C-
induced DPCs, while inactivation of Rep does not (Figures 2, 4, and 5).  While dinG and 
uvrD mutants are hypersensitive, the amount of DPC-induced SsrA tagging was not 
reduced in these mutants. Therefore, DinG and UvrD do not appear to be necessary to 
release the nascent transcript to allow tmRNA action (unless they have overlapping 
roles, but note that single mutants are hypersensitive). It remains possible that DinG 
and/or UvrD releases stalled RNA polymerase at a DPC, but that this step is not needed 
for tmRNA action. 
HepA (RapA), a member of the SWI/SNF superfamily of helicase-like proteins, is 
an RNA polymerase binding protein that allows recycling of the polymerase at poorly 
characterized post-transcription/post-termination complexes that form in vitro (76,126). 
Given its recycling function, HepA presented as a candidate for releasing RNA 
polymerase and the nascent transcript from the DPC-blocked complexes. However, a 
HepA knockout strain was found to be no more sensitive to DPC formation than wild 
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type cells (Figure 2), even with concomitant inhibition of Rho activity (Figure 3), arguing 
against an involvement of HepA. 
E. coli RNAP can transcribe through reversibly bound proteins in vitro (82,99), 
and T7 RNAP can transcribe through a DPC in vitro, albeit with low frequency and in a 
mutagenic fashion (127). We were therefore interested in the possible role of factors that 
might promote polymerase read-through at blocking lesions. Transcription factors 
GreA, GreB and DksA interact with the secondary channel of RNA polymerase, and 
have been shown to decrease pausing and to stimulate elongation past a lesion or 
protein roadblock (80,82,128). We found that greA and greB mutants are no more 
sensitive to DPC formation than wild type cells, even when termination is decreased by 
decreasing Rho activity (Figures 2 and 3).   
The one transcription factor that we did find to be somewhat protective against 
aza-C-induced DPCs is DksA, but only when measured late in growth (Figures 2, 4, and 
6). DksA modulates transcription elongation outside of its transcription initiation roles, 
although the specific mechanism is not well defined. Perhaps most relevant to the 
present study, it has been proposed that DksA prevents transcription-replication 
conflicts by destabilizing paused transcriptional elongation complexes (73,81).  This 
factor does not appear to be important in releasing nascent transcripts from the DPC-
stalled complex for tmRNA action, because the knockout strain had increased rather 
than decreased SsrA tagging (Figure 6). The increased tagging observed in the DksA 
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knockout mutant suggests that DksA activity might instead be in competition with the 
factor(s) responsible for creating the substrates for the tmRNA system. One intriguing 
possibility is that DksA promotes transcription through DPCs, allowing bypass of the 
lesion when it is located on the template and/or the non-template strand. 
We have also considered the possibility that RNAP release and DPC repair are 
somewhat coupled, and have attempted to identify the repair pathway(s) for DPCs.  
This work has expanded on the aza-C hypersensitivity screen by identifying the exact 
positions of each of the transposon insertion sites, including those in the Mu transposon.  
In order to best understand the placement of Mu DNA in HK22, as well as to have a 
better understanding of the commonly used dinD::lacZ fusion, we also compiled the 
dinD:lacZ fusion sequence in its entirety.   
In addition to the aza-C hypersensitivity screen we sought to test other candidate 
mutants that might be expected to impact survival after DPC formation.  Several of the 
genes identified from the transposon screen were previously implicated in genome 
stability, including the genes that encode recombination proteins RecA, RecC and RecG 
(Table 1). These proteins could play a direct role in resolving DPCs, or alternatively, they 
could be involved in repairing DNA ends that are secondary effects of DPCs (e.g. breaks 
generated at stalled replication forks; see (42,129,130)). Even though aza-C-induced 
DPCs lead to fork stalling, we detected little or no effect on aza-C sensitivity from 
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knocking out the RecF protein, which plays a key role in the consequences of fork 
stalling from UV-induced lesions (119,120). 
On the other hand, recombination proteins could potentially play a more direct 
role in DPC repair. An attractive model is provided by the pathway of meiotic 
recombination, where Mre11/Rad50 complex cleaves DNA near an SPO11-DNA 
covalent complex to initiate a double-strand break repair event (116). This pathway was 
also implicated in repair of topoisomerase cleavage complexes (116). The homolog of the 
Mre11/Rad50 complex in E. coli is SbcCD, although the role of this protein is quite 
distinct from that of Mre11/Rad50 (131,132). Strikingly, SbcCD can cleave DNA in vitro 
near proteins that are very tightly bound to the end (115), and so we asked whether 
SbcCD might be involved in repair of DPCs. However, we found no change in aza-C 
sensitivity in a SbcC knockout mutant, strongly arguing against this possibility.  
DnaJ functions as a co-chaperone to the E. coli Hsp70 protein DnaK but also has 
DnaK-independent activities (121,122). To further explore the role of DnaJ in aza-C 
sensitivity, we also generated and tested a dnaK knockout mutant. The dnaK mutant 
turned out to be modestly resistant to aza-C treatment (Figure 3D and Supplemental 
Figure 4A). This indicates that the role of DnaJ in aza-C sensitivity is DnaK-independent, 
and perhaps also that DnaK can sequester DnaJ and reduce its ability to function in a 
DPC-relevant pathway. A different interpretation is that dnaK mutants overproduce heat 
shock proteins (133), and perhaps one or more heat shock proteins assist in survival after 
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aza-C. In general, given the broad roles of HflC, DnaJ and DnaK in protein metabolism, 
it will be important to decipher whether aza-C sensitivity is modulated by direct or 
indirect effects. 
In summary, our studies have identified DksA as a potential factor that assists 
transcription elongation during DPC formation, presumably by aiding in transcription 
past a lesion on the non-template strand.  The factors DinG and UvrD are also important 
factors for protection against DPCs, and these proteins might be involved in releasing 
stalled RNA polymerase.   We provided evidence against involvement of several 
RNases, Rep, Mfd, Rho, GreAB and HepA in any pathway that is protective against aza-
C-induced DPCs.  We have yet to discover pathway by which the tmRNA system gains 
access to ribosomes within DPC-stalled transcription/translation complexes, further 
emphasizing the knowledge gap that exisits for tmRNA biology. 
 
2.4 Materials and Methods 
Materials 
Aza-C was obtained from Sigma-Aldrich, nitrocellulose membranes (Protran® 
BA 85) from Whatman, and polyclonal M.EcoRII antibody from Proteintech Group, Inc 
(custom generated). LB broth contained Bacto tryptone (10 g/L), yeast extract (5 g/L) and 
sodium chloride (10 g/L), supplemented with the appropriate antibiotics. Antibodies 
against the SsrA tag was kindly provided by Tania Baker (MIT). 
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E. coli strains 
HK21 is a derivative of strain ER1793 (obtained from New England Biolabs) and 
has the following genotype: F- fhuA2 Δ(lacZ)r1 glnV44 e14-(McrA-) trp-31 his-1 rpsL104 
xyl-7 mtl-2 metB1 Δ(mcrC-mrr)114::IS10) ΔsulA (Keio deletion) dinD::lacZ. Western blots 
were done using the HK22 strain (84). E. coli strains for the candidate gene approaches 
were constructed by P1 transduction of deletions from the Keio collection (114) into 
strain HK22 (same as HK21 except lacking the dinD::lacZ fusion), selecting for the 
kanamycin resistance marker inserted at the Keio deletion site. Plasmid pBAD-MEcoRII 
was then transformed into each strain following confirmation of the gene knockout. 
Plasmids 
Plasmid pBAD-MEcoRII was used to express M.EcoRII(84).  This plasmid is a 
pBAD33 derivative (98) which carries chloramphenicol resistance and the M.EcoRII 
coding sequence under control of an arabinose-inducible promoter. Expression of 
M.EcoRII from this plasmid is repressed with glucose (0.2%) and activated with 
arabinose (0.05%).   Plasmid pR234 is a pKK223-3 derived plasmid with the M.EcoRII 
gene controlled by a Ptac promoter (87).  Plasmid pRK1, a vector control for pR234, was 
constructed by cleaving pR234 with BamH1 and religating, which removes the entire 
M.EcoRII coding sequence.  pCA24N-recG is from the ASKA collection of E. coli ORF 
without the GFP or His tag (102).  RecG is expressed from the PT5-lac promoter that can be 
activated by IPTG.   
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Growth kinetics for aza-C sensitivity 
Aza-C sensitivity was measured with continuous growth curves in a 
temperature-controlled ELx808™ Absorbance Microplate Reader. Overnight cultures in 
LB media at 37°C were diluted to an OD630 of 0.5, diluted 1:2000 in LB with 
chloramphenicol and 0.05% arabinose, and then mixed with an equal volume (75 l 
each) of LB containing serial dilutions of aza-C (15 g/ml) in 96-well plates. The cells 
were grown in the plate reader at 37°C with constant shaking, and OD630 was measured 
every 15 minutes for 18 hours. 
Western blots for SsrA tagging 
SsrA tagging levels were analyzed in mutant derivatives of the HK22 pBAD-
M.EcoRII strain background. Cells were pregrown overnight in LB media at 37°C in the 
presence of 0.2% glucose, and then diluted to an OD560 of 0.1. The cells were then grown 
to an OD560 of 0.5 in the same media, with or without aza-C (50 g/ml). Cells were then 
harvested by centrifugation, washed once with LB, and finally resuspended in LB 
containing arabinose (0.05%) to induce M.EcoRII expression. After one hour at 37°C with 
shaking, cell samples equivalent to 2 ml of OD560 = 0.5 were harvested, incubated in an 
ethanol/dry ice bath for at least 15 minutes, and then stored at -20°C. 
Frozen cell pellets were thawed at room temperature and resuspended in 25 l of 
water and 25 l of sample buffer (20% glycerol, 100 mM Tris pH 6.8, 2% SDS, 2% β-
mercaptoethanol, and bromophenol blue), and boiled for 5 min in a water bath. An 
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aliquot (15 l) of each sample was loaded onto a 7.5% polyacrylamide (Tris-HCl) gel and 
run for approximately 2 h in 25 mM Tris-Glycine buffer containing SDS (0.1%). The 
portion of the gel containing proteins larger than about 75 kDa was cut off and stained 
with Coomassie blue dye to serve as a loading control. The remaining portion of the gel 
was transferred to a nitrocellulose membrane for 60 min at 12 V using a Genie Blotter 
transfer device (Idea Scientific Co.). The blot was blocked for 1 h in 20% non-fat milk 
powder solution (Biorad) in Tris-buffered saline (TBS). The membrane was incubated 
overnight at 4°C with polyclonal ssrA primary antibody and Tween (0.1%), and then 
washed three times with TBS buffer at room temperature (10 min each). The membrane 
was incubated with secondary antibody (IRDye 800CW-conjugated goat anti-rabbit IgG 
(LI-COR®)) for 1 hour, and the washes were repeated. After air-drying, the membrane 
was scanned on an Odyssey Imaging System (LI-COR Biosciences), and quantified using 
the Odyssey software. 
Spot tests for aza-C and quinolone sensitivity 
Overnight cell cultures in LB (plus chloramphenicol) were diluted to roughly 4 x 
108 cell/ml. Ten-fold serial dilutions were then generated across a microtitre plate and 5 
µl of each dilution was spotted onto LB plates with appropriate antibiotics and the 
indicated aza-C, ciprofloxacin, or nalidixic acid concentration. The plates were incubated 
overnight at 37°C. 
 
 63 
3. Examining the mechanisms of elongation inhibition 
for Actinomycin D and Streptolydigin 
The work for the Actinomycin D portion of this chapter was assisted by Ramsey 
Al-Khalil, an undergraduate researcher in our lab. 
3.1 Introduction 
In the previous Chapter, we found that the biology at the sites of DPCs is quite 
complex, with various factors competeing to assist with the stalled replication, 
transcription, and translation, as well as the repair of the DPC.   Therefore, an alternative 
approach was necessary to specifically isolate the effect on transcription.  For the 
purposes of these studies we chose Streptolydigin and Actinomycin D.  However, the 
precise mechanisms of inhibition by these two inhibitors are not fully understood, and 
therefore in this Chapter we address some of the uncertainties that could complicate the 
study of transcription.  
Streptolydigin is a transcription elongation inhibitor that inhibits RNA chain 
elongation (57-59).  Stl binds directly to RNAP, interacting with both the β and β’ 
subunits to stabilize the straight-bridge-helix RNAP-active-center conformational state 
(60,61).  This stabilization prevents normal conformational changes necessary for 
translocation of the growing nascent chain (60,61).  Stl binding does not appear to alter 
nucleotide binding to RNAP, phosphodiester bond formation, or DNA translocation 
(61).  Elongation complexes stalled by Stl are very stable in vitro; complexes are still 
bound to DNA after 50 minutes of high Streptolydigin treatment, and removal of Stl 
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results in resumption of transcription after a delay in vitro (59).  However, the stability 
and duration of Stl-RNAP interactions in vivo is uncertain, as are the specific 
requirements for Stl binding to RNAP.  
We are also interested in the fate of elongation complexes stalled by the 
eukaryotic transcription inhibitor Actinomycin D.  ActD is a small molecule with 
antibiotic and anticancer capabilities (62,63).  It is primarily known as a DNA 
intercalator, with the ability to intercalate into double stranded DNA, bind to single-
stranded DNA, and hemi-intercalate into single stranded DNA.  It is hypothesized that 
ActD binds to the distorted DNA at the ends of the transcription bubble, preventing 
RNAP elongation, but the exact mechanism of this inhibition is unknown (63).  For 
instance, it remains to be answered whether ActD impedes RNAP translocation simply 
due to DNA intercalation, or if it directly interacts with RNAP as well as DNA.   
In this Chapter, we address several of the questions surrounding elongation 
inhibition by Stl and ActD.  These topics include the stability of RNAP-Stl interactions, 
the effect of pausing frequency on the effectiveness of the inhibitors, and the potential 
for ActD-RNAP interactions.  We will show that Stl binding is transient, and that 
pausing frequency directly correlates with both Stl and ActD efficiency.  We isolate 
several RNAP mutants that are resistant to ActD treatment and propose that the method 
of RNAP inhibition by ActD is more than just simple steric hindrance due to DNA 
intercalation. 
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 3.2 Results 
Sensitizing E. coli cells to Streptolydigin and Actinomycin D  
E. coli cells are resistant to both Actinomycin D and Streptolydigin and require 
modifications to the cell membrane to become sensitive.  TolC is an outer membrane 
porin that is the outer membrane component of several multi-drug efflux systems; tolC 
mutations in E. coli cause susceptibility to a variety of antibiotics, including 
Streptolydigin (60).  For our Stl studies we primarily used EW1b cells, which are known 
to have a disruption in the tolC gene.  When EW1b cells were first isolated it was 
thought that there was a deletion in the tolC gene , as no revertants were found by the 
author (134).  However, PCR of the tolC gene in EW1b cells shows a 1 kb increase in size 
compared to the wildtype tolC sequence, leading us to believe the disruption was an 
insertion.  In order to identify this insertion, we sequenced the full tolC gene in EW1b 
and found that there is an IS5 insertion 191 bp into the tolC gene in EW1b cells. 
To make E. coli  sensitive to ActD, we first attempted to treat cells with EDTA in 
a checkerboard assay similar to the bicyclomyin/aza-C double-drug assay used in 
Chapter 2, as sub-inhibitory levels of EDTA increases susceptibility to ActD (135).  We 
were successful in making E.coli sensitive to ActD; however, cell growth was 
inconsistent using this method and results were thus hard to interpret.  To establish a 
more controlled assay system, we began testing gene knockouts that could also modify 
the cell susceptibility to antibiotics.  We first tested MG1655 tolC cells for ActD 
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sensitivity; however, these cells proved to be as resistant as MG1655 cells.  
Communication with Dr. Meta Kuehn led us to test pal and mrcB mutants, as these had 
been shown in her lab to be sensitive to ActD treatment.  Pal is a peptidoglycan-
associated lipoprotein that is a part of the Tol/Pal system, which functions to maintain 
cell envelope integrity.  MrcB is an inner membrane enzyme catalyzing the 
transglycosylation and transpeptidation of peptidoglycan precursors; accordingly, MrcB 
mutants have decreased peptidoglycan layer density leading to hypersensitivity to 
certain antibiotics.  Growth sensitivity tests with MG1655 pal and MG1655 mrcB cells 
confirmed that these cells are sensitive to ActD (Figure 14).  MG1655 mrcB cells grew 
more consistently in our ActD sensitivity tests conducted in the microtiter plates across 
several assays on different days, and MG1655 pal cells were four-fold more sensitive in 
solid plate assays (where much greater volumes of ActD are needed).  Therefore both 
cells lines were utilized where technically advantageous.  
 
Stl does not cause replication-transcription collisions, consistent with transient 
pausing of RNAP 
It has been shown that washing out Stl in in vitro studies results in resumption of 
elongation, implying that Stl only transiently binds to RNAP (59).  We wanted to 
confirm that this is true for in vivo RNAP-Stl interactions.  To do so, we employed the 
method of Tehranchi et al. in using SOS induction as an indicator for transcription arrest.   
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Figure 14: MG1655 pal and mrcB mutants are sensitive to Actinomycin D 
Panel A is a representative drug response curve for MG1655 cells,  which are not 
sensitive to ActD treatment.  In Panel B, MG1655 pal and mrcB mutants were tested for 
ActD sensitivity using the same method.  Deletions of both pal and mrcB make the 
membrane more permeable and allow ActD to penetrate the cells.  Error bars are the 
standard deviation for three independent cultures. 
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They used serine hydroxamate (SHX), which causes amino acid starvation and 
subsequent translation and transcription arrest, to examine the effect of DksA activity on 
transcription and replication.  They found that removing DksA during SHX treatment 
led to replication-transcription collisions.  These collisions resulted in DNA damage that 
induced the SOS response (81).  If Stl is forming a permanent or stable interaction with 
RNAP, it should also result in replication-transcription collisions and downstream SOS 
induction.  However, if the pausing is only transient, there is most likely enough time 
for replication to resume before fork collapse.  In this scenario there would be no 
induction of the SOS response.   
To test for SOS induction during Stl treatment we performed quantitative RecA 
western blots on cells treated with Stl.  As shown in Figure 15, we found no increase in 
RecA levels during Stl treatment (Mfd results are addressed in Chapter 4).  This strongly 
suggests that Stl binding is transient in vivo. 
 
In vitro elongation reactions stalled by Stl and ActD 
The effect of adding Stl and ActD to elongation complexes in vitro have been 
studied before, yet these systems always employed total genomic DNA as a substrate.  
We wanted to monitor the effect of these drugs on transcription in cleaner system using 
a carefully controlled PCR product as a DNA template.  We used a PCR fragment from 
the pDE13 plasmid which contains a transcript with a λPR  promoter and tR2 terminator   
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Figure 15: Stl treatment does not induce the SOS response 
EW1b or EW1b mfd cells were grown in LB with or without Stl treatment as described in 
Materials and Methods.  A standard curve of RecA protein was run on the same gel with 
the samples for accurate quantitation.  RecA amounts for each sample were calculated 
by equating band intensity with a RecA amount, then adjusting for starting cell 
concentration and sample dilution (calculated from the BCA quantitation) to give RecA 
levels/OD/mL.  Three repetitions for each sample were measured, and the error bars 
reflect the standard deviation of these samples.   
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(136).  Transcription from this template in the absence of CTP allows for a stalled 
elongation complex at +24.  The general protocol was to make open complexes by 
mixing DNA and RNAP in transcription buffer and preincubating at 37 °C.  Then 
heparin and ATP, CTP and radioactive GTP in buffer were added at low levels to have 
one RNAP stalled at +24 per DNA molecule.  All 4 nucleotides were added at saturating 
levels to allow for full length product formation from complexes not inhibited by the 
respective drugs.   
Surprisingly, the addition of Stl did not lead to any inhibition of RNAP (Figure 
16A), even at levels of Stl that were able to completely block transcription in vitro using 
coliphage T4 DNA as a substrate (59).   Several attempts at troubleshooting the system 
were made, such as omitting Mfd buffer (which has fairly high glycerol content), adding 
more Stl, room temperature vs 37 °C, using less ATP, and omitting heparin.  Under 
every condition tested Stl failed to inhibit RNAP.  We propose that Stl is unable to bind 
to rapidly elongating RNAP, and instead must wait for RNAP to pause or otherwise be 
held in the “open” conformation due to structural considerations (See Discussion).  
We next attempted similar tests in vitro with Actinomycin D.  Unlike Stl, ActD 
efficiently inhibited elongation in our system.  As shown in Figure 16B, ActD inhibited 
nearly all full length transcript production at 0.8 µM.  Instead, a new band appears at 
roughly +50, indicating strong ActD inhibition of transcription at this location.  In the  
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Figure 16: In vitro elongation assays with inhibitor treatment 
Panel A is an in vitro assay monitoring the effect of Stl and Mfd treatment.  Transcription 
was carried out using radioactive GTP, which allows for visualization of resulting 
RNAP products.   FL= Full length product, + 24= Complex stalled or released at +24 on th 
transcript. Number list on the side of the gel indicates the amount of Stl added to each 
sample.  400 nM Mfd was added where indicated.  In Panel B, in vitro reactions testing 
the ability of ActD to stall elongation complexes were conducted.  FL= Full length 
product, +50= Complex stalled or released at +50, + 24= Complex stalled or released at 
+24.  Numbered list on the side of the gel indicates the amount of ActD added to each 
sample. 
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pDE13 template there is a GCGC at position +53, which would be expected to be a 
strong ActD binding site due to increased hydrogen bonding (64) and would explain the 
band at +50.  Other GC pairs exist in the template which could lead to the faint bands 
seen in the lanes.   
We were surprised to find that there is a very tight window for the titration of 
ActD.   In Figure 16B, full length production was essentially unaffected at 0.16 µM (the 
next lowest level tested), and additional assays have shown that full length transcript 
levels at 0.67 µM are roughly the same as untreated reactions.  It has been shown that 
ActD has very slow on- and off- rates of binding, and the tight titration window is 
consistent with the idea that once ActD binds to DNA its inhibition of RNAP is very 
stable.    
 
Modulating RNAP speed affects cell sensitivity to Stl 
If Stl binding requires RNAP to be paused or otherwise held in an open 
conformation, it stands to reason that altering the pausing frequency of polymerase  
could potentially alter a particular mutant’s sensitivity to Stl.  It has been well 
documented that many Rifampicin resistant RNAP mutants have altered termination 
and pausing activities (137-139).  Specifically, Fischer and Yanofsky showed that the 
RpoB2 mutant has decreased termination and pausing activities, resulting in an overall 
 73 
increase in transcription elongation rate.  Conversely, the RpoB8 mutant has increased 
pausing and termination, resulting in an slower elongation rate (137).  We decided to 
utilize the properties of these two mutants and test for changes in Stl sensitivity.  As 
shown in Figure 17A, the EW1b rpoB8 mutants were markedly hypersensitive to Stl 
treatment, while the EW1b rpoB2 mutants were slightly resistant.   
We made MG1655 mrcB rpoB8 and rpoB3595 double mutants to test if altering 
RNAP pausing frequency also affects sensitivity to Actinomycin D.  RpoB3595 is a “fast” 
(less pausing, faster rate of elongation) polymerase with properties similar to RpoB2 
(140).  MG1655 mrcB rpoB8 mutants were no more sensitive to ActD than wildtype, 
however the MG1655 mrcB rpoB3595 mutants were very resistant to ActD treatment 
(Figure 17B).  All rpoB mutants were confirmed with sequencing.  The extreme level of 
ActD resistance caused by the rpoB3595 mutation could possibly indicate that this 
mutant is capable of causing structural rearrangements that prevent ActD from 
inhibiting RNAP (see Discussion).  These results confirm that the pausing frequency of 
the polymerase can affect sensitivity to elongation inhibitors.   
 
Testing Rifampicin-resistant mutants for ActD sensitivity 
Given that there has been no evidence for direct RNAP-ActD interactions, we 
were surprised to find that modulations in RNAP can lead to ActD resistance.  We 
therefore screened additional rifampicin-resistant mutants for their effects on ActD  
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Figure 17: Drug sensitivity profiles for RNAP mutants with altered pausing 
frequencies 
Hypersensitivity profiles for RNAP mutants with altered transcription properties were 
conducted as in Figure 2.  In Panel A, RNAP mutants with point mutations in RpoB 
were tested for Stl sensitivity.  EW1b rpoB8 mutants are known to as “slow” 
polymerases, while EW1b rpoB2 mutants are known to be “fast” polymerases.  In Panel 
B, MG1655 mrcB rpoB8 and MG1655 mrcB rpoB3595 mutants were tested for ActD 
sensitivity.  RpoB3595 is another “fast” polymerase mutant with similar properties as 
RpoB2.  Error bars represent the standard deviation for three independent cultures. 
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sensitivity.  MG1655 mrcB cells were plated on plates containing rifampicin, and 40 
independent colonies were tested for ActD sensitivity.  Each mutant was tested with our 
standard growth assay, and mutants with potential resistance were restruck and 
screened a second time.  Those that passed both tests were sequenced and triplicates 
were tested in our quantitative assay (Table 4a and Figure 18 A-C).  20 of the 40 mutants 
were also sequenced regardless of sensitivity to get a rough sample of the mutations that 
do not lead to resistance (Table 4b).  Out of the 40 mutants, we found 8 mutations in 6 
positions that resulted in ActD resistance when tested in triplicate, and no mutants that 
were hypersensitive.  Some of the mutants (including S574Y and Q148L) were isolated 
multiple times.  The location of the mutations in the folded protein was determined by 
aligning the E.coli RNAP protein sequence with the T. aquaticus sequence and mapping 
the mutations to the crystal structure of T. aquaticus RNAP complexed with rifampicin.   
The mutations were located fairly evenly around the Rif binding pocket (Figure 19).  One 
of the mutants, RifR22, clearly showed ActD resistance, yet grew inconsistently and did 
not show any mutation in the two typical locations of Rif-resistant mutations in rpoB or 
in all of rpoC. 
 
Isolating ActD resistant mutants 
 We were also interested in identifying other RNAP mutations that lead to ActD 
resistance outside of the Rif binding pocket.  Identification of additional mutations could 
shed light on the interactions between RNAP-ActD and further characterize the  
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Figure 18: Identifying Actinomycin D-resistant mutants 
In Panel A-C, the ActD sensitivity profiles for rifampicin-resistant mutants that are also 
ActD-resistant are shown.  The mutants are listed by the mutation that leads to 
rifampicin and ActD resistance.  Error bars are representative of the standard deviation 
for 3 independent cultures.  In Panel D, six MG1655 pal ActD resistant mutants were 
tested for Sytox green incorporation.  Wildtype MG1655 and MG1655 pal cells were 
included for comparison.  Fluorometer reading is the average of two readings for the 
same sample. 
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Table 4a: RpoB mutations that lead to ActD resistance 
Mutant # Mutation 
Carol Gross 
Nomenclature (140) 
2 S574F   
5 I572F RpoB7 
18 D516G   
19 S512Y   
22 unknown   
21 S574Y   
26 S574Ya   
27 Q148L   
28 Q148La   
30 H526Y RpoB2 
32 Q148L   
37 S574Fa   
39 G534C   
 
a These mutants passed the first round of screening, but were not tested in triplicate due 
to redundancy 
 
Table 4b: RpoB mutations that do not lead to ActD resistance 
Mutant # Mutation Carol Gross Name 
1 L511P    
23 Q513L RpoB101 
24 T563P RpoB3370 
33 D516N RpoB113 
34 I572T   
36 S574Yb   
38 H526Q   
40 S531F RpoB 114 
 
b This mutant passed the first round of screening but failed in the second 
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Figure 19: KiNG image of RNAP complexed with Rifampicin 
This figure is a KiNG stereoimage of RNAP complexed with Rifampicin showing the 
position of the mutations that lead to ActD resistance.  The RNAP backbone is shown in 
grey, the sidechains are shown in blue, the sidechains that are mutated in ActD resistant 
cells are shown in yellow, and rifampicin is shown in pink. 
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mechanism of ActD inhibition of elongation.  We plated dilutions of MG1655 pal cells on 
both LB and ActD (25 µg/mL) to isolate ActD resistant colonies, and found a mutation 
frequency of 9.85 x 10-6.  However, when we sequenced both the rpoB and rpoC genes in 
several of the ActD resistant mutants, we found no mutations in either gene. 
Given the high mutational frequency, we were concerned that ActD might itself 
be a mutagen.  We took MG1655 pal cells that were either untreated, treated with 50 
µg/mL ActD, or treated with 100 µg/mL ActD for 15 or 30 minutes and plated them on 
Rifampicin plates to compare mutational frequencies.  The relative (drug/no drug) 
mutational frequencies were 0.5 and 0.6 for the 15 minute and 30 minute samples 
respectively for the 50 µg/mL ActD treated cells, and 1 and 0.4 for the 15 minute and 30 
minute samples for the 100 µg/mL ActD treated cells.  These results show ActD-induced 
mutagenesis is not the cause of the high frequency of ActD resistant cells.   
Another model for the high number of ActD resistant cells is that there is a 
secondary mutation that is overcoming the pal mutation, which would restore the 
integrity of the cell membrane and prevent uptake of the drug.  Sytox Green 
(Lifetechnologies) fluoresces when it intercalates into DNA, and cannot enter cells with 
intact membranes.  To measure Sytox incorporation, we spun down overnights of six 
different ActD-resistant colonies, and MG1655 negative control, and a MG1655 pal 
control, resuspended in Tris-HCl, and treated with Sytox for 5 min in the dark.  
Fluorescence was measured with an excitation of 500 nm and an emission of 550 nm.  As 
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shown in Figure 18D, fluorescence levels for each of the 6 mutants were much closer to 
MG1655 pal levels than MG1655, implying the membranes are still compromised.  
However, the possibility still exists that another mutation, such as one that increases the 
activity of a drug exporter, is modifying cell sensitivity to ActD in a way that does not 
explain the molecular mechanism of ActD inhibition on transcription. 
 
 3.3 Discussion 
The antibiotics Streptolydigin and Actinomycin D are widely known for their 
ability to stall transcription elongation complexes.  However, several key questions 
remain about the mechanism of their inhibition which are addressed in this chapter.  
Wildtype E. coli is resistant to both Stl and ActD, requiring modifications to be made to 
the cells for study in this host system.  For our Stl studies we use the cell line EW1b, which 
has an insertion in the tolC gene and is therefore deficient in the efflux pump that 
normally pumps out Stl.  For ActD studies, we found that deleting pal and mrcB in 
MG1655 cells makes the membrane more permeable to the drug. 
The ability to remove Stl and resume elongation in in vitro studies implies that 
the binding is transient, but this has yet to be shown in vivo (59).  One way to monitor 
the length of elongation stalling is the identification of replication-transcription 
collisions.  Replication-transcription collisions can occur in healthy cells, as the 
replication machinery travels over 10 times faster than transcription.  While co-
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directional collisions do not impede replication, head-on collisions and those with 
stalled complexes lead to replication fork collapse, induction of the SOS damage 
response pathway, and cell death (38,39,70,81,141).  Therefore, we tested cells treated 
with Stl for SOS induction using RecA western blots and found no changes in RecA 
levels with Stl treatment, supporting the model of transient Stl binding. 
We also examined elongation inhibition of both drugs in vitro.   In the Stl in vitro 
studies, Stl failed to inhibit RNAP at all levels tested, including those well above levels 
shown previously to inhibit RNAP in vitro when the substrate was coliphage T4 DNA.  
We believe that in our system transcription is too rapid to allow for Stl binding; 
presumably RNAP needs to be held in an “open” conformation for some period of time 
to allow for Stl binding.  Stl binds near the active site in the center of the “crab claw” of 
RNAP.  For this to occur, Stl most likely enters through the secondary channel, which is 
only accessible while RNAP is held in an open conformation.  Rapidly elongating RNAP 
would only be in an “open” conformation for a very short period of time during the 
nucleotide addition cycle, while paused and backtracked complexes are held in the open 
conformation (Dr. Dorthy Erie, personal communication).  A similar mechanism was 
shown for GreA activity, which is able to reactivate RNAP when it is kinetically trapped 
in an inactive [open] conformation (136).  
In the ActD in vitro studies, 0.8 µM ActD was sufficient for nearly complete 
RNAP inhibition.  However, we found that the titration window for ActD is very tight, 
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as ActD at 0.67 µM hardly impeded transcription.  The ActD-DNA interaction, in 
particular with undistorted DNA, is quite slow to reverse (62); perhaps under our 
conditions once ActD is present at high enough levels the binding is essentially 
irreversible.  Accordingly, we have been unable thus far to create conditions that allow 
for the resumption of elongation after initial ActD inhibition.  Further studies will be 
necessary to be able to test Mfd release of RNAP stalled by either inhibitor in vitro. 
Given our proposal that Stl binding requires RNAP to be held in an open 
conformation, such as at a pause site, we hypothesized that altering the pausing 
frequency of RNAP could affect Stl and ActD sensitivity.  We looked at RNAP mutants 
known to have altered elongation properties and showed that the increased pausing 
frequency can cause hypersensitivity to Stl treatment, while decreased pausing 
frequency can cause resistant to both Stl and ActD.  This further supports our suspicions 
that Stl binds more efficiently to paused RNAP. 
 We also screened 40 Rif-resistant colonies to expand on the finding of a RpoB 
mutant that is resistant to ActD.  We found 8 mutations in 6 locations that lead to ActD 
resistance, further confirming the role RNAP structure can play in causing ActD 
resistance.  The extreme resistance of several of the rpoB mutants to ActD is not likely 
due to a simple decrease in pausing frequency; rather, it is more consistent with ActD 
being nearly completely unable to inhibit these RNAPs.  We hypothesize that these 
mutations cause structural rearrangements in the RNAP-DNA-ActD complex.  These 
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structural rearrangements could potentially be alterations to the DNA structure in the 
transcription bubble, as it has been proposed that ActD binds to distorted DNA at the 
ends of the transcription bubble (64).  ActD binding and release rates are increased with 
DNA distortion (62), and possibly the DNA in the transcription bubble is distorted in 
such a way that ActD does not stably bind to DNA.   
In an alternative model, if RNAP and ActD interact directly, the rpoB mutations 
could cause structural rearrangements to the ActD-RNAP interface.  This model 
resembles the inhibition mechanism of topoisomerase inhibitors, which bind to both 
specific DNA targets and the topoisomerase.  In vitro mutational studies showed that 
inhibitors are highly specific for the DNA sequences immediately flanking the cleaved 
DNA, and photocrosslinking experiments showed 3-azido-AMSA crosslinks to the base-
pairs flanking the cleaved bonds (142,143).  Additionally, mutations overlapping the 
active site in the T4 topoisomerase genes gp39 and gp52 alter sensitivity to both 
quinolones and antitumor agents, implying that these inhibitors bind to a conserved site 
in topoisomerase (144).  ActD is well-known as a DNA intercalator, yet it could also 
directly interact with RNAP near the Rif binding site.   
We set out to identify other RNAP mutants that are resistant to ActD outside the 
Rif binding site in an attempt to separate these two models.  We easily isolated ActD-
resistant mutants, and found a surprisingly high mutation frequency leading to ActD 
resistance.  While we showed that the membrane of the mutant cells were still 
 84 
compromised, the possibility still exists that these mutations are causing up-regulation 
of a transporter system that is pumping ActD back out of the cells.  This could be similar 
to the case of Stl; E. coli cells treated with EDTA presumably can uptake Stl due to a 
more permeable membrane, but the drug is pumped backed out via the TolC system.  
tolC mutants are resistant to ActD, but other export systems exist that could be 
producing the resistance phenotype.  A greater understanding of the high mutation rate 
is necessary before attempting to elucidate the mechanism of ActD inhibition by 
mutational screening. 
 
3.4 Materials and Methods 
Materials 
Luria–Bertani broth (LB) contained Bacto tryptone (10 g l-1), yeast extract (5 g l-
1), and sodium chloride (10 g l-1) and was used for all bacterial growth (with 
appropriate antibiotics for plasmid selection and the indicated additions); Nitrocellulose 
membrane (Protran® BA 85) was from Whatman; Streptolydigin was the generous gift 
of Konstantin Severinov (Waksman Institute of Microbiology) and José Salas 
(Universidad de Oviedo; Actinomycin D was ordered from Sigma; RecA antibodies 
were purchased from Abcam.  RNA polymerase was kindly provided by Dorthy Erie 
(University of Chapel Hill).   
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E. coli strains:  
EW1b [F-, lacY1 or lacZ4, tsx-64, glnV44(AS), gal-6, LAM-, hisG1(Fs), DtolC5, 
argG6, rpsL (allele 8, 104 or 17), malT1(LamR)] was obtained from the E. coli Genetic 
Stock Center (Yale University).  MG1655 [F- lambda- ilvG- rfb-50 rph-1] was obtained 
from the E. coli Genetic Stock Center (Yale University).  MG1655 and EW1B derivatives 
were constructed by phage P1-mediated transduction from the Keio collection (114).  The 
rpoB8,  rpoB2, and rpoB3595 mutants were P1 transduced from the Carol Gross collection 
(140).  Mutations were confirmed with PCR and sequencing.    
Growth kinetics for Stl and ActD sensitivity 
Overnight cultures in LB were diluted to roughly 4 * 106 cell/ml in LB, and 75 ml 
was delivered to each well in a microtiter plate. 75 ml of Stl or ActD at twice the 
indicated concentration (or drug-free control) was also added to each well, for a total 
volume of 150 ml per well.  The plate was incubated at 37°C for 12 h with constant 
shaking in a BioTek ELx808 Microplate Reader. The optical density (at 630 nm) of each 
well was read every 15 min.  
 
Western Blots 
Quantitative RecA Western blots were analyzed in EW1b and EW1b mfd cells.  
Cells were pregrown overnight in LB media at 37 °C then diluted to an OD560 of 0.1.  The 
 86 
cells were grown to OD560 0.5 and treated with 5 µg/mL Stl or LB for 1 hour, when 8 x 
108cells were collected for each sample.  Cell pellets were stored at -20 °C.   
Pellets were thawed at room temp and resuspended in 100 µl of 20 mM 
potassium phosphate pH 7.4, 1 mM EDTA, and 0.5 mM DTT.  20 µL was diluted 1/5 om 
0.5% SDS and boiled for 10 minutes.  Protein concentration in the cell lysates were 
measured using BCATM Protein Assay Kit (Thermo Scientific) against BSA standards.  
The amount of protein loaded per gel was equal to 24 µL of the most dilute sample.     
Samples were loaded onto a 7.5% polyacrylamide (Tris-HCl) gel and run for 
approximately 2 h in 25 mM Tris-Glycine buffer containing SDS (0.1%).  Known 
amounts of RecA protein were also loaded to create a standard curve, allowing for 
quantitation of RecA levels for each sample 
The portion of the gel containing proteins larger than about 75 kDa was cut off 
and stained with Coomassie blue dye to serve as a loading control. The remaining 
portion of the gel was transferred to a nitrocellulose membrane for 60 min at 12 V using 
a Genie Blotter transfer device (Idea Scientific Co.). The blot was blocked for 1 h in 20% 
non-fat milk powder solution (Biorad) in Tris-buffered saline (TBS). The membrane was 
incubated overnight at 4°C with polyclonal RecA primary antibody and Tween (0.1%), 
and then washed three times with TBS buffer at room temperature (10 min each). The 
membrane was incubated with secondary antibody (IRDye 800CW-conjugated goat anti-
rabbit IgG (LI-COR®)) for 1 hour, and the washes were repeated. After air-drying, the 
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membrane was scanned on an Odyssey Imaging System (LI-COR Biosciences), and 
quantified using the Odyssey software. 
In vitro transcription reactions 
For in vitro reactions with Stl, open complexes were formed by adding 20 nM 
DNA template (254-bp PCR fragment from pDE13 containing the λPR  promoter and tR2 
terminator) and 20 nM RNAP in 1x transcription buffer (80 mM Tris-HCl pH 8.0, 200 
mM KCl, 16 mM MgCl2, 200 uM EDTA pH 8.0, 1 mM DTT, 0.05 mg/mL BSA and 16% 
Glycerol).  Open complexes were incubated at 37 °C for 10 minutes.  Elongation to +24 
was carried out by adding NTPs (200 µM ATP, 0.3 µM 32P– GTP, and 15 µM UTP) and 
heparin in 1X transcription buffer and incubating at room temp for 5 min.  Stalled 
complexes were split into 25 µL each and reactions were treated with 200 µM of UTP, 
GTP, and CTP, 4 mM ATP, the indicated amount of Stl, and either 400 nM Mfd or the 
equivalent volume of Mfd storage buffer and incubated at 37 °C for 5 min.   
For the reactions containing ActD, +24 complexes were set up in the same 
manner as the Stl reactions and split into 25 µL reactions.  Complexes were treated with 
the indicated amount of ActD or 1x transcription buffer and incubated at 37 °C for 10 
min.  200 µM of each NTP was added and complexes were incubated for 1 min at room 
temp.   
All reactions were quenched with 50% formaldehyde and 10x native loading dye 
and placed on ice until being loaded in the gel.  Samples were loaded into 8 M urea, 20% 
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polyacrylamide native gels and run at 100 V until the loading dye had run about 9/10 of 
the gel length.  The bottom portion of the gel (containing the majority of the free 
nucleotides) was excised and the gel was exposed to a phosphoimager screen overnight. 
Actinomycin D mutagenesis test 
MG1655 pal cells were pregrown overnight in LB and diluted to approximately 
OD560 0.1.  Cells were grown in LB to OD560 0.5, when they were treated with either LB, 50 
µg/mL ActD, or 100 g/mL ActD.  2 mL of an untreated control sample was taken before 
drug treatment. 4 x 108 cells were collected at 15 and 30 minutes, spun down, and plated 
onto plates containing rifampicin (100 µg/mL). 
Sytox Green test for membrane integrity 
MG1655 pal cells were pregrown overnight in LB and plated on LB plates 
containing Actinomycin D (25 µg/mL).  Six resulting ActD-resistant colonies were 
pregrown overnight.  1 mL of overnight culture was spun down and resuspended in 600 
µL of Tris-HCl.  Sytox Green (Lifetechnologies; 3 mM) was added to the cells for 5 min 
in the dark.  Fluorescence was measured with an excitation of 500 nm and an emission of 
550 nm.   
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4. Fate of transcription elongation complexes stalled by 
exogenous elongation inhibitors  
Some of this work was published in Molecular Microbiology (84).  The 
work for the Actinomycin D portion of this chapter was assisted by Ramsey Al-
Khalil, an undergraduate researcher in our lab. 
 
 4.1 Introduction 
With the increased understanding of Stl and ActD inhibition of transcription from 
Chapter 3, we are able to address the cellular response to RNAP stalled by Stl and ActD 
(46,59).  This allows us to isolate the effects of stalled transcription, eliminating many of 
the secondary effects that complicate the studying of blocked transcription using DPCs.  
Therefore, the primary goal of this Chapter is to understand how cells clear elongation 
complexes blocked by Stl and ActD.    
While it has been shown that Stl-RNAP complexes are stable in vitro and can be 
reactivated with the removal of Stl (59,75), the fate of elongation complexes stalled by Stl 
in vivo is currently unknown.  In contrast to the in vitro studies, von Meyenburg and 
colleagues showed that elongation complexes are inactivated upon Stl treatment in vivo.  
To monitor the effect of Stl on elongation complexes, they treated cells with Rif and Stl 
and measured both RNA and protein synthesis.  Treatment with Stl (100 µg/mL) 
resulted in a halt in RNA synthesis, with removal of the drug resulting in a resumption 
of elongation after a delay.  Surprisingly, when these conditions were repeated with the 
addition of Rifampicin after the removal of Stl, there was no new RNA and protein 
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synthesis; instead RNA and protein levels decreased slightly.  This implies that the Stl-
stalled complexes are unable to continue elongation even when the drug is removed, 
and in the absence of Rif, elongation only continues due a new round of initiation.  It 
was this result that led them to suggest that Stl treatment renders RNAP susceptible to 
interactions with an unknown termination factor, leading to release of the complex (58).  
To date this termination factor remains unknown, and no additional evidence has been 
presented.  Therefore, we set out to determine the mechanism of RNAP release during 
Stl treatment. 
We show here that mfd knockout cells are slightly resistant to Stl treatment, and 
Mfd-overexpressing cells are hypersensitive, implicating the transcription-coupled 
repair pathway in recognizing Stl-stalled RNAP.  It is of interest to see if mfd mutants are 
also resistant to ActD for two reasons: 1) To see if Mfd activity is general to multiple 
transcription inhibitors and 2) To see if the model presented in E. coli could be relevant 
for eukaryotes.  The second point is of particular interest given that certain platinum 
resistant tumors have been shown to have elevated levels of CSB, the eukaryotic 
homolog to Mfd, (145) and could potentially be hypersensitive to ActD.   
In this Chapter, we propose a model in which Mfd-mediated release of RNAP 
stalled by Stl or ActD is in balance with natural elongation that can occur once the drug 
binding is reversed.  Overexpression of Mfd results in a tipping of the balance towards 
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premature termination, leading to cell death.  These results are consistent for both Stl 
and ActD, implying that they could be relevant for eukaryotic systems as well. 
 
4.2. Results 
The transcription coupled repair pathway recognizes Stl-stalled RNAP 
von Meyenburg et al. showed that Stl-stalled RNAP is released in vivo but did not 
identify the protein responsible (58).  We previously hypothesized that the transcription-
coupled repair factor Mfd was the release factor, and a previous lab member showed 
mfd mutants are partially resistant to Stl (84).  These data were confirmed using the drug 
sensitivity profile tests used in previous chapters (Figure 20A).  We were also interested 
in testing cells overexpressing Mfd, and found that increasing Mfd activity by leads to 
hypersensitivity to Stl (Figures 20B) (84).  These results were surprising given Mfd’s 
currently understood role as a beneficial repair protein, as removal of Mfd typically 
hinders cell survival under certain stressful conditions.    
We were then interested in testing mfd mutants with the eukaryotic transcription 
inhibitor Actinomycin D to see if the results remain consistent for multiple inhibitors.   
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Figure 20: Effect of Mfd on cell growth during Stl and ActD treatment .  
In Panel A, three independent cultures of EW1b (WT) or EW1b mfd were tested for Stl 
sensitivity using a microtiter plate sensitivity assay as in Figure 2.  In Panel B, EW1b 
cells carrying pCA24N-Mfd, which expresses Mfd on an IPTG inducible promoter, were 
tested for Stl sensitivity as in Panel A.  In Panels C and D, MG1655 (WT) and mutant 
derivatives were tested for ActD sensitivity as in Panel A.   Panels A-C have an endpoint 
of 50% of the maximum growth rate, while Panel D is the comparative titration curve for 
the same cells as in Panel C using 10% of the maximum growth rate as the endpoint.  
Error bars for all panels are representative of the standard deviation for three 
independent cultures.  
 
 
 
 93 
MG1655 mrcB mfd double mutants were constructed using the Keio collection and tested 
for ActD sensitivity using the same hypersensitivity profile test.  When using an end 
timepoint of 50% of the maximum growth rate the MG1655 mrcB mfd cells were only  
 slightly resistant to ActD treatment (Figure 20C).  However, by the end of exponential 
growth the MG1655 mrcB mfd cells were clearly resistant compared to MG1655 mrcB 
cells (Figure 20D), supporting a more general role for Mfd in recognizing RNAP stalled 
by elongation inhibitors. 
 
Candidate mutant approach to look for other proteins that recognize Stl-stalled RNAP 
There are two potential models for the resistance of mfd cells: either release of 
stalled RNAP complex is needed for growth and Mfd is interfering with the release 
pathway, or Mfd is releasing RNAP and this activity is detrimental to cell growth.  In the 
latter case, the transient pausing demonstrated in Chapter 3 indicates that Mfd would be 
releasing polymerases that would otherwise be able to complete transcription, resulting 
in detrimental premature termination.  To separate these two possibilities, we first need 
to identify any other proteins that could potentially respond to Stl-stalled elongation 
complexes.  We first looked at transcription terminator Rho using the same double-drug 
titration as with Aza-C (see Chapter 2) and found that reducing transcription terminator 
Rho activity using bicylomycin does not result in increased sensitivity to Stl (data not 
shown) (84).  We then tested several factors known to affect transcription elongation and 
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termination: GreA, GreB, HepA, DinG, UvrD, Rep, and DksA(see Introduction in 
Chapter 2).  YejH was also added to this list, as it is a putative helicase that, when 
overexpressed, can complement UV damage repair in mfd deficient cells (146).  We also 
tested double mutants to look for functional redundancy.  uvrD rep double mutants are 
lethal, presumably due to blockages to replication that are normally cleared by these 
proteins, but the addition of a recF mutation can restore viability ((71) and references 
therein). 
Using the same drug sensitivity profile test we found no mutants that were 
strongly hypersensitive to Stl treatment (Table 5).  Some single and double mutant 
strains, however, were slightly resistant to Stl, including dksA, rep, dksA mfd, mfd yejH, 
dinG rep, and rep mfd mutants.  dksA cells were resistant only at low levels of Stl, while 
dksA mfd cells appear to have an additive resistance.  rep cells were only very slightly 
resistant, and the dinG rep and mfd rep cells were resistant at the same level as the rep 
single mutant (Figure 21 and data not shown).  The mfd yejH strains were also only as 
resistant as the mfd single mutant.  Therefore it appears that the proteins that 
consistently recognize Stl-stalled RNAP are Rep and Mfd, with DksA influencing cell 
growth at low levels of Stl treatment.   
We also attempted a screen for Stl hypersensitive and resistant mutants to obtain 
a comprehensive list of mutants that alter cell sensitivity to Stl.  However, this screen  
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Table 5: Stl hypersensitivity profile results for transcription elongation and 
termination factors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Strain Growth compared to WT in the  
presence of Stl 
greA No change 
Rho (Bcm) No change 
dinG No change 
uvrD No change 
yejH No change 
dinG, uvrD No change 
uvrD/recF/rep No change 
rep Slightly Resistant 
dinG/rep Slightly Resistant 
 dksA Resistant (low levels of Stl) 
mfd Resistant 
dksA/mfd Resistant 
yejH/mfd Resistant 
rep/mfd Resistant 
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Figure 21: Stl hypersensitivity profiles of mutants resistant to Stl. 
Three independent cultures of EW1b (WT) or mutant derivatives were tested for Stl 
sensitivity using a microtiter plate sensitivity assay as in Figure 2, with error bars 
indicating the standard deviation of each.  The endpoint OD was taken at 50% of the 
maximum growth rate. 
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proved to be technically challenging due to the resistance of normal bacteria to Stl and 
was later abandoned in favor of other directions. 
 
Mfd activity creates substrates for the tmRNA system 
In Chapter 2 we showed that the tmRNA system is vital for cell survival during 
DPC formation.  This is due to the necessity of recycling the stalled ribosomes, since the 
coupling of transcription and translation results in both process being stalled at DPCs.  
Therefore, treatment with Stl is also expected to block translation, and cells could 
require the presence of the tmRNA system during Stl treatment.  To verify the 
requirement of the tmRNA system for cell survival we treated smpB knockouts with Stl.  
SmpB is an essential cofactor to the tmRNA system that assists with tmRNA binding to 
the ribosome.  We found that smpB knockouts were hypersensitive as expected (Figure 
22A)  (84).   
If Mfd is responsible for releasing Stl-stalled polymerases, the release of the 
nascent transcript would allow translation to continue to the end of the transcript and 
open up the A-site of the ribosome for tmRNA binding.  It then follows that Mfd is 
responsible for creating the substrates for the tmRNA system, and removing Mfd would 
therefore remove the necessity of the tmRNA system as there would be no increase in 
substrates during Stl treatment.  We therefore constructed smpB mfd double mutants to 
test their sensitivity to Stl.  As shown in Figure 22C, smpB mfd mutants lose the 
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hypersensitivity of a smpB single mutant.  This implies that Mfd is capable of creating 
substrates for the tmRNA system.  However, the double mutant was also less resistant to 
Stl than a mfd single mutant, suggesting the tmRNA is capable of contributing to cell 
survival even in the absence of Mfd.  As a comparison we constructed a smpB rep double 
mutant, since rep cells were also slightly resistant to Stl treatment.  In contrast to the 
smpB mfd cells, the smpB rep  double mutants were just as hypersensitive to Stl as a smpB 
single mutant, implying that rep cells are resistant due to an activity unrelated to RNAP 
release (Figure 22D).   
To confirm that Mfd activity directly results in increased tmRNA tagging, we 
treated cells overexpressing Mfd with Stl and conducted western blots looking for 
tmRNA tagging.  To overexpress Mfd we used EW1b cells containing pCA24N-Mfd, 
which overexpresses MFD from an IPTG inducible promoter.  Cells overexpressing Mfd 
had greatly increased levels of tmRNA tagging compared to cells containing a vector 
plasmid during Stl treatment (See Figure 23), confirming Mfd mediated termination is 
creating substrates for the tmRNA system.  We also were surprised to find that 
overexpression of Mfd, even in the absence of Stl treatment, led to tmRNA tagging.  This 
indicates that Mfd has termination activity in wildtype cells, which is addressed in 
Chapter 5. 
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Figure 22: Stl hypersensitivity profiles for smpB mutants 
EW1b (WT) or mutant derivatives were tested for Stl sensitivity as in Figure 2. Three 
independent cultures were measured for each strain.  The error bars indicate the 
standard deviation for these cultures. mfd single mutant data is from Figure 20, shown 
again here for easy comparison.  The loss of hypersensitivity in the mfd smpB double 
mutant compared to the smp single mutant indicates a loss of substrates for the tmRNA 
system.  However, the loss of resistance in the mfd smpB double mutant compared to the 
mfd single mutant shows that tmRNA is capable of contributing to cell survival even in 
the absence of Mfd. 
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Figure 23: tmRNA tagging in Mfd-overexpressing cells 
EW1b cells containing pCA24N-Mfd, which encodes Mfd on an IPTG inducible 
promoter, were grown to OD560 0.5 with or without IPTG. They were then treated with 
Stl at 5 µg/mL (or left untreaded) for one hour.  Western blots were conducted with 
antibodies against the degradation tag encoded by tmRNA.  EW1B cells are protease 
proficient, so any tagging shown here has overwhelmed the protease system. 
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The hypersensitivity of rpoB8 mutants to Stl is partially due to Mfd-induced 
termination  
We found in Chapter 3 that rpoB8 mutants, which have increased pausing 
frequency, are hypersensitive to Stl.  The hypersensitivity of the rpoB8 mutant could 
potentially be due to the decreased elongation rate of the polymerase; the longer the  
RNAP is on the template, the more time Stl has to bind and slow the polymerase down 
further.  It could also be due to increased termination by Mfd.  To test these different 
models, we constructed a mfd rpoB8 mutant and compared it to a wildtype cells and mfd 
and rpoB8 single mutants.  As shown in Figure 24, the mfd rpoB8 double mutant is 
slightly more sensitive than the mfd single mutant, implying that the slow speed of the 
RpoB8 mutant is enough to cause some sensitivity to Stl.  However, the mfd rpoB8 
double mutant is significantly more resistant to Stl than the rpoB8 single mutant, 
implying that Mfd termination is also responsible for some of the hypersensitivity of the 
rpoB8 mutant.  This confirms that both the pausing frequency of the polymerase and 
Mfd termination contribute to overall transcription rates during Stl treatment. 
 
In vitro reactions with elongation inhibitors and Mfd 
In order to confirm that the in vivo data is truly the result of Mfd release of 
inhibitor-stalled RNAP, efforts were made to recreate this system in vitro.  The end goal 
was to compare the amount of full length product in the presence and absence of Mfd.  
The first control test was to verify that Mfd releases nucleotide-starved RNAP (similar to  
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Figure 24: Drug sensitivity profiles monitoring the effect of Mfd activity on RpoB 
mutants 
Hypersensitivity profiles for RNAP mutants with altered transcription properties were 
conducted as in Figure 2. The effect of Mfd on the slow RpoB8 mutant was tested using 
a mfd RpoB8 double mutant.  Error bars are representative of the standard deviation for 
three independent cultures. 
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(147)).  As shown in Figure 25A, nucleotide-starved elongation complexes are able to 
form full length transcripts when all four nucleotides are added, but not if they are 
preincubated with Mfd and high levels of ATP.  This implies Mfd releases stalled RNAP 
in an ATP-dependent manner (requiring more than 200 µM ATP) during the 
preincubation step, and therefore the full length complexes do not form when all four 
NTPs are added.   
We next needed to verify that addition of all four nucleotides at the same time as 
Mfd would allow for full length transcript production.  Once RNAP is elongating Mfd 
cannot release it, as it must have an opposing force to dislodge the stable RNAP-DNA 
interactions.  However, we were concerned that Mfd might release the stalled RNAP 
before elongation could resume.  As shown in Figure 25B, resumption of elongation out-
competes Mfd activity.  We also noticed that there is significantly less +24 transcript in 
the Mfd treated samples.  Perhaps this is indicating that there are small amounts of 
RNase present in the samples, and Mfd release of the +24 transcripts results in them 
being more vulnerable to degradation.  In the absence of Mfd, the RNA would still be 
attached to the ternary complex and possibly protected from this degradation. 
Even though it appeared Stl is not inhibiting elongation, if Stl is halting RNAP 
temporarily, Mfd might be able to terminate those complexes.  Therefore we tested a 
titration of Stl with Mfd present.  As shown in Figure 16, addition of Mfd did not result 
in an accumulation of intermediate length transcripts.  Further attempts to stall RNAP,  
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Figure 25: In vitro assay for Mfd-mediated release of Stl-stalled RNAP 
Panel A is an in vitro assay monitoring Mfd release of nucleotide-starved RNAP.  
Transcription was carried out using radioactive GTP, which allows for visualization of 
resulting RNA products.  +24 = product resulting from a nucleotide stalled RNAP at +24 
of the transcript.  FL= full length RNA product.  The addition of Mfd and high ATP 
levels results in a loss of full length products.  Panel B is a control for the competition 
between productive elongation and Mfd activity.  The presence of full length products in 
lanes 5-8 indicate that productive elongation occurs before Mfd can release nucleotide 
starved RNAP.  In Panel C the ability of Mfd to release ActD-stalled complexes was 
tested.  Reactions containing stalled complexes were diluted to create sub-inhibitory 
levels of ActD, yet full length products were unable to form even in the absence of Mfd. 
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such as by introducing a strong pause site and preincubating with Stl, would have to be 
made for completion of these studies. 
In Chapter 3 we showed that ActD treatment in vitro apparently completely 
inhibits elongation at 0.8 µM, while is virtually ineffective at 0.67 µM.  To be able to 
measure Mfd activity, we need to have an intermediate level of ActD treatment that 
causes some stalling (creating substrates for Mfd), yet allows for full length production if 
Mfd does not release RNAP.  Therefore we tried treating with inhibitory levels of ActD 
to cause stalling, then diluting to sub-inhibitory levels to allow for release.  As shown in 
Figure 25C, dilution was not sufficient to cause release of ActD (see Lane 5, where the 
diluted should have been able to produce full-length transcripts if ActD was released). 
Further experiments are thus necessary to monitor Mfd activity (see Discussion). 
 
4.3 Discussion 
The data presented here provide evidence for a model in which the transcription-
coupled repair pathway leads to premature termination of transcription stalled by 
elongation inhibitors.  We have shown that knocking out Mfd leads to resistance to Stl or 
ActD treatment, while overexpressing Mfd leads to hypersensitivity to both inhibitors.  
This is in direct contrast to Mfd’s well-characterized role as a beneficial repair protein, 
where Mfd activity is necessary for cell survival during DNA damage (such as with UV 
treatment).   
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The hypersensitivity of Mfd-overexpressing cells to Stl and ActD opens up 
intriguing possibilities for use of ActD in eukaryotic combination therapies.  Eukaryotic 
transcription coupled repair is similar to that of bacteria, yet the specific mechanisms 
and proteins involved are more complicated.  In yeast, the transcription coupled repair 
pathway is primarily mediated by Rad26, the yeast homologue of Mfd.  It has been 
proposed that the helicase-like activity of Rad26 can help alter the structure of RNAPII, 
allowing nucleotide excision repair to fix the damage and RNAPII to resume productive 
elongation.  When RNAPII is left permanently trapped Rad26 forms a complex with 
Def1 and induces degradation of RNAPII by ubiquitin-mediated degradation.  Similar to 
the dual activities of Mfd, Rad26 alone appears to protect RNAPII from Def1-dependent 
degradation, preventing detrimental termination of elongation (148).  It has also been 
shown in human cells that RNAPII degradation occurs after UV treatment, and that this 
degradation is dependent on the human transcription coupled repair factors CSA and 
CSB  (149), although the exact fate of RNAPII during transcription-coupled repair in 
eukaryotes is still under debate.  Furthermore, certain platinum-resistant tumors have 
been shown to have elevated levels of CSB (145).  It would be interesting to see if ActD 
treatment stimulates RNAPII degradation in these platinum-resistant tumors in a similar 
manner as Stl treatment stimulates release of RNAP in Mfd-overexpressing E. coli cells. 
To verify that Mfd is the main response factor to these inhibitors, and not a 
competitor to a beneficial repair pathway, we used a candidate mutant approach and 
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tested the Stl sensitivity to known transcription elongation and termination factors.  No 
mutants tested were hypersensitive, and only dksA and rep cells showed slight resistance 
to Stl.  DksA is an elongation factor that does not appear to have any RNAP releasing 
activity; instead DksA has shown to promote RNAP elongation (81).  Rep is known to 
remove proteins bound to DNA ahead of the replication forks, and specifically has been 
shown to remove RNAP during transcription/translation collisions (70,71).  We propose 
Rep is removing a small fraction of stalled RNAP ahead of replication forks.  This 
activity does not apparently create substrates for the tmRNA system, suggesting that the 
stalled ribosomes have already been released (see below).  It is also interesting to note 
that while rep single mutants and rep dinG mutants are resistant, the uvrD rep recF triple 
mutant is sensitive to Stl at wildtype levels.   
In Chapter 2 we identified the involvement of the tmRNA system in cell survival 
with aza-C treatment, but were unable to identify the factor(s) that allow tmRNA to bind 
to the A-site of the stalled ribosome.  In this chapter we showed tmRNA also assists in 
cell survival during Stl treatment, and that Mfd is the release factor responsible for the 
majority of tmRNA activity by releasing RNAP and the nascent transcript.  Presumably, 
the stalled ribosome continues translating until the end of the nascent transcript, where 
the A-site would be left empty and tmRNA can act.  The fact that smpB mfd mutants 
were more sensitive to Stl than mfd single mutants suggests that tmRNA is still capable 
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of releasing some stalled ribosomes in an Mfd-independent manner.  This activity could 
be precluding Rep’s removal of RNAP ahead of the stalled ribosome.    
We found in Chapter 3 that rpoB8 mutants, which have increased pausing 
frequency, are hypersensitive to Stl.  This is presumably due to Stl binding more 
frequently to the paused polymerases.  However, we also show here that part of the 
hypersensitivity of this mutant to Stl is due to the increased time for Mfd to release 
RNAP, providing further evidence for the model where Mfd termination is in 
competition for normal elongation.   
Taken together with the previous data, we proposed the following model for Stl-
induced stalling of elongation.  In the absence of Mfd activity, Stl treatment stalls RNAP 
only transiently, and normal elongation can continue.  Because the A-site is never 
unoccupied, tmRNA is unable to access the stalled ribosome, making the tmRNA system 
dispensable in mfd cells.  However, when Mfd is present some of the Stl-stalled RNAP is 
released before Stl binding reverses.  tmRNA then recycles the stalled ribosome and tags 
the peptide for degradation.  When Mfd is overexpressed, Mfd out-competes productive 
elongation and the cells become hypersensitive. 
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4.4 Materials and Methods 
Materials 
Luria–Bertani broth (LB) contained Bacto tryptone (10 g l-1), yeast extract (5 g l-
1), and sodium chloride (10 g l-1) and was used for all bacterial growth (with 
appropriate antibiotics for plasmid selection and the indicated additions); Nitrocellulose 
membrane (Protran® BA 85) was from Whatman; Streptolydigin was the generous gift 
of Konstantin Severinov (Waksman Institute of Microbiology) and José Salas 
(Universidad de Oviedo); Actinomycin D was purchased from Sigma; RNA polymerase 
was kindly provided by Dorthy Erie (University of Chapel Hill); ssrA antibodies were a 
generous gift from Tania Baker (MIT). 
E. coli strains 
EW1b [F-, lacY1 or lacZ4, tsx-64, glnV44(AS), gal-6, LAM-, hisG1(Fs), DtolC5, 
argG6, rpsL (allele 8, 104 or 17), malT1(LamR)] was obtained from the E. coli Genetic 
Stock Center (Yale University).  MG1655 [F- lambda- ilvG- rfb-50 rph-1] was obtained 
from the E. coli Genetic Stock Center (Yale University).  MG1655 and EW1B derivatives 
were constructed by phage P1-mediated transduction.  Knockouts of mrcB, greA, greB, 
hepA, dksA, dinG, uvrD, rep, yejH, and smpB were P1 transduced from the Keio collection 
(114). The rpoB8,  rpoB2, and rpoB3595 mutants were P1 transduced were from the Carol 
Gross collection (140).  Mutations were confirmed with PCR and sequencing.    
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Plasmids 
pCA24N-Mfd is from the ASKA collection of E. coli ORFs without the GFP or His 
tag (102).  Mfd is expressed from the PT5-lac promoter that can be activated by IPTG.  
pDE13 was generously provided by Dorthy Erie (University of Chapel Hill) (150). 
Growth kinetics for Stl and ActD sensitivity 
Overnight cultures in LB were diluted to roughly 4 x 106 cell/ ml in LB 
(containing chloramphenicol for plasmid-containing cells), and 75 µl was delivered to 
each well in a microtiter plate. 75 µl of Stl or ActD at twice the indicated concentration 
was also added to each well, for a total volume of 150 µl per well.  The plate was 
incubated at 37°C for 12 h with constant shaking in a BioTek ELx808 Microplate Reader. 
The optical density (at 630 nm) of each well was read every 15 min.  
For analyzing drug sensitivities, the time at which cell growth reached 50% of the 
maximum velocity in the absence of the drug was first calculated and considered to be 
the endpoint of growth.  The OD at this time was then taken for each of the drug 
concentrations.  Each drug OD was divided by the end-point OD for the no-drug 
control, to account for any growth deficiencies for the mutant strains.  The ODs in each 
drug concentration was divided by the no-drug OD, then plotted against drug 
concentration. 
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Western Blots 
SsrA tagging levels were analyzed in EW1b cells containing pCA24N-Mfd or the 
pCA24N control. Cells were pregrown overnight in LB media containing 
chloramphenicol at 37 °C then diluted to an OD560 of 0.1.  The cells were grown in LB 
and chloramphenicol to OD560 0.5 and treated with 5 µg/mL Stl or LB for 1 hour, when 
4x 108cells were collected for each sample.  Cell pellets were stored at -20 °C.   
Frozen cell pellets were thawed at room temperature and resuspended in 25 l of 
water and 25 l of sample buffer (20% glycerol, 100 mM Tris pH 6.8, 2% SDS, 2% β-
mercaptoethanol, and bromophenol blue), and boiled for 5 min in a water bath. An 
aliquot (15 l) of each sample was loaded onto a 7.5% polyacrylamide (Tris-HCl) gel and 
run for approximately 2 h in 25 mM Tris-Glycine buffer containing SDS (0.1 
 The portion of the gel containing proteins larger than about 75 kDa was cut off 
and stained with Coomassie blue dye to serve as a loading control. The remaining 
portion of the gel was transferred to a nitrocellulose membrane for 60 min at 12 V using 
a Genie Blotter transfer device (Idea Scientific Co.). The blot was blocked for 1 h in 20% 
non-fat milk powder solution (Biorad) in Tris-buffered saline (TBS). The membrane was 
incubated overnight at 4°C with polyclonal ssrA primary antibody and Tween (0.1%), 
and then washed three times with TBS buffer at room temperature (10 min each). The 
membrane was incubated with secondary antibody (IRDye 800CW-conjugated goat anti-
rabbit IgG (LI-COR®)) for 1 hour, and the washes were repeated. After air-drying, the 
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membrane was scanned on an Odyssey Imaging System (LI-COR Biosciences), and 
quantified using the Odyssey software. 
In vitro reaction 
For in vitro reactions looking for full length transcript production in the presence 
of Mfd, open complexes were formed by adding 20 nM DNA template (254 bp PCR 
fragment from pDE13 containing the λPR  promoter and tR2 terminator) and 20 nM RNAP 
in 1x transcription buffer (80 mM Tris-HCl pH 8.0, 200 mM KCl, 16 mM MgCl2, 200 uM 
EDTA pH 8.0, 1 mM DTT, 0.05 mg/mL BSA and 16% Glycerol).  Open complexes were 
incubated at 37 °C for 10 minutes.  Elongation to +24 was carried out by adding NTPs 
(200 µM ATP, 0.3 µM 32P– GTP, and 15 µM UTP) and heparin in 1X transcription buffer 
and incubating at room temp for 5 min.  Stalled complexes were split into 25 µL each 
and reactions were treated with 400 µM Mfd and the indicated amount of ATP for 15 
minutes at 37 °C.  200 µM of UTP, GTP, and CTP were added at room temperature for 3 
minutes.   
For the reaction monitoring the competition of Mfd and elongation, stalled 
complexes were formed as above and split into 25 µL reactions.  For the reactions 
labeled “Mfd added first, 400 µM Mfd was preincubated with stalled complexes for 12 
minutes at the indicated temperature.  All four nucleotides (200 µM each) were then 
added for 3 minutes.  For the reactions labeled “all added together”, 400 µM Mfd was 
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added with all four nucleotides (200 µM each) and incubated for at the indicated 
temperature and time.    
 For the ActD dilution assay, ActD stalled complexes were treated with 200 µM 
of UTP, CTP, and GTP, 4 mM ATP, and 400 nM Mfd (or storage buffer) and incubated at 
room temp for 10 minutes.  1x transcription buffer was added to dilute the reaction 4-
fold, resulting in an ActD concentration of 0.2 µM, and incubated at room temp for 3 
min.   
All reactions were quenched with 50% formaldehyde and 10x native loading dye 
and placed on ice until being loaded in the gel.  Samples were loaded into 8 M urea, 20% 
polyacrylamide native gels and run at 100 V until the loading dye had run about 9/10 of 
the gel length.  The bottom portion of the gel (containing the majority of the free 
nucleotides) was excised and the gel was exposed to a phosphoimager screen overnight. 
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5. Mfd alters global transcription patterns in undamaged 
Escherichia coli cells 
5.1 Introduction 
Mfd, the transcription-coupled repair factor in E. coli, is a well-studied enzyme 
known for decreasing mutation frequency and facilitating strand-specific DNA repair 
(66,91,151,152).  In addition, recent literature has expanded the known roles of Mfd to 
reach beyond transcription-coupled repair in E. coli.  As shown in Chapter 3, cells 
lacking Mfd are resistant to Streptolydigin, implying a role for Mfd in termination of 
stalled transcription complexes in the absence of any DNA damage (84).  Mfd has been 
shown to terminate transcription stalled by nucleotide deprivation (also without any 
DNA damage) (147).  Selby and Sancar found evidence that suggests Mfd might act on 
paused RNAP (69).   It has also been suggested by Hanawalt and colleagues that 
transcription paused at natural pause sites are subject to gratuitous TCR (153), though it 
has never been directly proven.  Accordingly, it stands to reason that Mfd might play a 
role in transcription termination in undamaged cells.  The purpose of this Chapter is to 
identify the effects of Mfd on global transcription patterns in undamaged cells. 
Mechanistically, Mfd is recruited to a stalled elongation complex through its 
RNAP binding domain D4, binding directly upstream of the transcription bubble (30,67).  
Subsequent DNA binding leads to a conformational shift, causing movement of the 
helical hairpin into the dsDNA binding cleft.  This hairpin serves as a ratchet, pushing 
RNAP forward and DNA backwards.  Depending on various factors such as sequence 
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and RNAP conformation, Mfd then either enhances forward translocation or removes 
the stalled RNAP from the DNA.  For instance, if RNAP is backtracked, Mfd uses its 
ATP dependent translocase activity to push forward backtracked RNAP.  This 
concomitantly rewinds the transcription bubble from upstream and unwinds the 
RNA/DNA hybrid, allowing for resumption of elongation (67,68).   When there is a 
physical obstruction in the way, such as a DNA-bound protein or DNA lesion, this 
ratcheting motion is proposed to dislodge RNAP from DNA (66,69).  If the block was 
induced by DNA damage, once RNAP has been cleared from the DNA UvrA is 
recruited to the site via Mfd’s UvrA binding site in the N-terminal UvrB homology 
domains (66,67), initating nucleotide excision repair.  If there is no DNA-damage, such 
as the case of natural pauses, Mfd is potentially capable of terminating transcription in a 
manner that is dependent on the conformation of RNAP. 
There are three types of pauses to consider in E. coli: class 1 (hairpin dependent 
pauses), class II (backtracking), and ubiquitous pauses.  Class I pauses inhibit elongation 
through RNA hairpin–RNAP interactions that stabilize the RNA 3’ end in a frayed or 
hypertranslocated position (154,155).  Backtracking in class II hybrids is caused by weak 
RNA:DNA hybrids; backtracking causes upstream sliding of RNAP and occlusion of the 
active site with nascent RNA (156-158).  Ubiquitous pauses are less well studied, but are 
proposed to involve structural rearrangements of RNAP that result in a temporarily 
inactivated intermediate (136).  This inactivated intermediate can either be restarted 
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(resulting in the appearance of a ubiquitous pause) or result in a longer-lived pause 
(class I or class II) (33).  Single molecule studies show that ubiquitous pauses do not 
backtrack (33).   
For Mfd to be able to terminate transcription at pause sites or other locations, 
certain requirements must be met.  First, RNAP must already be stalled; it has been 
shown that Mfd has no effect on either Rho-dependent or independent terminators (69), 
and Mfd is outcompeted by elongation at physiological levels of NTPs (147).  Second, 
the σ factor must be released, as Mfd requires 25 bases of DNA template upstream of the 
stalled RNAP to act on stalled RNAP, and this site is occupied by σ when present 
(9,147).  It has also been shown directly that the presence of σ70  blocks Mfd’s ability to 
remove stalled polymerases (147).  Furthermore, the RNAP would most likely need to be 
stalled in such a way that it was not backtracked, as this would simply result in forward 
translocation (see above).   
In this Chapter, we use RNAseq technology as well as cell-based assays to 
further examine the role of Mfd as a transcription regulator in undamaged cells.  We 
show evidence that alterations to Mfd levels in the cell cause vast global transcriptome 
changes, and suggest that Mfd might regulate the transcription of genes that affect 
growth rate and DNA replication.  We also investigate the location of Mfd-induced 
termination, with a particular focus on the possibility of termination occurring at pause 
sites, and find that surprisingly Mfd appears to be affecting gene transcription at or near 
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promoters.  Taken together, this further expands the role of Mfd well beyond that of a 
simple repair factor. 
 
5.2 Results 
 Mfd has termination activity in wildtype cells 
While mfd cells have no noticeable phenotype during normal growth (84), we 
have previously noticed that cells containing plasmids that carried the Mfd gene have 
growth deficiencies.  EW1b cells containing pMfd19, which overexpresses Mfd from its 
natural promoter, grew much more poorly than EW1b cells containing a vector plasmid: 
the cells have a decreased maximum growth rate and a lower maximum cell density 
when grown in a liquid culture (data not shown and (84)).  Overexpressing Mfd from 
the IPTG inducible pCA24N-Mfd plasmid, which expresses Mfd at high levels, is lethal 
when grown in our standard sensitivity assay (data not shown).  This implies that too 
much Mfd activity in wildtype cells is detrimental to cell growth.     
Given our previous findings with Mfd (See Chapter 4), we wanted to see if the 
detrimental activity of Mfd was premature termination.  If Mfd is causing premature 
termination, it would be creating substrates for the tmRNA system.  As shown in Figure 
23, we found evidence for tmRNA tagging in Mfd-overexpressing cells even in the 
absence of Stl.  To further characterize this tagging, we performed western blots using 
an antibody against the degradation tag of tmRNA and looked for the presence of 
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tmRNA-terminated peptides during various times of Mfd overexpression.  We found 
that tmRNA tagging was indeed induced in a time dependent manner during 
overexpression of Mfd, with detectable peptide accumulation at about 30 minutes 
(Figure 26).  This data implies that Mfd has low levels of termination activity in WT 
cells, and this activity is exacerbated when Mfd is overexpressed.  One possibility is that 
Mfd is terminating elongation in undamaged cells at natural pause sites, which in some 
conformations might be fairly similar to Stl-stalled polymerases. 
 
Testing for DNA damage due to aberrant Mfd activity 
It has been suggested that RNA polymerase stalled at a natural pause site might 
lead to gratuitous TCR, leading to DNA damage and possible mutations (153).  While 
never directly proven, there have been low levels of Uvr-ABC excision detected on 
undamaged DNA in vivo and in vitro (159).  Therefore aberrant Mfd activity due to 
overexpression might lead to recruitment of UvrA to undamaged sites.  We tested uvrA 
knockouts to see if deleting uvrA alleviates cell sensitivity to pMFD19.  We found no 
difference in cell growth in EW1b uvrA pMfd19 cells compared to EW1b pMFD19 cells 
(Figure 27A). We also treated both cell lines with Streptolydigin to stimulate stalling and 
found no difference (Figure 27B).  Therefore we were unable to detect UvrA-dependent 
gratuitous TCR.  
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Figure 26: tmRNA tagging in cells overexpressing Mfd. 
Panel A: Extracts from MG1655 cells containing pCA24N-Mfd were analyzed by 
Western blotting with polyclonal antibodies to the degradation tag of tmRNA.  Western 
blot was conducted as stated in Materials and Methods.  Panel B: Tagging levels are 
expressed as a ratio of tmRNA tagging levels relative to the no drug control.  
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Figure 27: Sensitivity of uvrA cells to expression of Mfd. 
EW1b and EW1b uvrA cells containing either pMfd19 or the parent pBR322 plasmid 
were tested for sensitivity to Mfd expression and transcription elongation inhibitor 
Streptolydigin using a microtiter plate sensitivity assay.   Panel A is representative 
growth curves for the wild type and mutant cell lines respectively without any Stl 
treatment. Panel B is the comparative titration curve using 50% of the maximum 
exponential rate as an endpoint. Panel C is the quantitation of the LexA western blots.  
Western blots and analysis were performed as in Figure 25 except polyclonal LexA 
antibodies were used as the primary antibody.  Error bars are representative of the 
standard deviation of three independent cultures. 
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We also wanted to see if overexpressing Mfd led to UvrA-independent DNA 
damage, and therefore tested for SOS induction after Mfd overexpression.  We 
attempted to perform quantitative RecA western blots as a measure of SOS, but we 
found that RecA levels were greatly decreased in Mfd overexpressing cells (data not 
shown).  This is presumably due to Mfd affecting recA RNA levels, most likely by 
terminating its transcription.  We then chose to perform Western blots using a primary 
antibody against LexA, as monitoring LexA degradation is another accepted way to look 
at SOS induction and would not be affected by alterations to transcription (81).  We 
found the LexA levels were unchanged in Mfd-overexpressing cells, indicating a lack of 
DNA damage in these cells (Figure 27C).  
 
Mfd alters transcription patterns in undamaged cells 
Since Mfd-overexpression appears to be lead to termination in WT cells, it 
reasonably follows that Mfd might be affecting global transcription patterns.  Therefore, 
we performed RNAseq analysis on three MG1655 mfd cells lines and looked for 
expression changes when compared to MG1655 cell lines.  We chose MG1655 as our 
background as it has been fully sequenced and annotated and is commonly accepted as 
a standard K-12 strain (160).  Using three independent control and mutant cells lines for 
comparison allowed us to normalize the data using the TMM method, which adjusts for 
variations in RNA levels between isolates.  We can then calculate statistically significant 
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differences between cell lines, and therefore all genes included in further analysis were 
those that passed a significance cut-off p>0.05.   
Under the conditions listed above we found that 94 genes were affected 2-fold or 
more in the mfd cells, representing 2% of annotated genes in MG1655.  Of these, a total of 
75 genes are overexpressed more than 2-fold in mfd cells, and an additional 116 are 
overexpressed 1.5-fold to 2 fold in mfd cells (Table 6).  Furthermore, we found 18 genes 
were repressed more than 2-fold in mfd cells (along with mfd itself), and another 17 genes 
were repressed 1.5-2 fold (Table 7).  Given the uneven distribution of overexpressed 
versus repressed genes (75 vs 18), it appears as if Mfd preferentially acts as a negative 
regulator of gene expression. 
To categorize these genes we utilized the Database for Annotation, Visualization  
and Integrated Discovery (DAVID) program to sort genes based on their GO-terms 
(161,162).  P-values for significance were calculated using the Fisher Exact test.  
Functional analysis using GO-terms of the overexpressed genes showed that ncRNA 
metabolic process genes, nucleobase, nucleoside and nucleotide interconversion genes, 
and DNA replication genes were well represented (Table 8A).  Nearly half of the 
repressed genes are involved in carbohydrate catabolic processes (Table 8B).  When the 
genes that are overexpressed 1.5-fold to 2-fold are included, roughly 10% (20 out of 191) 
of the total genes are ncRNA metabolic process genes, giving a Fisher Exact p-value of  
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Table 6: Genes overexpressed >2-fold (p>0.05) in mfd cells 
Upregulated 
genes 
Fold 
difference 
Upregulated 
genes 
Fold 
difference 
Upregulated 
genes 
Fold 
difference 
yhfY 9.82 mscS 2.50 aroH 2.20 
ypdK 4.43 rzoR 2.46 valZ 2.18 
ynfA 3.84 iraM 2.43 dnaG 2.17 
yghG 3.50 appY 2.42 yfcJ 2.17 
yghF 3.26 gltD 2.39 yecF 2.16 
nrdF 3.17 rsxA 2.37 rnc 2.16 
yliF 3.16 ybjG 2.36 pabA 2.16 
yceA 3.14 tadA 2.35 valT 2.14 
omrA 3.14 phoU 2.34 ykiA 2.13 
lysT 3.12 leuW 2.34 yojI 2.12 
rzpD 3.04 mltF 2.34 udk 2.12 
apt 2.99 yjeA 2.34 ydgK 2.11 
pyrF 2.84 lysW 2.33 yadS 2.11 
pppA 2.79 mgrR 2.32 ygdQ 2.11 
ycaD 2.78 ybjX 2.32 rlmD 2.10 
yliE 2.76 rfaH 2.30 rsmG 2.10 
queD 2.76 dnaA 2.30 yjhD 2.09 
lysQ 2.71 ybgT 2.29 rzpR 2.08 
yciH 2.64 rsxB 2.27 dusC 2.08 
lysY 2.64 mnmG 2.26 gltB 2.07 
lysZ 2.63 ybgE 2.26 slyX 2.06 
rlmF 2.59 lysV 2.25 dnaN 2.05 
gpt 2.59 tusA 2.24 ileU 2.04 
gltW 2.58 cydB 2.24 secE 2.03 
omrB 2.58 yghE 2.23 yhfZ 2.02 
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Table 7: Genes repressed >2-fold (p>0.05) in mfd cells 
Downregulated 
Genes 
Fold 
Difference 
mfd 14.03 
nanA 4.86 
malF 4.19 
malK 3.98 
astC 3.62 
yihN 3.34 
malM 3.34 
yihM 3.07 
fruB 2.77 
dgsA 2.65 
fumC 2.54 
fruK 2.33 
malS 2.20 
rbsD 2.20 
sthA 2.19 
sdhD 2.13 
malI 2.10 
sdhA 2.07 
clpS 2.06 
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Table 8a: GO annotations with significant representation in genes 
overexpressed >2-fold in mfd cells. 
GO Term Role Genes % p-value 
GO:0015949 
Nucleobase, nucleoside 
and nucleotide 
interconversion 
pyrF, apt, nrdF, gpt, 
udk 
6.7 3.70E-07 
GO:0034660 
ncRNA metabolic 
process 
tusA, tadA, rsmG, rnc, 
mnmG, rlmF, yjeA, 
dusC 
10.7 3.10E-06 
GO:0006261 
DNA-dependent DNA 
replication 
dnaA, dnaG, dnaN 4 5.20E-03 
GO:0044271 
Nitrogen compound 
biosynthetic process 
pryF, aroH, apt, gltD, 
gpt, pabA, queD, udk, 
gltB 
12 1.70E-03 
GO:0008219 Cell death rzpR, rzpD, rzoR 4 1.00E-02 
 
 
Table 8b: GO annotations with significant representation in genes  
repressed >2-fold in mfd cells 
 
 
 
GO Term Role Category Genes % p-value 
GO:0016052 
carbohydrate catabolic 
process 
malM, fruK, malK, 
malI, malF, fruB, malS 
rbsD 44.4 3.50E-08 
GO:0046356 
acetyl-CoA catabolic 
process sdhA, sdhD, fumC 16.7 6.80E-05 
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1.2 x 10-12.  In addition, the number of genes involved in DNA replication increases to 6% 
(11 out of 191) with a p-value of 4.1 x 10-9.   
 One indirect model for the effects on transcription is that Mfd could potentially 
only be affecting transcription of a one or a few transcription factors, which would then 
have a more global downstream effect.  Therefore we searched for known transcription 
factors as listed on RegulonDB among our list of affected genes and cross-referenced the 
lists of overexpressed and repressed genes with the genes that those transcription factors 
regulate (163). There were two overexpressed and two repressed transcription factors in 
mfd cells, namely appY and dnaA (overexpressed) and dgsA and malI (repressed).  
However, none of the genes that these transcription factors regulate were changed in 
mfd cells (data not shown).   Therefore it appears as if Mfd is having a direct effect on 
gene expression. 
 
Mfd potentially targets transcription of RNAs  
In addition to the GO annotations noted previously, which only consider protein 
coding genes, we noticed that several of the genes that are overexpressed in mfd cells are 
tRNA genes.  In fact, 11 of the 75 genes overexpressed >2-fold are tRNA molecules: lysT, 
lysQ, lysY, lysZ, leuW, lysW, lysV, valT, ileU, valZ, gltW.  An additional 8 are upregulated 
1.5-2 fold.  Of the 11 tRNA genes found in ribosomal operons 7 were found to be 
overexpressed >1.5-fold, indicating that Mfd potentially targets rRNA operons. 
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Unfortunately, we cannot monitor rRNA levels using RNAseq, as the high expression of 
rRNA compared to tRNA and mRNA require them to be removed during library 
preparations.  10 of the 19 tRNA genes are found on two clusters of tRNA genes outside 
of the rRNA operons, suggesting that these clusters might be operons also regulated by 
Mfd.  In addition to the tRNA 3 other genes overexpressed >2-fold (omrA, omrB, and 
mgrR) are small regulatory RNAs, based on the list of small regulatory RNA identified 
in the EcoCyc database (164) (p-value 0.035).  Taken together with the large number of 
RNA modifiers overexpressed in mfd cells, this data strongly implies Mfd plays a role in 
negatively regulating RNA biology. 
 
Potential connection to growth rate regulation 
The specific targeting of tRNA genes, particularly those in ribosomal RNA 
operons, RNA modifiers, and DNA replication also suggests Mfd might play a role in 
growth rate regulation.  Growth rate determination in E. coli is primarily controlled by 
the number of ribosomes available in the cell, with the rate of rRNA synthesis being 
most sensitive to changes in growth conditions (165-168).  rRNA synthesis is control by 
the two alarmone molecules ppGpp and pppGpp, affecting both stringent response and 
growth rate regulation (169).  The transcription factor DksA also acts synergistically with 
ppGpp, although DksA also plays a ppGpp independent role on gene regulation 
(170,171).  Therefore we compared the genes affected by dksA and ppGpp deficiencies to 
 128 
those affected by a mfd deficiency.  We found that of the 18 genes downgregulated in mfd 
mutants, 6 genes were also downregulated in dksA mutants (fruK, fumC, malF, malK, 
malM, and sdhA), giving a p-value of 6.21 x 10-6  using a Fisher exact test.  Four of those 
genes (malF, malK, malM, and fumC) were also downregulated in the ppGppo strain, 
giving a p-value of 1.27 x 10-3.  Of the genes overexpressed in mfd mutants, only four 
genes (apt, pyrF, yciH, and yecF) were overexpressed in a dksA strain (p-value 0.29).  It is 
of note that the experiments with the dksA and ppGppo strains excluded all rRNA and 
tRNAs, and therefore they were excluded from this comparison.  However, ppGpp and 
DksA stimulate expression of rRNAs, while Mfd apparently represses transcription of 
tRNAs, especially those included in rRNA operons.  Taken together, it appears as if Mfd 
may contribute to growth rate regulation, but in a manner that only partially overlaps 
the function of ppGpp and DksA.  See Discussion for further comments. 
 
Mfd-overexpression leads to dramatic global transcription pattern changes 
Given that overexpressing Mfd lead to tmRNA tagging, we also tested for 
changes in global gene expression in Mfd-overproducing cells.  Two MG1655 pCA24N-
Mfd cell lines were submitted for RNAseq analysis, along with two MG1655 pCA24N 
cell lines for controls, using the same growth and sequencing conditions as previously 
stated.  ANOVA analysis was used to compare results from the two groups, with the 
caveat that using only two cell lines for each does not allow us the same statistical 
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confidence as before.  Mfd overexpressing cells had a dramatic change in global 
transcription patterns, with 103 genes overexpressed more than 2-fold (including Mfd) 
and 1019 genes repressed 2-fold or more (data not shown).  However, when the list of 
genes that are overexpressed in mfd cells are cross referenced to the genes that are 
repressed in Mfd-overexpressing cells, only 10 genes overlap (out of a potential 75).  
Therefore it appears as if Mfd has different targets when Mfd levels are artificially high. 
One trivial reason for the vast genomic changes in Mfd overexpressing cells 
could be due to generic changes due to protein overexpression, rather than specific 
activity of Mfd.  Therefore we compared the list of genes overexpressed and repressed 2-
fold in Mfd overexpressing genes to the list of genes found to be affected by 
recombinant protein overexpression in MG1655 pPROEx-CAT containing cells, which 
overexpresses chloramphenicol acetyltransferase on an IPTG inducible promoter (172).  
Surprisingly, only 71 of the repressed genes and 2 of the overexpressed genes in Mfd-
overexpressing cell lines overlapped with the genes overexpressed and repressed, 
respectively, in the MG1655 pPROEx-CAT cells (data not shown).  While our data does 
not quantitatively list the degree to which genes are affected by increases in Mfd 
activity, it is apparent that Mfd activity does induce gross genomic changes that are not 
simply due to generic recombinant protein affects. 
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Mfd-overexpressing cells have preferential transcription changes in the terminus 
region 
To see if Mfd is preferentially targeting genes in a particular area of the 
chromosome we plotted the location of each of the genes that are overexpressed and 
repressed in mfd cells.  When plotted along chromosome position the affected genes 
seem to be fairly evenly distributed (Figure 28A).  Genes that are overexpressed in Mfd-
overexpressing cells also were fairly evenly distributed (Figure 28B).   In contrast, read 
coverage profiles of for each of the Mfd-overexpressing cell lines show that transcription 
of the majority of the terminus region is downregulated (Figure 29).  When the gene 
RPKM values for Mfd overexpressing cells are compared to WT cells, it is further 
apparent that there is a cluster of genes in the terminus region that is downregulated 
(Figure 28C).  Specifically, 92 of the 250 annotated genes between TerA and TerC are 
downregulated (Fisher p-value = 0.00007).  One possibly is that overexpressing Mfd 
causes downstream structural rearrangements of the terminus region (See Discussion).   
 
Gene expression deviates at or near promoters 
The use of RNAseq allows us to look specifically at where transcription is 
deviating between WT and mfd cell lines.  We have hypothesized that Mfd is terminating 
transcription during elongation, possibly during natural pauses of RNA polymerase.  If 
this is true, one might expect to have a higher chance to find specific sites of termination  
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Figure 28: Location of overexpressed and repressed genes in mfd cells. 
Panel A is the chromosome position of overexpressed (green diamonds) and repressed 
(yellow diamonds) genes in mfd cells.  Panel B is the chromosome position of 
overexpressed (green diamonds) genes in Mfd overexpressing cells.  Panel C is the 
MG1655 pCA24N log2 RPKM values plotted against MG1655 pCA24N-Mfd log2 values.  
A perfect 1:1 ratio is plotted as a black line.  Genes falling off this line are under- or over- 
represented in Mfd-overexpressing cells.  Genes in the terminus region (between TerA 
and TerC) are plotted in red.  Genes in the terminus region that are repressed in Mfd-
overexpressing cells are boxed in red.     
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Figure 29: Read coverage profiles for WT and Mfd-overexpressing  cells 
Panels A and B are the read coverage profiles generated by Geneious Pro for the entire 
chromosome for a representative MG1655 (A) and MG1655 pCA24N-Mfd (B) cell line.  
The highly underrepresented Ter region in MG1655 pCA24N-Mfd cells is highlighted 
(red box).  Panel C is the read coverage profiles generated by for a representative 
MG1655 pCA24N cells in the terminus region (between TerA and TerC).  Panel D is the 
read coverage profiles for a representative MG1655 pCA24N-Mfd cell line in the same 
terminus region as C.   
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in longer operons.  Therefore, we identified all the genes that are overexpressed 2-fold or 
more in mfd knockout cells that belong to operons.  A total of 22 operons included 
overexpressed genes. Using JMP Genomics and Microsoft Excel, read coverage maps 
were generated for both WT and mfd strains by averaging the read coverage per every 
100 bp, then averaging the three replicates.  Read coverage for both cell types was then 
plotted as a function of chromosome position.  Surprisingly, read coverage for all 
deviated from WT at or near the promoter for all operons examined (see Figure 30A).  
We did not find any evidence for decreases in read coverage in the wildtype cells 
compared to the mfd knockout read coverage within the body of the operon, as would be 
expected if Mfd is terminating transcription in wildtype cells.   
To get a more precise idea of where WT and mfd gene expression were deviating, 
average read coverage for every 5 base pairs was calculated and plotted for dnaN, an 
example gene that is overexpressed in mfd cells.  While the pattern of read coverage was 
consistent between the two strains, it was clearly apparent that the level of RNA in mfd 
cells deviated from wildtype near the promoter (Figure 31A).  To pinpoint the exact 
location of deviation, the ratio of read coverage was taken for mfd/WT cells and plotted, 
with the deviations from a ratio of 1 indicating the location where transcription was 
affected.  Transcription deviated <20 bp from the promoter (Figure 31B).  This data 
contradicts our model that Mfd is terminating during elongation.  It instead indicates  
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Figure 30: Representative read coverage profile for MG1655 and mfd cell lines 
Panel A is the read coverage profile of a representative operon including genes that are 
overexpressed in mfd cells.  Curves were generated by connecting the log2 RPKM data for 
100 bp bins.  The four genes, yciS, yciM, pyrF, and yciH are all part of one operon, with a 
second promoter present which transcribes pyrF and yciH separately.  Transcription 
proceeds from left to right.  Panel B is a representative operon including genes that are 
repressed in mfd cells.  fruB, fruK, and fruA are expressed together starting from the fruB 
promoter.  Transcription proceeds from right to left (blue arrow).  Operon information 
was taken from Ecocyc (164).   
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Figure 31: Representative read coverage profile for MG1655 and mfd cell lines using 5 
bp bins. 
Panel A is the read coverage profile for the dnaA gene generated from the log2 RPKM 
values for 5 bp bins.  Transcription proceeds from right to left (blue arrow).  Read 
coverage from mfd cell line (red) deviates from MG1655 coverage (blue) within 15 bp 
from each promoter (green triangle and purple diamond). Panel B is the ratio of mfd 
RPKM values to wildtype RPKM values plotted against chromosome location.  
Deviations from 1 represent overexpression or repression. 
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that Mfd is either directly terminating transcription at the promoter, or causing a 
secondary effect at the promoters of these genes. 
Given that Mfd does not appear to be terminating during elongation, we were 
then curious about the reverse condition, where Mfd activity appears to be promoting 
gene expression (represented by the downregulated genes in the mfd mutant).  If Mfd is 
negatively affecting gene production near promoters, is it also capable of enhancing 
gene production at promoters?  We found 8 operons included repressed genes, and 
plotted the read coverage maps using the 100 bp bins RPKM data.  Like the 
overexpressed genes, mfd coverage deviated from the wildtype coverage near promoters 
(Figure 30B).  Analysis using 5 bp bins of the malK gene (which is repressed in mfd cells) 
confirmed the deviation occurred <20 bp from the promoter (data not shown). 
To broaden our search for termination sites outside of operons we looked for 
locations in the gene coverage maps where there is a sharp drop-off in read coverage in 
the MG1655 coverage maps that were not present in the mfd coverage.  This would 
indicate a position where Mfd is terminating transcription in wildtype cells but not in 
mfd cells.  Therefore we used the RPKM data for the 100 bp bins, and averaged 3 bins 
together, starting with every bin, to smooth out the noise in the data.  The slope in-
between each averaged bin set was taken for both cell lines and plotted against each 
other.  All mfd slopes and WT slopes less than -1 (as we were looking for sharp drops in 
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WT cells) were plotted against each other to highlight outliers with negative WT slopes 
and neutral or positive Mfd slopes (see Figure 32A).  Each transition examined occurred  
in-between genes (see Figure 32B for a representative example), further emphasizing 
that Mfd effects were occurring near promoters.  As a control, we examined the reverse 
conditions, where there were sharp drops in mfd cell lines that were not in the MG1655 
cells lines. The only dramatic read changes were due to the sharp drop in read 
expression at the mfd gene in the mfd cell lines as expected, confirming the validity in our 
method in identifying bona fide expression level transitions. 
As a large number of genes were downregulated in Mfd-overexpressing  cell 
lines, we also conducted a similar analysis of read coverage in MG1655 pCA24N cells vs 
MG165 pCA24N-Mfd cell lines.  Not surprisingly, we found numerous points where 
there was a large drop in Mfd-overexpressing cells that was not present in WT cells.  
After examining several of these points, it became quickly apparent that the large 
number of outliers were due to transitions from repressed genes to genes with similar 
expression as WT.  Therefore, we narrowed our search to look for transitions that 
occurred within genes.  Using both bin RPKM data and gene annotations , we screened 
through the genes with more than a 5-fold change in expression from beginning to end 
(roughly 20 genes) and identified two genes with the desired characteristic in both Mfd-
overexpressing strains: ycjM and macB (See Figure 33).  Structural analysis of the 
sequence surrounding the drop did not suggest the presence of an RNA hairpin,  
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Figure 32: Sharp drops in read coverage in WT cells 
Panel A is the comparison of changes in read coverage for each 100 bp averaged bin for 
WT (MG1655) and mfd cells. Locations of interest are those with a large negative WT 
slope and a small mfd slope.  The point circled in red is the location examined in Panel B.  
Panel B is the read coverage profiles for MG1655 and mfd cells, with the transition of 
interest shown in the red box.  While this is the target profile, it does not indicate a drop 
in transcription coverage within a gene, and instead reflects the transition in-between 
genes. 
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Figure 33: Sharp coverage drops within genes in Mfd-overexpressing cells. 
Read coverage profiles for the genes with a sharp cut-off in the middle of the gene 
generated by Geneious.  The drop off in Panel B occurs in the ycjM gene, and the drop 
off in Panel D occurs in the macB gene.   
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strongly suggesting against a possible type 1 pause site as the cause of elongating 
pausing/termination.   
To further examine the possibility of pause sites as Mfd termination sites, we 
examined the read coverage profiles for known type 1 (hairpin dependent) and type 2 
(backtracking) pause sites in both mfd and Mfd-overexpressing cells, including the his, 
trp, and ops operators.  There were no indications of termination at the pause sites for all 
locations examined (data not shown).  Taken together, our data strongly suggests a 
model by which Mfd is directly affecting transcription at or near transcription start sites. 
 
5.3 Discussion 
In this Chapter we have presented evidence for a role for Mfd outside of DNA 
repair, showing that Mfd affects transcription in normal wildtype cells.  We found that 
cells overexpressing Mfd have severe growth defects, and overexpressing Mfd at high 
levels is lethal.  Mfd-overexpressing cells have increased levels of tmRNA tagging even 
without any exogenous inhibitors, implying that Mfd is capable of prematurely 
terminating transcription.  We looked for aberrant transcription-coupled repair activity 
due to high Mfd levels, but deleting uvrA, the first protein to respond in the nucleotide 
excision repair pathway, did not relieve the growth sensitivity. 
We then looked for alterations in genomic transcription in both mfd and Mfd-
overexpressing cells to further characterize the Mfd termination activity.  We subjected 
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RNA from MG1655 mfd and MG1655 pCA24N-Mfd cells to deep sequencing analysis 
and compared the resulting read coverage profiles to their respective parent cells.  We 
found 94 genes affected 2-fold or more in the mfd cells, representing 2% of annotated 
genes in MG1655.  This is less than other global transcription regulators, such as dksA 
(~7%), ppGpp (6%), and H-NS and Fis (~5% each), suggesting that Mfd has more 
directed targets for regulation (171,173,174).  Of the 94 genes, 75 were downregulated 
and included ncRNA metabolic process genes, nucleobase, nucleoside and nucleotide 
interconversion genes, DNA replication, and tRNA genes.  The remaining 19 genes were 
upregulated and half were genes involved in carbohydrate catabolic process.     
Many of the genes we found affected by deleting mfd are involved in growth rate 
regulation, such as tRNA, RNA modifiers, and DNA replication.  Several of the tRNA 
genes upregulated in mfd cells are located in rRNA operons.  Unfortunately, the 23S 
rRNA, 16S rRNA, and 5S rRNA are removed in the library prep of RNAseq due to their 
high abundance compared to mRNA, so we were unable to see if these RNAs are 
reduced in mfd cells.  However, it is possible the entire operon is upregulated in mfd 
cells, and if so Mfd activity would then be downregulating growth rate by directly 
affecting ribosome levels.  This could then explain the severe growth defects of Mfd-
overexpressing cells.  However, further experiments are needed to fully understand 
Mfd’s role in growth rate regulation.  For example, it appears that Mfd is affecting global 
growth rate and not stringent response, as only 4 genes overlap between the genes 
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repressed by Mfd and those affected by deleting dksA or decreasing ppGpp levels.  Deep 
sequencing analysis of RNA from cells at different stages of growth could address this 
question.      
 In contrast with this negative regulator role, however, we found that a 
significant portion of the downregulated genes in mfd cells overlapped with genes 
affected by deleting dksA and reducing ppGpp levels, implying there might be some 
overlap between Mfd’s transcriptional regulation and activity of these regulators.  One 
caveat to this comparison is that our samples were collected during elongation phase 
(OD560 0.5) while the samples in the dksA study were collected at the start of stationary 
phase (OD560 1.5), when stringent response is expressed.   We also compared growth 
rates for mfd, dksA, and mfd dskA cells and found that the double mutants had a slightly 
decreased growth rates compared to either single mutant (the ratios for mutant/wildtype 
growth rates are 0.983, 0.850, and 0.814 for mfd, dksA, and mfd dksA cells, respectively), 
suggesting there might be some redundancy in activities.  Furthermore, DksA has been 
shown to prevent replication-transcription complexes in a manner independent of its 
transcription initiation activities (which are responsible for the stringent response), 
although the exact mechanism of this activity is unknown (81).  Perhaps this activity is 
functionally similar to Mfd’s ability to stimulate backtracked elongation complexes, and 
the overlap in genes affected reflects this mutual activity.   
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We also looked at the effect of overexpressing Mfd on transcriptional patterns 
and found that nearly a fourth of the genes in MG1655 are affected, with the vast 
majority of them being downregulated.  We also ruled out that these changes were due 
to just overexpressing a generic protein by comparing the genes affected to those 
affected by overexpressing chloramphenicol acetyltransferase.  While we could not 
statistically compare which genes are upregulated or repressed, we were able to look at 
read coverage profiles to determine if any particular location of the chromosome was 
targeted.  The terminus region, in particular the region between terA and terC, was 
severely downgregulated in the Mfd-overexpressing cells.  One possibility for this 
targeting is due to altered transcription of proteins involved in terminus region 
structure, and more quantitative studies of gene expression should shed light on the 
possibility of this occurring.  Another alternative model is that prophages and other 
horizontally acquired genes in the terminus region are targeted by Mfd activity.  
Interestingly, there was one gene, ydbA, in the terminus region with that was very highly 
upregulated (Figure 28).  This gene is interrupted by an insertion element, and only the 
downstream portion of the gene is upgregulated.  Genes with an insertion element in 
other locations in the chromosome (specifically gatR, yhcE, and yhiS) were identified that 
did not have this profile, meaning this effect is not generic to interrupted genes (data not 
shown).  Transcription terminator Rho is also known to silence prophages and 
horizontally acquired genes  (175,176).  However, when we compared the genes affected 
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by Mfd-overexpressing cells with those that are affected by bicyclomyin treatment 
(which inhibits Rho activity, from (175)), we found no significant overlap between the 
two systems.  While the Rho study was done using microarray and our Mfd 
overexpression data is not quantitative, it would appear that Mfd and Rho have 
different termination targets. 
We hypothesized that Mfd was terminating transcription at natural pause sites, 
and yet the read coverage data contradicted this by showing that termination was 
occurring at or near promoters.  We looked specifically for locations in the chromosome 
where there were sharp drops in read coverage profiles, yet were unable to find any 
sharp changes that did not occur at transcription start sites in either mfd or Mfd-
overexpressing cells.  When we narrowed the search to sharp drops within genes, we 
found two genes in the Mfd overexpressing cell lines with the desired characteristic, 
confirming that our method of searching was accurate.  Even if these are bona fide cases 
of transcription termination within genes, our data clearly supports a model where the 
majority of the influence on genomic expression by Mfd is occurring near promoters. 
Whether Mfd is directly or indirectly affecting gene expression at promoters still 
remains to be answered.  One model is that Mfd is terminating transcription just 
downstream of the promoter due to a secondary protein.  For example, it has been 
shown in B. subtilis that Mfd releases RNAP stalled at a CRE binding site 64 bp 
downstream of the promoter dra–nupC–pdp operon (177).  There could perhaps be some 
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sort of protein or sequence causing RNAP to stall just downstream of the promoter in 
these genes, causing them to be targeted by Mfd.  However, in this case we would 
expect to see the short transcripts produced due to transcription leading to the blocking 
protein.  It is possible that the resulting RNA is rapidly degraded.  While this seems 
unlikely due to the high sensitivity of RNAseq, RT-PCR or other specific studies of genes 
known to be downregulated by Mfd could rule out this possibility.   
Another model is that Mfd is somehow directly affecting polymerase at 
promoters.  While the exact kinetic and mechanistic details of promoter escape in vivo 
are not fully understood, current evidence shows that RNAP does not simply bind to 
promoters and rapidly begin elongating.  Initiation complexes typically undergo several 
rounds of abortive initiation (12), with the rate of escape depending on multiple factors 
(12-14).  A more recent study using CHIP-chip analysis showed RNAP is bound to 
several promoters without any transcriptional activity, which they call “poised 
promoters” (18).  However, one question that remains in this model is how Mfd releases 
RNAP with sigma present.  Mfd requires 25 base pairs of DNA template upstream of the 
stalled RNAP to act on stalled RNAP, and this site is occupied by σ when it is present 
(9,147).  While the question of the presence of the sigma factor remains, it possible that 
Mfd is somehow affecting promoter escape. 
We conclude that Mfd is capable of affecting gene expressing in wildtype cells, 
providing a novel role for Mfd as a transcription regulator.  While further studies are 
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necessary to determine the specific targets for Mfd activity, it appears that Mfd is 
targeting the transcription of genes directly or indirectly near promoters. 
 
5.4 Materials and Methods 
Materials 
Luria–Bertani broth (LB) contained Bactotryptone (10 g l-1), yeast extract (5 g l-1), 
and sodium chloride (10 g l-1) and was used for all bacterial growth (with appropriate 
antibiotics for plasmid selection and the indicated additions); Nitrocellulose membranes 
are from iBlot Gel Transfer stacks (Invitrogen); tmRNA antibodies were a generous gift 
from Tania Baker (MIT).  RecA and LexA antibodies were purchased from Abcam and 
Pierce, respectively.   
E. coli strains 
MG1655 [F- lambda- ilvG- rfb-50 rph-1] was obtained from the E. coli Genetic 
Stock Center (Yale University).  MG1655 mfd and MG1655 uvrA were made by P1 
transduction of mfd::kan and uvrA:kan, respectively, from the Keio collection with the 
Kanamycin resistance cassette still remaining.   
Plasmids 
pMFD19 is pIBI25 derivative that carries the mfd gene with its natural promoter 
and confers ampicilian resistance. The plasmid was created by Selby and Sancar (69) and 
was provided by Dr. Sancar.  pCA24N-Mfd is from the ASKA collection of E. coli ORF 
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without the GFP or His tag (102).  Mfd is expressed from the PT5-lac promoter that can be 
activated by IPTG. 
Western Blots for RecA, LexA, and tmRNA tagging 
RecA, LexA, and tmRNA tagging levels were analyzed in MG1655 cells 
containing pCA24N-Mfd. For the RecA and LexA western blots, cells were pregrown 
overnight in LB media at 37°C in the presence of chloramphenicol (30 µg/mL), and then 
diluted to an OD560 of 0.1. The cells were then grown to an OD560 of 0.5 in the same 
media, when a 2 mL aliquot of cells was pelleted and frozen.  The cells for the tmRNA 
western blots were grown in the same manner except cells were treated with 100 µM 
IPTG for the indicated times when they reached OD560 0.5.  At each timepoint, 2 mL 
worth of OD560 0.5 cells were removed and frozen.  2 mL of untreated cells were 
removed at OD560 0.5 as a control. 
For all western blots, the frozen cell pellets were thawed at room temperature, 
resuspended in 25 µL water and 25 µL SDS loading buffer (20% glycerol, 100 mM Tris 
pH 6.8, 2% SDS, 2% β-mercaptoethanol, and 0.1 mg Bromophenol blue), vortexed, and 
boiled for 5 minutes.  Lysates were loaded onto a 4-20% Mini-PROTEAN TGX gels (Bio-
Rad Laboratories) and the gels were run at constant voltage (200 V) for 45 min in 25 mM 
Tris-Glycine buffer with 0.1% SDS.  For the RecA and LexA western blots, protein 
concentrations in the cell lysates were measured using a BCA Protein Assay Kit (Thermo 
Scientific) using BSA standards.   Gels were transferred to a nitrocellulose membrane for 
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60 min at 12 V using a Genie Blotter transfer device (Idea Scientific Co.). The blot was 
blocked for 1 h in 20% non-fat milk powder solution (Biorad) in Tris-buffered saline 
(TBS). The membrane was incubated overnight at 4°C with either polyclonal RecA, 
LexA, or tmRNA tag primary antibody and Tween (0.1%), and then washed three times 
with TBS buffer at room temperature (10 min each). The membrane was incubated with 
secondary antibody (IRDye 800CW-conjugated goat anti-rabbit IgG (LI-COR®)) for 30 
min, and the washes were repeated. After air-drying, the membrane was scanned on an 
Odyssey Imaging System (LI-COR Biosciences), and quantified using the Odyssey 
software (version 3.0). 
Growth kinetics for uvrA pMfD19 cells 
Overnight cultures of MG1655 and MG1655 uvrA cells containing pMfd19 were 
pregrown in LB containing ampicillin (50 µg/mL).  Cells were diluted to an OD630 of 0.5, 
diluted 1:200 in LB with ampicillin, and then mixed with an equal volume (75 µl each) of 
LB containing serial dilutions of Stl (starting at 4.5 µg/ml) in 96-well plates. The cells 
were grown in a BioTek ELx808 Microplate Reader at 37°C with constant shaking, and 
OD630 was measured every 15 minutes for 18 h.  Cell growth was analyzed as in previous 
chapters. 
Deep sequencing analysis 
Three independent isolates of MG1655 and MG1655 mfd cells were grown to 
approximately mid-log phase (approximately OD560 0.5) in LB, when 2 mL worth of 
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OD560 0.5 cells were collected and frozen.  For the Mfd overexpressing experiments, 
MG1655 pCA24N and MG1655 pCA24N-Mfd cells were grown to roughly OD560 0.25 
and treated with 100 mM IPTG for 1 hour.  Cell pellets were lysed and RNA collected 
using Qiagen’s RNeasy Plus Mini Kit with Qiagen Bacteria Protect RNA kit.  RNA 
samples were then treated with DNase (New England Biolabs) for 30 min at 37 °C.  
Reactions were stopped by adding 5 mM EDTA and incubating at 75 °C for 10 minutes.   
Library preparation, rRNA depletion, and deep sequencing were performed at 
the Sequencing Facility of the Duke Institute for Genome Sciences & Policy (IGSP).  
rRNA was depleted using Ribo-Zero™ rRNA Removal Kits (Epicentre).   Deep 
sequencing was performed via Illumina HiSeq™ (50 bp single reads).  The sequencing 
reads (approximately 13 to 25 million per sample) were imported into Geneious Pro 
(Biomatters) and assembled to the reference chromosome MG1655 (GenBank Accession 
Number 000913.2). The assembly process was set to medium/low sensitivity on 
Geneious, with the following parameters: 10% gaps allowed per read; word length of 18; 
index word length of 13; words repeated more than 12 times ignored; 20% maximum 
mismatches per read; and maximum ambiguity of 4.  Read coverage maps and RPKM 
data was subsequently generated by Geneious.  BAM files of the resulting assembly data 
were exported to JMP Genomics (SAS).  TMM normalization and ANOVA analysis of 
the read samples were conducted in JMP. 
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Sharp changes in read coverage 
To locate sharp read changes in the Mfd-overexpressing cells, we first eliminated 
genes that were less than 400 bp long (too small for our analysis) and had RPKM values 
less than 2.5 (poor expression).  We then took the transcription start and end values and 
rounded to the nearest hundred basepair to allow for alignment with the 100 bp bin 
RPKM values.  We also added/subtracted 100 bp from the ends to minimize expression 
overlaps between genes.  We then took the ratio of the beginning 100 bp RPKM value to 
the end value for each gene in each cell line, accounting for gene directionality.  The 
resulting ratios for the Mfd-overexpressing cell lines were then divided by the WT ratios 
to identify genes with sharp drops in expression levels only in the Mfd-overexpressing 
cell lines.   
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6. Conclusions and Future Directions 
6.1 Summary of Results 
In this dissertation, we examined the fate of transcription elongation complexes 
stalled by DNA-protein complexes, Streptolydigin, and Actinomycin D.  Transcription is 
a vital process for protein production and cell survival, and therefore it is important to 
know how the cell responds to these types of stress.  Stalled transcription complexes can 
also lead to replication-transcription collisions, which can lead to DNA damage, 
genomic rearrangements, and cell death (31,70,81).  The cell must therefore have a way 
to clear these complexes, either by restarting them or removing them from DNA.  
Understanding how the cell responds to blockages in transcription provides insight into 
the requirements for productive elongation.  Furthermore, several antibiotics function 
by blocking transcription, and understanding how the cell responds to these inhibitors 
could give insights on how to make the inhibitors more effective.   
DNA-protein crosslinks form when proteins become covalently trapped on 
DNA.  The type of proteins and the locations where they form all vary, making DPC 
study quite difficult.  As a result, they are one of the more poorly understood forms of 
DNA damage.  We use 5-azacytidine as a model system to combat the inherent 
variability of DPC study.  Aza-C is a cytidine analog that covalently traps cytosine 
methyltransferases at known recognition sequences.  Using this system, we showed that 
the tmRNA system is required for cell survival during DPC formation due to its ability 
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to recycle stalled ribosomes.  This raised the question of how tmRNA is able to access 
the stalled ribosome.  Previous members of our lab looked at tmRNA tagging levels of 
aza-C hypersensitive mutants, but did not identify and mutants with decreased tagging 
that would be expected to release RNAP.  In this study, we looked for evidence of A-site 
cleavage by testing candidate rnase knockout mutants, but again did not find a role for 
A-site cleavage in cell survival during DPC formation.   The mechanism for tmRNA 
activity during DPC formation is still unknown.   
The aza-C hypersensitivity screen conducted previously identified uvrD and 
dinG knockouts as hypersensitive to aza-C, potentially indicating that these are the 
factors responsible for clearing stalled RNAP.  We also discovered that dksA knock-out 
mutants are slightly resistant to Aza-C treatment, and have increased levels of tmRNA 
tagging.  DksA is an elongation factor that could be competing with the release 
mechanism responsible for tmRNA activity.   These results expanded upon our 
previously proposed “chain-reaction” model (See Figure 34).  
Using the same genetic screening and candidate mutant approach, we also 
attempted to identify the mechanism for the repair of DPCs, and ruled out many 
pathways that could be expected to be involved.  We did find that dnaK mutants are 
resistant to aza-C treatment.  Taken together with the previous discovery that dnaJ 
mutants are hypersensitive, we propose that there could be some DnaJ-dependent, 
DnaK-independent protein degradation involved in DNA repair.       
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Figure 34: Model for the fate of elongation complexes at DPCs 
DPC formation leads to transcriptional and translational stalling.  The stalled RNAP can 
either be cleared most likely through the activities of UvrD and DinG, or it can 
potentially continue elongation with the assistance of DksA.  The tmRNA system is also 
responsible for clearing the stalled ribosomes in an A-site cleavage-independent manner.  
The model shown here has tmRNA clearing the ribosomes before the release of RNAP, 
but the exact order of these steps has not been elucidated. 
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Because the study of the effect of DPCs on transcription is complicated by the 
other uncertainties inherent in DPC formation (such as how DPCs are repaired), we 
used the elongation inhibitors Streptolydigin and Actinomycin D to isolate the effects on 
transcription.  We showed that Stl binding is transient and suggest that RNAP needs to 
be held in an open conformation for efficient inhibition.  This latter finding was 
supported by the discovery that a mutant polymerase with increased pausing is 
hypersensitive to Stl, while a mutant polymerase with decreased pausing is resistant.  
We also found that a mutant polymerase with decreased pausing is dramatically 
resistant to ActD, providing surprising evidence for the role of RNAP dynamics in ActD 
sensitivity.  We looked for additional Rif-resistant mutations in the β subunit of RNAP 
that lead to ActD resistance, and identified 8 mutations in 6 positions that lead to 
resistance.  This data suggests a novel mechanism for ActD inhibition of RNAP that is 
more complicated than just steric hindrance on DNA. 
With our increased understanding of Stl and ActD inhibition, we were able to 
address the question of the fate of transcription complexes stalled by exogenous 
inhibitors.  Contrary to DPCs, the transcription-coupled repair pathway appears to clear 
stalled elongation complexes, competing with productive elongation that could occur 
once the drug binding reverses.  We also provided evidence indicating that Mfd removal 
of elongation complexes creates the substrates necessary for the involvement of the 
tmRNA system.  Mfd termination was also shown to be responsible for part of the  
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Figure 35: Model for the fate of elongation complexes stalled by Stl 
During Stl treatment, Mfd is responsible for releasing the majority of Stl-stalled 
transcripts.  This creates substrates for the tmRNA system, which then recycles the 
stalled ribosomes on the nascent transcript.  The tmRNA system is also capable of 
releasing a small amount of ribosomes without Mfd activity.  Rep also releases a small 
amount of RNAP, presumably ahead of replication forks.  In the absence of Mfd, the 
transient nature of Stl binding allows for the proper resumption of the majority of the 
elongation complexes. 
 156 
hypersensitivity of rpoB8 mutants, potentially due to the increased amount of paused 
polymerases that are targets for Mfd termination.  Taken together, we propose that Mfd 
termination and productive elongation are in competition with one another during 
elongation inhibitor treatment.  See Figure 35 for our proposed model.   
We also propose a novel role for Mfd in regulating global gene expression when 
there is no DNA damage or exogenous inhibitors present.  Cells overexpressing Mfd 
were shown to have increased levels of tmRNA tagging, which implies Mfd activity is 
leading to transcription termination either directly or indirectly.  This termination does 
not appear to be due to aberrant NER repair.  If Mfd is terminating elongation, it could 
be expected to be altering global transcription patterns, and therefore we subjected RNA 
isolated from mfd and Mfd-overexpressing cells to RNAseq.  In the mfd knockout cells 
we found that genes involved in ncRNA metabolic processes, nucleotide 
interconversion, and DNA replication were upregulated.  Many tRNA genes, in 
particular several located in rRNA operons, were also upregulated.  Genes involved in 
catabolic processes were downregulated, several of which overlapped with genes that 
are downregulated in dksA and ppGpp° cells.  Taken together, the RNAseq results 
implied that Mfd might play a role in growth rate regulation.           
In the Mfd-overexpressing cells, nearly a fourth of the annotated genes in 
MG1655 were affected, with the vast majority of these affected genes downregulated.  
The Terminus region was particularly underrepresented in Mfd-overexpressing cells.  
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This data supported our model that Mfd activity results in transcription termination.  
With the discovery that Mfd negatively affects cells expressing an RNAP mutant with 
increased pausing, we hypothesized that Mfd is terminating transcription at natural 
pause sites.  Surprisingly, analysis of the location of deviation between mfd and wildtype 
read coverage showed that transcription profiles deviate at or near promoters at nearly 
all locations examined.  We propose instead that Mfd is either directly or indirectly 
affecting promoter escape.   
 
6.2 “Chain-reaction” model for DPC consequences 
In Chapter 2 we introduced the “chain-reaction model” for the effects on DPC 
formation on translocating proteins.  Our lab previously showed the replication forks 
are inhibited by DPCs (42), and here we show genetic evidence that DPCs block 
transcription and translation.  The tmRNA system is recruited to remove the stalled 
polymerase, while the RNAP is cleared via an unknown mechanism.  Presumably, once 
the stalled translation and elongation complexes are cleared the DPC itself can be 
repaired.   
The most likely candidates for RNAP release during DPC formation are DinG 
and UvrD.  Transposon insertions in these genes resulted in hypersensitivity to aza-C, 
and these proteins have been shown to promote cell survival during 
replication/transcription collisions (70).  Furthermore, UvrD has been implicated as 
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having a general role in removing proteins from DNA to assist with the translocation of 
replication forks (71).  Conversely, DksA activity appears to be detrimental to cell 
survival during DPC formation, which could potentially be related to its competition 
with tmRNA recycling.  Further genetic tests with DinG, UvrD, DksA, and SmpB in 
various double-mutant combinations could shed light on the interplay of these 
pathways.  In vitro elongation studies would also be useful in confirming the details of 
this model.  First, assays utilizing a template with a DPC (similar to the one used in (43)) 
could be employed to look for proteins capable of releasing RNAP, including DinG and 
UvrD.  The use of DksA in these studies could also show if it is capable of promoting 
transcription past the lesion, or if it competes with release if a release protein is 
confirmed. 
In this model, we have yet to discern whether the release of the ribosome or the 
RNAP occurs first.  If RNAP is released first, the nascent transcript would also be  
released, allowing translation to continue to the end of the transcript and tmRNA to 
bind to the empty A-site.  However, tmRNA has been shown to rescue ribosomes at rare 
codons, indicating that there is a mechanism for tmRNA activity when ribosomes are 
stalled in the middle of a transcript (88).  Given that ribosome pausing stimulates both 
A-site cleavage and tmRNA activity, and that the first step of tmRNA rescue is binding 
to the empty A-site of a ribosome, it was proposed that these two pathways were 
coupled (90).    However, it has since been shown that RNase II activity is required for 
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A-site cleavage (124), yet a recent study by the same lab showed that tmRNA tagging 
levels are unaffected in RNase II deficient cells (90).  Therefore, a mechanism must exist 
in the cells for tmRNA to act on ribosomes stalled in the middle of a transcript that is 
independent of RNase II–mediated A-site cleavage.  
   
6.3 Repair of DPCs 
The repair of DPCs has been an ongoing topic of interest in our lab.  While it was 
not a direct aim of this dissertation, genetic tests were conducted in an effort to at 
minimum identify potential repair pathways.  To this end, we found that dnaK mutants 
were resistant to DPC formation.  When taken together with the discovery that dnaJ 
mutants are hypersensitive, these data present two possible pathways for the role of 
these chaperone proteins: DnaJ might be repairing DPCs directly, with DnaK partially 
competing with this activity, or the induction of heat shock proteins in dnaK mutants is 
facilitating repair and DnaJ assists in cell survival in another manner.   Further 
experiments are needed to separate these two possibilities. 
To identify if DnaJ is affecting DPC repair directly, an assay measuring the level 
of DPCs in vivo would be of great use.  A previous member of our lab presented a 
promising Western-based assay for monitoring DPC formation in vivo, showing that he 
could detect DNA-bound MTase in a western blot, running slower than free MTase 
(Kenny Kuo, unpublished results).  Once fully developed, this assay could be used to 
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monitor the level of DPC formation in dnaJ knockout cells.  Additionally, the 2D-gel 
based assay used to show that DPCs block replication (42) could be used to monitor the 
blockage of replication in dnaJ and dnaK cells, as alterations in the levels of blocked 
replication forks would indicate changes in the efficiency of  DPC repair. 
To test if stimulation of heat shock proteins is the cause for the resistance to aza-
C in dnaK mutants, the effects of DPC formation during a 42 °C pulse treatment (to 
induce heat shock expression) could be tested.  Conversely, the heat shock response can 
be initiated by overexpressing RpoH (sigma 32) (178), so aza-C hypersensitivity profiles 
for cells overexpressing RpoH could also answer if the heat shock response is 
responsible for cell survival during DPC formation. 
 
6.4 Actinomycin D mechanism of inhibition 
To understand the mechanism of ActD inhibition, we would like to characterize 
mutations that lead to ActD resistance.  However, we found a surprisingly high rate of 
mutation frequency leading to ActD resistance, implying there might be a mechanism 
for overcoming ActD entry into the cell even when the membrane is compromised.  This 
system could potentially play a role in the mechanisms of ActD resistance, or it could be 
a more trivial way for the cell to not be affected by the drug.  One possibility in the latter 
scenario is that the drug is being pumped out via an efflux system.  Therefore we would 
like to test knockouts of different efflux systems for their sensitivity to ActD.  A recent 
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study identified 20 different proteins belonging to five families that are capable of 
transporting various classes of antibiotics and small molecules (179).  We would like to 
test knockouts of these genes to see if we can identify the system(s) responsible for the 
ActD resistance.   
The intercalation of Actinomycin D into DNA has been well established (63,64).  
However, the fact we were able to isolate rpoB mutants that are resistant to ActD 
suggests that there could potentially be direct interactions between ActD and RNAP 
once RNAP transcribes to the site of ActD intercalation.  We would be greatly interested 
in seeing if ActD binds directly to RNAP, or if it is the properties of the RNAP mutants 
that lead to resistance to ActD.  One potential assay for this would be to test various 
RNAP mutants, in particular RpoB2 and RpoB8, in an in vitro system using ActD 
treatment.  We could monitor the transcription rates for each mutant in the absence of 
ActD, then see how transcription varies when ActD is added.  If RNAP and ActD are 
interacting directly, you would expect there would be multiple possible substitutions in 
the putative ActD binding site of RNAP that could lead to ActD resistance.  
Additionally, more comprehensive screening of rpoB mutants could further detail the 
putative ActD binding site.     
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6.5 Factors that recognize Stl-stalled RNAP 
Unlike RNAP stalled by DPCs, Stl-stalled RNAP is primarily cleared by the the 
transcription-coupled repair pathway.  However, our genetic studies also indicated that 
Rep activity also inhibits cell survival during Stl treatment.  Like DinG and UvrD, Rep is 
capable of releasing RNAP when replication forks collide (70,71).  Rep travels with the 
replication fork and acts as a “bulldozer” to remove proteins that would otherwise 
impede translocation (71).  We propose that Mfd is the primary factor that removes Stl-
stalled RNAP, while Rep removes a small fraction when replication forks collide with 
the immobile RNAP.  Similar to DinG and UvrD, this activity does not appear to lead to 
tmRNA activity, and instead another mechanism must be employed for tmRNA 
recycling.  
We attempted to analyze drug sensitivity profiles with cells overexpressing Rep, 
but found that full expression of Rep from the pCA24N plasmid with IPTG  induction 
was lethal.  A cleaner expression system is needed to be certain Rep activity is 
detrimental to cell growth during Stl treatment.  One option is the pBad plasmid system, 
which is fully titratable in specially designed cell lines such as BW27783 (98,180).  In vitro 
studies looking for Rep termination could also be conducted in a similar manner to Mfd 
(see below) to see if Rep is capable of releasing Stl-stalled RNAP, although it might need 
to be part of a replication fork to be active.         
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6.6 In vitro elongation studies with Streptolydigin and 
Actinomycin D 
In vitro elongation studies can help give insight into both the mechanism of 
inhibition and the factors capable of releasing stalled RNAP.  As mentioned previously, 
they can be applied to all three methods of inhibition used in this dissertation.  
However, certain technical challenges were presented in the previous chapters that need 
to be addressed for these types of assays.  
For reactions involving Stl, we must first identify the conditions in which Stl is 
capable of inhibiting RNAP.  Using the PCR fragment from pDE13 as a template, Erie et 
al. showed that nucleotide starved RNAP undergoes conformation switches between the 
activated and inactivated states as it attempts to undergo further rounds of nucleotide 
addition (136).  While addition of a proper nucleotide proceeds rapidly, the 
misincorporation of an incorrect nucleotide occurs at a much slower rate, which could 
potentially give Stl enough time to bind to an inactivated state ((136) and Dorthy Erie, 
personal communication).  Therefore a preincubation step with Stl could lead to 
inhibition of elongation in our current assay.  To expand upon our hypothesis that Stl 
binding requires a paused or otherwise arrested RNAP, we could use a template with a 
well-studied pause site and see if Stl is capable of stalling RNAP on this template.   
In order to study the role of transcription factors such as Mfd in removing stalled 
RNAP, we propose expanding the current studies to using a bead-based assay to 
directly monitor transcript release.  These assays are based on the work of Park et al. 
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(147), who used DNA templates bound to a magnetic bead to separate RNA transcript 
products into “pellet” (still in the ternary complex and thus attached to the magnetic 
beads) and “supernatant” (released from the complex) fractions.  In this manner, we 
could study the release of transcripts under conditions that do not promote full-length 
transcript production, such as in the case of a tight ActD complex.   
The proposed method is as follows: PCR of the pDE13 fragment is conducted 
using a biotin labeled primer, and the resulting products are pre-bound to streptavidin-
coated magnetic beads.  +24 complexes are formed in a similar manner as previously, 
including a pre-incubation step with ActD or Stl.  All four nucleotides are then added to 
allow for elongation to continue if possible, assuring that complex stalling is now to due 
the presence of the inhibitor and not nucleotide starvation.  A long incubation with Mfd 
(or another potential release factor) could then be implemented, and the reactions 
separated into pellet and supernatant fractions by magnetically capturing the beads.  We 
could then monitor the presence of transcripts smaller than the full-length product in the 
pellet or supernatant fractions, with the presence of transcripts in the supernatant 
indicating release.  This assay would allow for direct monitoring of release, instead of 
simply inferring release from the lack of full-length transcripts.  
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6.7 Identifying the targets of Mfd termination in wildtype cells 
We were surprised to find that cells overexpressing Mfd had high levels of 
tmRNA tagging even in the absence of Stl.  This implies that Mfd has termination 
activity in wildtype cells, which is further supported by the growth deficiencies of Mfd-
overexpressing cells.  However, our expression system is one that expresses Mfd at very 
high levels in an on-or off- manner.  More careful expression of Mfd would help 
separate out potential secondary effects of recombinant protein expression, such as by 
cloning Mfd into a pBad plasmid and expressing in BW27783 (see above).   
While not quantitative, the RNAseq data with the Mfd-overexpressing cells 
showed that cells undergo vast transcriptional modifications when Mfd activity is 
elevated.  Higher sample numbers would allow for statistical analysis of the genes 
affected, and could be useful in parsing out specific targets for Mfd activity.  In addition, 
we would like to introduce a control that isolates the effect of Mfd activity on gene 
expression.  Chambers et al. identified a point mutation in the TRG (translocase in RecG) 
domain that eliminates Mfd’s ability to release RNAP but not its ATPase or DNA 
binding abilities (125).  RNAseq studies using this mutant would serve as a solid control 
to remove genes affected by protein overexpression.    
The RNAseq results from the mfd mutant cell lines indicated a possible role for 
Mfd in global growth rate regulation.  Of particular interest are the changes to rRNA 
and tRNA levels, as these are the primary genes that regulate growth rate.  However, we 
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were unable to monitor changes in rRNA levels using RNAseq as these RNAs are 
removed during library formation.  RT-PCR of these genes from mfd cells could confirm 
the effect of Mfd on tRNA genes located in ribosomal operons, and further indicate if 
Mfd is affecting levels of rRNAs.  RNAseq analysis of mfd cells under different growth 
conditions, such as at different temperatures and different stages of growth could also 
help address if Mfd is affecting global growth rate. 
We also proposed that Mfd is affecting gene expression at promoters, potentially 
by affecting promoter escapes.  It is tempting to speculate that Mfd targets RNAP 
discovered to be “poised” at promoters (18).  To test this, ChIP-Seq experiments 
monitoring the location of RNAP in mfd mutants compared to wildtype cells could 
indicate if Mfd is affecting the distribution of RNAP in cells. 
 
6.8 Final Remarks 
The initial goal of this dissertation was to identify the fate of transcription 
elongation stalled at DNA damage in the form of DNA-protein crosslinks.  While we 
have identified candidate factors involved in recognizing stalled RNAP, the study of the 
effects of DPCs on elongation is complicated by the numerous primary and secondary 
effects of DPC formation; replication has been shown to be blocked by DPCs (42), and 
could also be colliding with RNAP that is already trapped at a DPC.  Repair factors 
attempting to repair the DPC might also be present, resulting in a potentially large “pile-
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up” at DPCs.  We had hoped that the use of Stl and ActD would provide a way to isolate 
the effects on transcription, particularly if the same pathway responded in both systems.  
However, our results imply that clearing of stalled RNAP complexes is more complex, 
and that different pathways can respond under different conditions.  
During DPC formation, the tmRNA system is responsible for clearing the stalled 
ribosomes in an A-site cleavage-independent manner.  The RNAP is also cleared most 
likely through the activities of UvrD and DinG.  DksA also assists in cell survival in a 
way that is counteractive to the tmRNA system.  This suggests that perhaps some 
transcription can occur past the lesion, though this is still highly speculative.  Notably, 
the transcription-coupled repair pathway does not assist in cell survival during DPC 
formation.  Given that Mfd is capable of releasing RNAP stalled at a bound protein in 
many other conditions (66,125,177), it appears that the activities of UvrD and DinG 
outcompete Mfd for RNAP binding.   
In the case of Stl and ActD inhibition, we propose that Mfd is responsible for 
releasing stalled polymerase, but this release causes a premature termination phenotype 
and is detrimental to cell growth.  This activity creates substrates for the tmRNA system, 
which accounts for part of the total tmRNA activity in the cell.  tmRNA is apparently 
capable of releasing a small fraction of ribosomes in the absence of Mfd, perhaps in a 
similar manner as with DPC formation.  Rep also removes Stl-stalled RNAP, 
presumably ahead of a colliding replication fork.  This most likely occurs after tmRNA 
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has already cleared the ribosomes, as Rep does not create substrates for the tmRNA 
system.  In the absence of Mfd, the transient nature of Stl binding allows for proper 
elongation to continue for the majority of elongation complexes.  tmRNA is apparently 
capable of releasing ribosomes during the short amount of time that they are stalled, as 
tmRNA contributes to cell survival in the absence of Mfd. 
This dissertation confirms previous studies that show the importance of 
transcription regulation in cell survival during stressful situations.  The cell has 
numerous, partially redundant pathways to help clear stalled transcription complexes 
and maintain a pool of productive RNAP via recycling.  Certain antibiotics can take 
advantage of these pathways, turning this recycling of RNAP into detrimental 
premature termination.  Elucidating the cellular consequences of transcriptional arrest 
assists in both the understanding of an essential cellular process and increases the 
potential for better antibiotic design and application. 
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Appendix I 
Gene Function 
dinG helicase, prevents replication/transcription collisions 
dksA transcription elongation factor; assists with stringent response 
dnaJ Chaperone 
dnaK Chaperone 
greA elongation factor; stimulates mRNA cleavage activity of RNAP 
greB elongation factor; stimulates mRNA cleavage activity of RNAP 
hepA RNAP recycling factor 
hflC component of hflCK complex; regulates FtsH protease 
lexA transcription repressor; suppresses the SOS response 
mfd transcription-coupled repair factor 
Mu 9 unknown function 
Mu Gam nuclease inhibitor 
nusA transcription terminator/antiterminator factor 
recA functions in DNA strand exchange and recombination  
recB helicase; essential for recombination and dsDNA break repair 
recC essential for recombination and dsDNA break repair 
recF functions in RecA-mediated recombination  
recG helicase; catalyzes branch migration on forked DNA structures 
rep helicase; removes proteins from DNA ahead of replication fork 
rho transcription termination factor 
rnase D 
exonuclease involved in the 3' ribonucleolytic processing of 
precursor tRNA 
rnaseII 3' exonuclease; involved in tRNA processing 
rnaseLS endoribonuclease that plays a role in mRNA degradation 
rnasePH 3'  exonuclease; involved in tRNA processing 
sbcCD 
exonuclease complex; inserts double-strand breaks in protein-
bound DNA 
smpB tmRNA cofactor; required for stable tmRNA binding to ribosomes 
ssrA specialized tmRNA; ribosome recycling 
trmH methyltransferase; methylates a subset of tRNAs and rRNAs 
umuCD translesion polymerase involved in SOS response 
uvrA subunit of the UvrABC nucleotide excision repair complex 
uvrD helicase; prevents replication/transcription collisions 
yejH putative helicase; complements UV repair damage 
 170 
References 
1. Landick, R., and Yanofsky, C. . (1987) In F. C. Neidhardt, J. L. I., K. B. Low, B. 
Magasanik, M. Schaechter, and H. E. Umbarger (ed.), Escherichia coil and 
Salmonella typhimurium: Cellular and Molecular Biology. American Society for 
Microbiology, Washington D.C., pp. 1276-1301. 
 
2. Landick, R., and Turnbough, C. L. (1992) In Yamamoto, S. L. M. a. K. R. (ed.), 
Transcriptional Regulation. Cold Spring Harbor Laboratory Press, Cold Spring 
Harbor, New York, pp. 407-446. 
 
3. Roberts, J.W., Shankar, S., Filter, J.J. (2008) RNA polymerase elongation factors. 
Annu. Rev. Microbiol., 62, 211-233. 
 
4. Zhang, G., Campbell, E.A., Minakhin, L., Richter, C., Severinov, K. and Darst, 
S.A. (1999) Crystal structure of Thermus aquaticus core RNA polymerase at 3.3 A˚ 
resolution. Cell, 98, 811–824. 
 
5. Cramer, P., Bushnell, D.A. and Kornberg, R.D. (2001) Structural basis of 
transcription: RNA polymerase II at 2.8 angstrom resolution. Science, 292, 1863-
1876. 
 
6. Minakhin, L., Bhagat, S., Brunning, A., Campbell, E.A., Darst, S.A., Ebright, R.H. 
and Severinov, K. (2001) Bacterial RNA polymerase subunit omega and 
eukaryotic RNA polymerase subunit RPB6 are sequence, structural, and 
functional homologs and promote RNA polymerase assembly. Proc Natl Acad Sci 
U S A, 98, 892–897. 
 
7. Werner, F. (2008) Structural evolution of multisubunit RNA polymerases. Trends 
in Microbiology, 16, 247-250. 
 
8. Mooney, R.A., Darst, S.A. and Landick, R. (2005) Sigma and RNA polymerase: 
An on-again, off-again relationship? Mol Cell, 20, 335–345. 
 
9. Marr, M.T., Datwyler, S.A., Meares, C.F. and Roberts, J.W. (2001) Restructuring 
of an RNA polymerase holoenzyme elongation complex by lambdoid phage Q 
protein. Proc Natl Acad Sci U S A, 98, 8972–8978. 
 
 171 
10. Ring, B.Z., Yarnell, W.S. and Roberts, J.W. (1996) Function of E. coli RNA 
polymerase sigma factor sigma 70 in promoter-proximal pausing. Cell, 86, 485-
493. 
 
11. Mooney, R.A. and Landick, R. (2003) Tethering sigma70 to RNA polymerase 
reveals high in vivo activity of sigma factors and sigma70-dependent pausing at 
promoter-distal locations. Genes Dev, 17, 2839-2851. 
 
12. Goldman, S.R., Ebright, R.H. and Nickels, B.E. (2009) Direct Detection of 
Abortive RNA Transcripts in Vivo. Science, 324, 927–928. 
 
13. Stepanova, E., Lee, J., Ozerova, M., Semenova, E., Datsenko, K., Wanner, B.L., 
Severinov, K. and Borukhov, S. (2007) Analysis of promoter targets for Escherichia 
coli transcription elongation factor GreA In vivo and in vitro. J Bacteriol, 189, 
8772–8785. 
 
14. Gourse, R.L., Gaal, T., Bartlett, M.S., Appleman, J.A. and Ross, W. (1996) rRNA 
transcription and growth rate-dependent regulation of ribosome synthesis in 
Escherichia coli. Annu Rev Microbiol, 50, 645-677. 
 
15. Vassylyev, D.G., Vassylyeva, M.N., Perederina, A., Tahirov, T.H. and 
Artsimovitch, I. (2007) Structural basis for transcription elongation by bacterial 
RNA polymerase. Nature, 448, 157-162. 
 
16. Bar-Nahum, G. and Nudler, E. (2001) Isolation and characterization of sigma(70)-
retaining transcription elongation complexes from Escherichia coli. Cell, 106, 443-
451. 
 
17. Mukhopadhyay, J., Kapanidis, A.N., Mekler, V., Kortkhonjia, E., Ebright, Y.W. 
and Ebright, R.H. (2001) Translocation of sigma(70) with RNA polymerase 
during transcription: fluorescence resonance energy transfer assay for movement 
relative to DNA. Cell, 106, 453–463. 
 
18. Reppas, N.B., Wade, J.T., Church, G.M. and Struhl, K. (2006) The transition 
between transcriptional initiation and elongation in E. coli is highly variable and 
often rate limiting. Mol. Cell, 24, 747–757. 
 
19. Vogel, U. and Jensen, K. (1995) The RNA chain elongation rate in Escherichia coil 
depends on the growth rate. J. Bacteriol., 176, 2807-2813. 
 172 
20. Liu, K., Zhang, Y., Severinov, K., Das, A. and Hanna, M.M. (1996) Role of 
Escherichia coli RNA polymerase alpha subunit in modulation of pausing, 
termination and anti-termination by the transcription elongation factor NusA. 
EMBO J., 15, 150–161. 
 
21. Nudler, E. (1999) Transcription elongation: structural basis and mechanisms. J. 
Mol. Biol., 288, 1–12. 
 
22. Erie, D.A. and Kennedy, S.R. (2009) Forks, pincers, and triggers: the tools for 
nucleotide incorporation and translocation in multi-subunit RNA polymerases. 
Current Opinion in Structural Biology, 19, 708–714. 
 
23. Toulokhonov, I., Zhang, J., Palangat, M. and Landick, R. (2007) A central role of 
the RNA polymerase trigger loop in active-site rearrangement during 
transcriptional pausing. Mol. Cell, 27, 406–419. 
 
24. Erie, D.A. (2002) The many conformational states of RNA polymerase elongation 
complexes and their roles in the regulation of transcription. Biochimica et 
Biophysica Acta, 1577, 224– 239. 
 
25. Erie, D.A., Yager, T.D. and Hippel, P.H.v. (1992) The single-nucleotide addition 
cycle in transcription: a Biophysical and Biochemical perspective. Annu. Rev. 
Biophys. Biomol. Struct., 21, 379-415. 
 
26. Temiakov, D., Patlan, V., Anikin, M., McAllister, W.T., Yokoyama, S. and 
Vassylyev, D.G. (2004) Structural basis for substrate selection by T7 RNA 
polymerase. Cell, 116, 381–391. 
 
27. Landick, R. (2006) The regulatory roles and mechanism of transcriptional 
pausing. Biochem. Soc. Trans., 34, 1062–1066. 
 
28. Artsimovitch, I. and Landick, R. (2000) Pausing by bacterial RNA polymerase is 
mediated by mechanistically distinct classes of signals. Proc. Natl. Acad. Sci. U. S. 
A., 97, 7090–7095. 
 
29. Toulokhonov, I., Artsimovitch, I. and Landick, R. (2001) Allosteric control of 
RNA polymerase by a site that contacts nascent RNA hairpins. Science, 292, 730–
733. 
 173 
30. Borukhov, S., Lee, J., Laptenko, O. (2005) Bacterial transcription elongation 
factors: new insights into molecular mechanism of action. Mol. Microbiol., 55, 
1315-1324. 
 
31. Dutta, D., Shatalin, K., Epshtein, V., Gottesman, M.E., and Nudler, E. (2011) 
Linking RNA Polymerase Backtracking to Genome Instability in E. coli. Cell, 146, 
533–543. 
 
32. Kireeva, M.L. and Kashlev, M. (2009) Mechanism of sequence-specific pausing of 
bacterial RNA polymerase. Proc. Natl. Acad. Sci. U. S. A., 106, 8900–8905. 
 
33. Neuman, K.C., Abbondanzieri, E.A., Landick, R., Gelles, J. and Block, S.M. (2003) 
Ubiquitous Transcriptional Pausing Is Independent of RNA Polymerase 
Backtracking. Cell, 115, 437–447. 
 
34. Lesnik, E.A., Sampath, R., Levene, H.B., Henderson, T.J., McNeil, J.A. and Ecker, 
D.J. (2001) Prediction of rho-independent transcriptional terminators in 
Escherichia coli. Nucleic Acids Res., 29, 3583–3594. 
 
35. Wilson, K.S. and Hippel, P.H.v. (1995) Transcription termination at intrinsic 
terminators: The role of the RNA hairpin. Proc. Natl. Acad. Sci. U. S. A., 92, 8793-
8797. 
 
36. Nudler, E. and Gottesman, M.E. (2002) Transcription termination and anti-
termination in E. coli. Genes to Cells, 7, 755–768. 
 
37. Peters, J.M., Vangeloff, A.D. and Landick, R. (2011) Bacterial Transcription 
Terminators: The RNA 3′-End Chronicles. J. Mol. Biol., 412, 793–813. 
 
38. Pomerantz, R.T., and O’Donnell, M. (2008) The replisome uses mRNA as a 
primer after colliding with RNA polymerase. Nature, 456, 762–766. 
 
39. Pomerantz, R.T., and O’Donnell, M. (2010) Direct restart of a replication fork 
stalled by a head-on RNA polymerase. Science, 327 590–592. 
 
40. Nakano, T., Morishita, S., Katafuchi, A., Matsubara, M., Horikawa, Y., Terato, H., 
Salem, A.M.H., Izumi, S., Pack, S.P, Makino, K., Ide, H. (2007) Nucleotide 
excision repair and homologous recombination systems commit differentially to 
the repair of DNA-protein crosslinks. Mol. Cell, 28, 147-158. 
 174 
41. Barker, S., Weinfeld, M., Murrary, D. (2005) DNA-protein crosslink: their 
induction, repair, and biological consequences. Mutational Research, 589, 111-135. 
 
42. Kuo, H.K., Griffith, J.D. and Kreuzer, K.N. (2007) 5-Azacytidine induced 
methyltransferase-DNA adducts block DNA replication in vivo. Cancer Res, 67, 
8248-8254. 
 
43. Som, S. and Friedman, S. (1994) Inhibition of transcription in vitro by binding of 
DNA (cytosine-5)-methylases to DNA templates containing cytosine analogs. J. 
Biol. Chem., 269, 25986-25991. 
 
44. Christman, J.K. (2002) 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of 
DNA methylation: mechanistic studies and their implications for cancer therapy. 
Oncogene, 21, 5483-5495. 
 
45. Santi, D.V., Norment, A., Garrett, C.E. . (1984) Covalent bond formation, between 
a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc. 
NatI. Acad. Sci., 81, 6993-6997. 
 
46. Som, S., Friedman, S. (1994) Inhibition of Transcription in vitro by Binding of 
DNA(Cytosine-5)-Methylases to DNA Templates Containing Cytosine Analogs. 
Journal of Biological Chemistry, 269, 25986-25991. 
 
47. Bhagwat, A.S., Roberts, R.J. (1987) Genetic Analysis of the 5-Azacytidine 
Sensitivity of Escherichia coli K-12. Journal of Bacteriology, 169, 1537-1546. 
48. Klimasauskas, S., Kumar, S., Roberts, R.J., Cheng, X. (1994) Hhal 
Methyltransferase Flips Its Target Base Out of the DNA Helix. Cell, 76, 357-369. 
 
49. Klimasauskas, S., Szyperski, T., Serva, S., Wuthrich, K. (1998) Dynamic modes of 
the flipped-out cytosine during HhaI methyltransferase–DNA interactions in 
solution. EMBO Journal, 17 317–324. 
 
50. O’Gara, M., Klimasauskas, S., Roberts, R.J., Cheng, X. (1996) Enzymatic C5-
Cytosine Methylation of DNA: Mechanistic Implications of New Crystal 
Structures for HhaI Methyltransferase-DNA-AdoHcy Complexes. J. Mol. Biol., 
261, 634–645. 
 
51. Gabbara, S., Bhagwat, A.S. (1995) The mechanism of inhibition of DNA (cytosine-
5-)-methyltransferases by 5-azacytosine is likely to involve methyl transfer to the 
inhibitor. Biochem. J., 307, 87-92. 
 175 
52. Friedman, S. (1986) Binding of the EcoRII methylaes to azacytosine-containing 
DNA. Nucleic Acids Research, 14, 4543-4556. 
 
53. Salem, A.M.H., Nakano, T., Takuwa, M., Matoba, N., Tsuboi, T., Terato, H., 
Yamamoto, K., Yamada, M., Nohmi, T., Ide, H. (2009) Genetic analysis of repair 
and damage tolerance mechanisms for DNA-protein cross-links in Escherichia 
coli. J. Bacteriol., 191, 5657-5668. 
 
54. Garcia, J.S., Jain, N., Godley, L.A. (2010) An update on the safety and efficacy of 
decitabine in the treatment of myelodysplastic syndromes Onco. Targets and 
Therapy, 3. 
 
55. Glover, A.B., Leyland-Jones, B.R., Chun, H.G., Davies, B., and Hoth, D.F.  . (1987) 
Azacitidine: 10 years later. Cancer Treatment Reports, 71, 737-746. 
 
56. Baylin, S.B., Esteller, M., Rountree, M.R., Bachman, K.E., Schuebel, K., Herman, 
J.G. (2001) Aberrant patterns of DNA methylation, chromatin formation and 
gene expression in cancer. Human Molecular Genetics, 7, 687-692. 
 
57. Siddhikol, C., Erbstoeszer, J.W., and Weisblum, B. (1969) Mode of Action of 
Streptolydigin. J. Bacteriol., 99, 151-155. 
 
58. Von Meyenburg, K., Nielsen, L.D., Johnsen, K., Molin, S., Svenningsen, B., and 
Miozzari, G. (1978) Reevealuation of the Mode of Action of Streptolydigin in 
Escherichia coli: Induction of Transcription Termination In Vivo. Antimicrobial 
Agents and Chemotherapy, 13, 234-243. 
 
59. Cassani, G., Burgess, R.R., Goodman, H.M., Gold, L. (1971) Inhibition of RNA 
polymerase by streptolydigin. Nat. New. Biol., 230, 197-200. 
 
60. Tuske, S., Sarafianos, S.G., Wang, X., Hudson, B., Sineva, E., Mukhopadhyay, J., 
Birktoft, J.J., Leroy, O., Ismail, S., Clark, A.D., Dharia, C., Napoli, A., Laptenko, 
O., Lee, J., Borukhov, S., Ebright, R.H., Arnold, E. (2005) Inhibition of Bacterial 
RNA Polymerase by Streptolydigin: Stabilization of a straight-bridge-helix 
active-center conformation. Cell, 122, 541–552. 
 
61. Temiakov, D., Zenkin, N., Vassylyeva, M. N., Perederina, A., Tahirov, T.H., 
Kashkina, E., Savkina, M., Zorov, S., Nikiforov, V., Igarashi, N., Matsugaki., N., 
Wakatsuki, S., Severinov, K., Vassylyev, D.G. (2005) Structural basis of 
transcription inhibition by antibiotic streptolydigin. Mol. Cell, 19, 655-666. 
 176 
62. Paramanathan, T., Vladescu, I., McCauley, M.J., Rouzina, I., and Williams, M.C. 
(2012) Force spectroscopy reveals the DNA structural dynamics that govern the 
slow binding of Actinomycin D. Nucleic Acids Res., 40, 4925–4932. 
 
63. Sobell, H.M., Jain, S.C., Sakore, T.D. and Nordman, C.E. (1971) Stereochemistry 
of Actinomycin–DNA Binding. Nat. New Biol., 231, 200-205. 
 
64. Sobell, H.M. (1985) Actinomycin and DNA transcription. Proc. Natl. Acad. Sci. U. 
S. A., 82, 5328-5331. 
 
65. Lian, C., Robinson, H. and Wang, A.H.J. (1996) Structure of Actinomycin D 
bound with (GAAGCTTC)2 and (GATGCTTC)2 and its binding to the 
(CAG)n:(CTG)n triplet sequence as determined by NMR analysis. J. Am. Chem. 
Soc., 118, 8791-8801. 
 
66. Selby, C.P., Sancar, A. (1993) Molecular mechanism of transcription coupling 
repair. Science, 260, 53-58. 
 
67. Deaconescu, A.M., Chambers, A.L., Smith, A.J., Nickels, B.E., Hochschild, A., 
Nigel J. Savery, N.J.,  Darst, S.A. (2006) Structural basis for bacterial 
transcription-coupled DNA repair. Cell, 124, 507–520. 
 
68. Roberts, J., Park, J-S. (2004) Mfd, the bacterial transcription repair coupling 
factor: translocation, repair, and termination. Current Opinion in Microbiology, 7, 
120-125. 
 
69. Selby, C.P., Sancar, A. (1995) Structure and function of transcription-repair 
coupling factor. II. Catalytic properties. J. Biol. Chem., 270, 4890-4895. 
 
70. Boubakri, H., de Septenville, A.L., Viguera, E., Michel, B. (2010) The helicases 
DinG, Rep, and UvrD cooperate to promote replication across transcription units 
in vivo. EMBO J., 29, 145-157. 
 
71. Guy, C.P., Atkinson, J., Gupta, M.K., Mahdi, A.A., Gwynn, E.J., Rudolph, C.J., 
Moon, P.B., van Knippenberg, I.C., Cadman, C.J., Dillingham, M.S. et al. (2009) 
Rep provides a second motor at the replisome to promote duplication of protein-
bound DNA. Mol. Cell, 36, 654-666. 
 
 177 
72. Kumari, A., Minko, I.G., Smith, R.L., Lloyd, R.S. and McCullough, A.K. (2010) 
Modulation of UvrD helicase activity by covalent DNA-protein cross-links. J. 
Biol. Chem., 285, 21313-21322. 
 
73. Trautinger, B.W., Jakataji, R.P., Rusakova, E. and Lloyd, R.G. (2005) RNA 
polymerase modulators and DNA repair activities resolve conflicts between 
DNA replication and transcription. Mol. Cell, 19, 247–258. 
 
74. Washburn, R.S., Gottesman, M.E. (2011) Transcription termination maintains 
chromosome integrity. Proc. Natl. Acad. Sci. U. S. A., 108, 792–797. 
 
75. Pavco, P.A., Steege, D.A. (1990) Elongation by Escherichia coli RNA polymerase is 
blocked in vitro by a site-specific DNA binding protein. J. Biol. Chem., 265, 9960-
9969. 
 
76. Sukhodolets, M.V., Cabrera, J.E., Zhi, H. and Jin, D.J. (2001) RapA, a bacterial 
homolog of SWI2/SNF2, stimulates RNA polymerase recycling in transcription. 
Genes Dev., 15, 3330-3341. 
 
77. Muzzin, O., Campbell, E.A., Xia, L., Severinova, E., Darst, S.A, and Severinov, K. 
(1998) Disruption of Escherichia coli HepA, an RNA polymerase-associated 
protein, causes UV sensitivity. J. Biol. Chem., 273, 15157-15161. 
 
78. Orlova, M., Newlands, J., Das, A., Goldfarb, A., and Borukhov, S. (1995) Intrinsic 
transcript cleavage activity of RNA polymerase. Proc. NatI. Acad. Sci. U.S.A., 92, 
4596-4600. 
 
79. Borukhov, S., Polyakov, A.,Nikiforov, V., and Goldfarb, A. (1992) GreA protein: 
A transcription elongation factor from Escherichia coli. Proc. NatI. Acad. Sci. U.S.A., 
89, 8899-8902. 
 
80. Toulme, F., Mosrin-Huaman, C., Sparkowski, J., Das, A., Leng, M., and 
Rahmouni, A. R. (2000) GreA and GreB proteins revive backtracked RNA 
polymerase in vivo by promoting transcript trimming. EMBO J., 19, 6853-6859. 
 
81. Tehranchi, A.K., Blankschien, M.D., Zhang, Y., Halliday, J.A., Srivatsan, A., Peng, 
J., Herman, C., Wang, J.D. (2010) The transcription factor DksA prevents conflicts 
between DNA replication and transcription machinery. Cell, 141, 595-605. 
 178 
82. Epshtein, V., Toulme, F., Rahmouni, A.R., Borukhov, S., and Nudler, E. (2003) 
Transcription through the roadblocks: the role of RNA polymerase cooperation. 
EMBO J., 22, 4719-4727. 
 
83. Krasich, R., Wu, S.Y., Kuo, H.K. and Kreuzer, K.N. (Unpublished) Functions that 
protect Escherichia coli from DNA-protein crosslinks. 
 
84. Kuo, H.K., Krasich, R., Bhagwat, A.S., Kreuzer, K.N. (2010) Importance of the 
tmRNA system for cell survival when transcription is blocked by DNA-protein 
cross-links. Mol. Microbiol., 78, 686-700. 
 
85. Keiler, K.C., Waller, P.R.H., Sauer, R.T. (1996) Role of a peptide tagging system in 
degradation of proteins synthesized from damaged messenger RNA. Science, 271, 
990-993. 
 
86. Roche, E.D. and Sauer, R.T. (2001) Identification of endogenous SsrA-tagged 
proteins reveals tagging at positions corresponding to stop codons. J. Biol. Chem., 
276, 28509–28515. 
 
87. Bandaru, B., Gopal, J. and Bhagwat, A.S. (1996) Overproduction of DNA cytosine 
methyltransferases causes methylation and C --> T mutations at non-canonical 
sites. J. Biol. Chem., 271, 7851-7859. 
 
88. Roche, E.D., Sauer, R.T. (1999) SsrA-mediated peptide tagging caused by rare 
codons and tRNA scarcity. EMBO J., 18, 4579-4589. 
 
89. Sunohara, T., Abo, T., Inada, T. and Aiba, H. (2002) The C-terminal amino acid 
sequence of nascent peptide is a major determinant of SsrA tagging at all three 
stop codons. RNA, 8, 1416–1427. 
 
90. Garza-Sanchez, F., Shoji, S., Fredrick, K., Hayes, C.S. (2009) RNaseII is important 
for A-site mRNA cleavage during ribosome pausing. Mol. Microbiol., 73, 882-897. 
 
91. Selby, C.P. and Sancar, A. (1994) Mechanisms of Transcription-Repair Coupling 
and Mutation Frequency Decline. Microbiological Reviews, 58, 317-329. 
 
92. Zwiefka, A., Kohn, H. and Widger, W.R. (1993) Transcription termination factor 
Rho: the site of bicyclomycin inhibition in E. coli. Biochemistry, 32, 3564–3570. 
 
 179 
93. Berenbaum, M.C. (1978) A method for testing for synergy with any number of 
agents. J. Infect. Dis., 137, 122–130. 
 
94. Botelho, M.G. (2000) Fractional inhibitory concentration index of combinations of 
antibacterial agents against cariogenic organisms. Journal of Dentistry, 28, 565-570. 
 
95. Gupta, M.K., Guy, C.P., Yeeles, J.T., Atkinson, J., Bell, H., Lloyd, R.G., Marians, 
K.J. and McGlynn, P. (2013) Protein--DNA complexes are the primary sources of 
replication fork pausing in Escherichia coli. Proc. Natl. Acad. Sci. U.S.A., 110, 7252-
7257. 
 
96. Choy, J.S., Aung, L.L.,1 and Karzai, A.W. (2007) Lon Protease Degrades Transfer-
Messenger RNA-Tagged Proteins. J. Bacteriol., 189, 6564–6571. 
 
97. Gottesman, S., Roche, E., Zhou, Y., Sauer, R.T. (1998) The ClpXP and ClpAP 
proteases degrade proteins with carboxy-terminal peptide tails added by the 
SsrA-tagging system. Genes Dev, 12, 1338-1347. 
 
98. Guzman, L.M., Belin, D., Carson, M.J. and Beckwith, J. (1995) Tight regulation, 
modulation, and high-level expression by vectors containing the arabinose PBAD 
promoter. J. Bacteriol., 177, 4121-4130. 
 
99. Jin, J., Bai, L., Johnson, D. S., Fulbright, R.M., Kireeva, M. L., Kashlev, M., Wang, 
M.D. (2010) Synergistic action of RNA polymerases in overcoming the 
nucleosomal barrier. Nat. Struct. Mol. Biol., 17, 745-752. 
 
100. Nakano, T., Ouchi, R., Kawazoe, J., Pack, S.P., Makino, K. and Ide, H. (2012) T7 
RNA polymerases backed up by covalently trapped proteins catalyze highly 
error prone transcription. J. Biol. Chem., 287, 6562-6572. 
 
101. Kalman, M., Murphy, H., and Cashel, M. (1992) The nucleotide sequence of recG, 
the distal spo operon gene in Escherichia coli K-12. Gene, 110, 95-99. 
 
102. Kitagawa, M., Ara, T.,  Arifuzzaman, M., Ioka-Nakamichi, T., Inamoto,E., 
Toyonaga, H.,  and Mori, H. (2005) Complete set of ORF clones of Escherichia coli 
ASKA library (A Complete Set of E. coli K-12 ORF Archive): Unique resources for 
biological research. DNA Research, 12, 291–299. 
 
103. Heitman, J., and Model, P. (1991) SOS induction as an in vivo assay of enzyme-
DNA interactions. Gene, 103, 1-9. 
 180 
104. Kenyon, C.J., and Walker, G.C. (1980) DNA-damaging agents stimulate gene 
expression at specific loci in Escherichia coli. Proc. Natl. Acad. U.S.A., 77, 2819-2823. 
 
105. Barron, C., and Bade, E.G. (1988) Transcriptional mapping of the bacteriophage 
Mu DNA. J. Gen. Virol., 69, 385-393. 
 
106. Akroyd, J., and Symonds, N. (1986) Localization of the gam gene of bacteriophage 
mu and characterisation of the gene product. Gene, 49, 173-182. 
 
107. Krause, H.M., Rothwell, M.R., and Higgins, N.P. (1983) The early promoter of 
bacteriophage Mu: definition of the site of transcript initiation. Nucleic Acids Res., 
11, 5483-5495. 
 
108. Abraham, Z.H.L., Symonds, N. (1990) Purification of overexpressed gam gene 
protein from bacteriophage Mu by denaturation-renaturation techniques and a 
study of its DNA-binding properties. Biochem. J., 269, 679-684. 
 
109. Shee, C., Cox, B.D., Gu, F., Luengas, E.M., Joshi, M.C., Chiu, L.Y., Magnan, D., 
Halliday, J.A., Frisch, R.L., Gibson, J.L. et al. (2013) Engineered proteins detect 
spontaneous DNA breakage in human and bacterial cells. eLife, 2, e01222. 
 
110. Casadaban, M.J., and Cohen, S.N. (1979) Lactose genes fused to exogenous 
promoters in one step using a Mu-lac bacteriophage: In vivo probe for 
transcriptional control sequences. Proc. Natl. Acad. Sci. U.S.A., 76, 4530-4533. 
 
111. Heitman, J. and Model, P. (1987) Site-specific methylases induce the SOS DNA 
repair response in Escherichia coli. J. Bacteriol., 169, 3243-3250. 
 
112. Hübner, P., Iida, S., Arber, W. (1987) A transcriptional terminator sequence in the 
prokaryotic transposable element IS1. Mol. Gen. Genet., 206. 
 
113. Maenhaut-Michel, G., Blake, C.E., Leach, D.R.F., and Shapiro, J.A. (1997) 
Different structures of selected and unselected araB-lacZ fusions. Mol. Microbiol., 
23, 1133-1145. 
 
114. Baba, T., Ara, T., Hasegawa, M., Takai, Y., Okumura, Y., Baba, M., Datsenko, 
K.A., Tomita, M., Wanner, B.L. and Mori, H. (2006) Construction of Escherichia 
coli K-12 in-frame, single-gene knockout mutants: the Keio collection. Mol. Syst. 
Biol., 2, 2006.0008. 
 181 
115. Connelly, J.C., de Leau, E.S., Leach, D.R. (2003) Nucleolytic processing of a 
protein-bound DNA end by the E. coli SbcCD (MR) complex. DNA Repair, 2, 795-
807. 
 
116. Neale, M.J., Pan, J. and Keeney, S. (2005) Endonucleolytic processing of covalent 
protein-linked DNA double-strand breaks. Nature (London), 436, 1053-1057. 
 
117. Schlacher, K., Pham, P., Cox, M.M., Goodman, M.F. (2006) Roles of DNA 
polymerase V and RecA protein in SOS damage-induced mutation. Chem. Rev., 
106, 406-419. 
 
118. Friedberg, E.C., Walker, G.C., Siede, W., Wood, R.D., Schultz, R.A. and 
Ellenberger, T. (2006) DNA Repair and Mutagenesis. Second ed. ASM Press, 
Washington, DC. 
 
119. Courcelle, J., Carswell-Crumpton, C. and Hanawalt, P.C. (1997) recF and recR are 
required for the resumption of replication at DNA replication forks in Escherichia 
coli. Proc. Natl. Acad. Sci. U.S.A, 94, 3714-3719. 
 
120. Courcelle, J., Donaldson, J.R., Chow, K.H. and Courcelle, C.T. (2003) DNA 
damage-induced replication fork regression and processing in Escherichia coli. 
Science, 299, 1064-1067. 
 
121. Langer, T., Lu, C., Echols, H., Flanagan, J., Hayer, M.K., Hartl, F.U. (1992) 
Successive action of DnaK, DnaJ and GroEL along the pathway of chaperone-
mediated protein folding. Nature, 356, 683-689. 
 
122. Schröder, H., Langer, T., Hartl, F.U.,  and Bukau, B. (1993) DnaK, DnaJ and GrpE 
form a cellular chaperone machinery capable of repairing heat-induced protein 
damage. EMBO J., 12. 
 
123. Hayes, C.S., Holberger, L.E. (2009) Ribosomal Protein S12 and Aminoglycoside 
Antibiotics Modulate A-site mRNA Cleavage and Transfer-Messenger RNA 
Activity in Escherichia coli. J. Biol. Chem., 284, 32188-32200. 
 
124. Hayes, C.S., and Sauer, R.T. (2003) Cleavage of the A site mRNA codon during 
ribosome pausing provides a mechanism for translational quality control. Mol. 
Cell, 12, 903-911. 
 182 
125. Chambers, A.L., Smith, A.J. and Savery, N.J. (2003) A DNA translocation motif in 
the bacterial transcription – repair coupling factor, Mfd. Nucleic Acids Res., 31, 
6409–6418. 
 
126. Jin, D.J., Zhou, Y.N., Shaw, G. and Ji, X. (2011) Structure and function of RapA: a 
bacterial Swi2/Snf2 protein required for RNA polymerase recycling in 
transcription. Biochim. Biophys. Acta., 1809, 470-475. 
 
127. Nakano, T., Ouchi, R., Kawazoe, J., Pack, S.P., Makino, K., Ide, H. (2012) T7 RNA 
polymerases backed up by covalently trapped proteins catalyze highly error 
prone transcription. J. Biol. Chem., 287, 6562-6572. 
 
128. Fish, R.N. and Kane, C.M. (2002) Promoting elongation with transcript cleavage 
stimulatory factors. Biochim. Biophys. Acta., 1577, 287-307. 
 
129. Seigneur, M., Bidnenko, V., Ehrlich, S.D. and Michel, B. (1998) RuvAB acts at 
arrested replication forks. Cell, 95, 419-430. 
 
130. Hong, G. and Kreuzer, K.N. (2003) Endonuclease cleavage of blocked replication 
forks: An indirect pathway of DNA damage from antitumor drug-topoisomerase 
complexes. Proc. Natl. Acad. Sci. U.S.A., 100, 5046-5051. 
 
131. Connelly, J.C., Kirkham, L.A. and Leach, D.R.F. (1998) The SbcCD nuclease of 
Escherichia coli is a structural maintenance of chromosomes (SMC) family protein 
that cleaves hairpin DNA. Proc. Natl. Acad. Sci. U.S.A., 95, 7969-7974. 
 
132. Connelly, J.C. and Leach, D.R. (2002) Tethering on the brink: the evolutionarily 
conserved Mre11-Rad50 complex. Trends in Biochemical Sciences, 27, 410-418. 
 
133. Straus, D., Walter, W., and Gross, C.A. (1990) DnaK, DnaJ, and GrpE heat shock 
proteins negatively regulate heat shock gene expression by controlling the 
synthesis and stability of sigma 32. Genes Dev., 4, 2202-2209. 
 
134. Whitney, E. (1971) The tolC locus in Escherichia coli K12. Genetics, 67, 39–53. 
 
135. Leivel, L. (1965) Actinomycin sensitivity of Escherichia coli produced by EDTA. 
Biochem. Biophys. Res. Commun., 28, 229-236. 
 
 183 
136. Erie, D.A., Hajiseyedjavadi, O., Young, M.C. and von Hippel, P.H. (1993) 
Multiple RNA polymerase conformations and GreA: control of the fidelity of 
transcription. Science, 262, 867-873  
 
137. Fisher, R.F. and Yanofsky, C. (1983) Mutations of the b subunit of RNA 
polymerase alter both transcription pausing and transcription termination in the 
trp operon leader region in vitro. J. Biol. Chem., 258, 8146-8150. 
 
138. Jin, D.J., Walter, W. A., Gross, C. A. (1988) Characterization of the termination 
phenotypes of rifampicin-resistant mutants. J. Mol. Biol., 202, 245–253. 
 
139. Neff, N.F., and Chamberlin, M.J. (1980) Termination of transcription by 
Escherichia coli ribonucleic acid polymerase in vitro. Effect of altered reaction 
conditions and mutations in the enzyme protein on termination with T7 and T3 
deoxyribonucleic acids. Biochemistry, 19, 3005-3015. 
 
140. Jun Jin, D., and Gross, C.A. (1988) Mapping and Sequencing of Mutations in the 
Escherichia coli rpoB Gene that Lead to Rifampicin Resistance. J. Mol. Biol., 202, 
45-58. 
 
141. Mirkin, E.V. and Mirkin, S.M. (2005) Mechanisms of transcription-replication 
collisions in bacteria. Mol. Cell. Biol., 25, 888–895. 
 
142. Freudenreich, C.H. and Kreuzer, K.N. (1993) Mutational analysis of a type II 
topoisomerase cleavage site: distinct requirements for enzyme and inhibitors. 
EMBO J., 12, 2085-2097. 
 
143. Freudenreich, C.H. and Kreuzer, K.N. (1994) Localization of an aminoacridine 
antitumor agent in a type II topoisomerase-DNA complex. Proc Natl Acad Sci U S 
A., 91, 11007-11011. 
 
144. Freudenreich, C.H., Chang, C. and Kreuzer, K.N. (1998) Mutations of the 
bacteriophage T4 type II DNA topoisomerase that alter sensitivity to antitumor 
agent 4'-(9-acridinylamino)methanesulfon-m-anisidide and an antibacterial 
quinolone. Cancer Res., 58, 1260-1267. 
 
 
 
 
 184 
145. Dabholkar, M., Thornton, K., Vionnet, J., Bostick-Bruton, F., Yu, J.J. and Reed, E. 
(2000) Increased mRNA levels of xeroderma pigmentosum complementation 
group B (XPB) and Cockayne’s Syndrome complementation group B (CSB) 
without increased mRNA levels of multidrug-resistance gene (MDR1) or 
metallothionein-II (MT-II) in platinum-resistant human ovarian cancer tissues. 
Biochemical Pharmacology, 60, 1611–1619. 
 
146. Baharoglu, Z., Babosan, A. and Mazel, D. (2013) Identification of genes involved 
in low aminoglycoside-induced SOS response in Vibrio cholerae: a role for 
transcription stalling and Mfd helicase. Nucleic Acids Res., [published ahead of 
print]. 
 
147. Park, J., Marr, M.T., Roberts, J.W. (2002) E.coli transcription repair coupling factor 
(Mfd protein) rescues arrested complexes by promoting forward translocation. 
Cell, 109, 757-767. 
 
148. Woudstra, E.C., Gilbert, C., Fellows, J., Jansen, L., Brouwer, J., Erdjument-
Bromage³, H., Tempst, P. and Svejstrup, J.Q. (2002) A Rad26±Def1 complex 
coordinates repair and RNA pol II proteolysis in response to DNA damage. 
Nature, 415, 929-933. 
 
149. McKaya, B.C., Chenb, F., Clarkeb, S.T., Wigginb, H.E., Harleyb, L.M. and 
Ljungman, M. (2001) UV light-induced degradation of RNA polymerase II is 
dependent on the Cockayne’s syndrome A and B proteins but not p53 or MLH1. 
Mutat. Res., 485, 93–105. 
 
150. Krugh, T.R. (1972) Association of actinomycin D and deoxyribodinucleotides as a 
model for binding of the drug to DNA. Proc. Natl Acad. Sci. U.S.A., 69. 
 
151. George, D.L. and Witkin, E.M. (1974) Slow excision repair in an mfd mutant of 
Escherichia coli B/r. Mol Gen Genet. , 133, 283--291. 
 
152. George, D.L. and Witkin, E.M. (1975) Ultraviolet light-induced responses of an 
mfd mutant of Escherichia coli B/r having a slow rate of dimer excision. Mutat. 
Res., 28, 347-354. 
 
153. Hanawalt, P., C. (2002) Subpathways of nucleotide excision repair and their 
regulation. Oncogene, 21, 8949 – 8956. 
 185 
154. Chan, C.L., Wang, D. and Landick, R. (1997) Multiple interactions stabilize a 
single paused transcription intermediate in which hairpin to 3' end spacing 
distinguishes pause and termination pathways. J. Mol. Biol., 268, 54-68. 
 
155. Artsimovitch, I. and Landick, R. (1998) Interaction of a nascent RNA structure 
with RNA polymerase is required for hairpin-dependent transcriptional pausing 
but not for transcript release. Genes Dev., 12, 3110-3122. 
 
156. Guajardo, R. and Sousa, R. (1997) A model for the mechanism of polymerase 
translocation. J. Mol. Biol., 265, 8-19. 
 
157. Komissarova, N. and Kashlev, M. (1997) RNA polymerase switches between 
inactivated and activated states By translocating back and forth along the DNA 
and the RNA. J. Biol. Chem., 272, 15329-15338. 
 
158. Nudler, E., Mustaev, A., Lukhtanov, E. and Goldfarb, A. (1997) The RNA-DNA 
hybrid maintains the register of transcription by preventing backtracking of 
RNA polymerase. Cell, 89, 33–41. 
 
159. Branum, M.E., Reardon, J.T. and Sancar A. . (2001) DNA repair excision nuclease 
attacks undamaged DNA.  A potential source of spontaneous mutations. J. Biol. 
Chem., 276, 25421-25426. 
 
160. Blattner, F.R., Plunkett, G. III, Bloch, C.A., Perna, N.T., Burland, V., Riley, M., 
Collado-Vides, J., Glasner, J.D., Rode, C.K., Mayhew, G.F., Gregor, J., Davis, 
N.W., Kirkpatrick, H.A., Goeden, M.A., Rose, D.J., Mau, B. and Shao,Y. (1997) 
The complete genome sequence of Escherichia coli K-12. Science, 277, 1453-1474. 
 
161. Huang, D.W., Sherman, B.T., and Lempicki, R.A. (2009) Systematic and 
integrative analysis of large gene lists using DAVID Bioinformatics Resources. 
Nature Protoc., 4, 44-57. 
 
162. Huang, D.W., Sherman, B.T., and Lempicki, R.A. (2009) Bioinformatics 
enrichment tools: paths toward the comprehensive functional analysis of large 
gene lists. Nucleic Acids Res., 37, 1-13. 
 
 
 
 
 186 
163. Salgado, H., Peralta-Gil, M., Gama-Castro, S., Santos-Zavaleta, A., Muñiz-
Rascado, L., García-Sotelo, J.S., Weiss, V., Solano-Lira, H., Martínez-Flores, I., 
Medina-Rivera, A. et al. (2012) RegulonDB (version 8.0): Omics data sets, 
evolutionary conservation, regulatory phrases, cross-validated gold standards 
and more. Nucleic Acids Res, 41, D203–D213. 
 
164. Keseler, I.M., Mackie, A., Peralta-Gil, M., Santos-Zavaleta, A., Gama-Castro, S., 
Bonavides-Martínez, C., Fulcher, C., Huerta, A.M., Kothari, A., Krummenacker, 
M. et al. (2013) EcoCyc: fusing model organism databases with systems biology. 
Nucleic Acids Res, 41, D605-612. 
 
165. Nomura, M., Gourse, R. and Baughman, G. (1984) Regulation of the synthesis of 
ribosomes and ribosomal components. Annu Rev Bichem, 53, 75–117. 
 
166. Bremer, H. and Dennis, P. (1996) In Neidhardt, F. (ed.), Escherichia coli and 
Salmonella. ASM Press, Washington, DC:, Vol. 2, pp. 1553-1569. 
 
167. Keener, J.N., M. (1996) In Neidhardt, F. (ed.), Escherichia coli and Salmonella. ASM 
Press, Washington, DC, Vol. 1, pp. 1417-1431. 
 
168. Gausing, K. (1977) Regulation of ribosome production in Escherichia coli: 
synthesis and stability of ribosomal RNA and of ribosomal protein messenger 
RNA at different growth rates. J. Mol. Biol., 115, 335–354. 
 
169. Jin, D.J., Cagliero, C. and Zhou, Y.N. (2012) Growth rate regulation in Escherichia 
coli. FEMS Microbiol Rev, 36, 269–287. 
 
170. Paul, B.J., Barker, M.M., Ross, W., Schneider, D.A., Webb, C., Foster, J.W. and 
Gourse, R.L. (2004) DksA: a critical component of the transcription initiation 
machinery that potentiates the regulation of rRNA promoters by ppGpp and the 
initiating NTP. Cell, 118, 311–322. 
 
171. Aberg, A., Fernandez-Vazquez, J., Cabrer-Panes, J.D., Sanchez, A. and Balsalobre, 
C. (2009) Similar and divergent effects of ppGpp and dksA deficiencies on 
transcription in Escherichia coli. J. Bacteriol., 191, 3226-3236. 
 
172. Haddadin, F.T., and Harcum, S.W. (2005) Transcriptome Profiles For High-Cell-
Density Recombinant and Wild-Type Escherichia coli. Biotechnol Bioeng., 90, 127-
153. 
 187 
173. Bradley, M.D., Beach, M.B., de Koning, A.P., Pratt, T.S. and Osuna, R. (2007) 
Effects of Fis on Escherichia coli gene expression during different growth stages. 
Microbiology, 153, 2922-2940. 
 
174. Hommais, F., Krin, E., Laurent-Winter, C., Soutourina, O., Malpertuy, A., Le 
Caer, J.P., Danchin, A. and Bertin, P. (2001) Large-scale monitoring of pleiotropic 
regulation of gene expression by the prokaryotic nucleoid-associated protein, H-
NS. Mol. Microbiol., 40, 20-36. 
 
175. Cardinale, C.J., Washburn, R.S., Tadigotla, V.R., Brown, L.M., Gottesman, M.E. 
and Nudler, E. (2008) Termination factor Rho and its cofactors NusA and NusG 
silence foreign DNA in E. coli. Science, 320, 935-938. 
 
176. Menouni, R., Champ, S., Espinosa, L., Boudvillain, M. and Ansaldi, M. (2013) 
Transcription termination controls prophage maintenance in Escherichia coli 
genomes. Proc. Natl. Acad. Sci. U. S. A., 110, 14414-14419. . 
 
177. Zeng, X., Galinier, A. and Saxild, H.H. (2000) Catabolite repression of dra–nupC–
pdp operon expression in Bacillus subtilis. Microbiology, 146, 2901–2908. 
 
178. Grossman, A.D., Straus, D.B., Walter, W.A. and Gross, C.A. (1987) Sigma 32 
synthesis can regulate the synthesis of heat shock proteins in Escherichia coli. 
Genes Dev., 1, 179-184. 
 
179. Nishino, K. and Yamaguchi, A. (2001) Analysis of a complete library of putative 
drug transporter genes in Escherichia coli. J. Bacteriol., 183, 5803-5812. 
 
180. Khlebnikov, A., Datsenko, K.A., Skaug, T., Wanner, B.L. and Keasling, J.D. (2001) 
Homogeneous expression of the P(BAD) promoter in Escherichia coli by 
constitutive expression of the low-affinity high-capacity AraE transporter. 
Microbiology, 147, 3241-3247. 
 
 
 
 188 
Biography 
Rachel Krasich was born on March 8, 1986 in St. Louis Park, Minnesota to John 
and Mary Krasich.  She graduated from Westfield High School in 2004 and attended 
college at Rose-Hulman Institute of Technology.  In 2008, she graduated summa cum 
laude with a Bachelor of Science in Biochemistry and Molecular Biology, a Bachelor of 
Science in Chemistry, and a Minor in Economics.  During her undergraduate years she 
conducted research at the Wells Center for Pediatric Research with Dr. David Ingram on 
endothelial colony forming cells.  Following graduation, Rachel attended Duke 
University to pursue of her doctoral degree in Dr. Kenneth Kreuzer’s laboratory.  While 
at Duke, her work has focused on transcriptional elongation inhibition. 
Publications:  
Kuo, H. K., Krasich, R., Bhagwat, A.S., Kreuzer, K.N. (2010) Importance of the tmRNA 
system  for cell survival when transcription is blocked by DNA-protein crosslinks, 
Molecular Microbiology 78(3):686-700. 
 
Yoder, M.C., Mead, L.E., Prater, D., Krier, T.R., Mroueh, K.N., Li, F., Krasich, R., Temm, 
C.J., Prchal, J.T., Ingram, D.A. (2007) Redefining endothelial progenitor cells via clonal 
analysis and hematopoietic stem/progenitor cell principals, Blood 109(5):1801-9. 
Manuscripts in Progress: 
 
Krasich, R., Wu, Y., Kuo, H.K., Kreuzer, K.N. (In Submission) Functions that protect 
Escherichia coli from DNA-protein crosslinks 
Krasich, R., Al-Khalil, R., Kreuzer, K.N. (In progress) Fate of transcription elongation 
complexes stalled by exogenous elongation inhibitors  
Krasich, R, Kreuzer, K.N. (In progress) Novel role of Mfd in undamaged cells 
